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This project was aimed at further elucidating the role of protein kinase C (PKC)-induced 
phosphorylation of troponin-I (cTnI) in cardiac contraction. We created a new transgenic mouse 
model (TG-E), expressing a mutant cardiac TnI constitutively pseudo-phosphorylated at the three 
PKC phosphorylation sites (S43, S45, T144 mutated to glutamate). 2D-DIGE (Difference in Gel 
Electrophoresis) gels indicated 7.2 ± 0.5% replacement, with no change in baseline level of 
actual phosphorylation of cTnI or other myofilamental proteins. Experiments were conducted in 
perfused isolated mouse hearts, isolated papillary muscles, and skinned fiber preparations. The 
mechanical measurements were complemented by biochemical and molecular biological 
measurements, and a mathematical model-based analysis for integrative interpretation. 
Compared to wild-type mice, TG-E mice exhibited negative inotropy in in vivo 
echocardiographic studies (9% decrease in fractional shortening), isolated hearts (14% decrease 
in peak developed pressure), papillary muscles (53% decrease in maximum developed force), 
and skinned fibers (14% decrease in maximally activated force, Fmax). Additionally, TG-E mice 
exhibited slowed relaxation in echocardiographic studies, isolated hearts, and intact papillary 
muscles. The TG-E mice showed no differences in calcium sensitivity, cooperativity, steady-
state force-ATPase relationship, and calcium transient (amplitude and relaxation). The four-state 
model of cardiac contraction was used for a model-based analysis of the data. The model was 
verified as a priori globally identifiable using a differential algebraic approach; however, 
automated optimization procedures proved to be unreliable. Instead we performed in silico 
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 v 
experiments, altering sets of parameters in an attempt to recreate our experimental data. The 
model-based analysis revealed that experimental observations in TG-E mice could be reproduced 
by two simultaneous perturbations: a decrease in the rate constant of crossbridge formation and 
an increase in calcium-independent persistence of the myofilament active state. In summary, a 
modest increase in PKC-induced cTnI phosphorylation can significantly regulate cardiac muscle 
contraction: (1) negative inotropy via decreased crossbridge formation and (2) negative lusitropy 
via persistence of myofilament active state. Based on our data and data from the literature we 
speculate that the effects of PKC-mediated cTnI phosphorylation are site-specific (S43/S45 vs. 
T144). 
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1.0  BACKGROUND 
1.1 CARDIAC MUSCLE PHYSIOLOGY 
The heart acts as a pump to move blood, the carrier of oxygen and nutrients, to the 
various tissues of the body. Blood enters the main pumping chambers, the ventricles, which 
contract, decreasing the volume inside the ventricle. This causes an increase in pressure which 
forces the blood to the lungs (from the right ventricle) or the rest of the body (from the left 
ventricle).  
 This contraction occurs because the heart is essentially a large muscle. The fundamental 
complete unit of force production is the sarcomere, but its control starts at a more macroscopic 
level. The electrical conduction system in the heart provides an electrical stimulus, an action 
potential (AP), to the heart muscle. The AP stimulates L-type calcium channels on the surface of 
the cell (the sarcolemma) to open, allowing the Ca2+ current (ICa) to carry extracellular calcium 
into the cell. Additional calcium enters the cell through the Na+-Ca2+ exchanger (NCX). This 
relatively small increase in intracellular calcium concentration is sensed by ryanodine receptors 
(RyR) on the surface of the sarcoplasmic reticulum (SR), an intracellular organelle analogous to 
the endoplasmic reticulum in non-muscle cells. Stimulating the RyR triggers the SR to release its 
vast stores of calcium, thus greatly increasing intracellular calcium concentration. This is 
referred to as calcium-induced calcium release (CICR). The relative contribution of the L-type 
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channels, NCX and SR to total intracellular calcium, however, varies between species [1], an 
important distinction when interpreting experimental data. Overall, there is a 10-20 fold increase 
in intracellular calcium concentration, from a diastolic concentration of ~ 100nM to a peak 
systolic concentration of 1000-2000nM [2].  
 
 
Figure 1-1. Schematic of Calcium Handling in the Ventricular Myocyte. 
 
The rise of intracellular calcium acts as a stimulus to the sarcomere. The sarcomere is 
highly structured, consisting of overlapping thin and thick filaments. The thick filament is 
comprised primarily of myosin, which makes up the filament and the head region. The myosin 
heads protrude from the filament surface at regular intervals. Each myosin has two heads and 
consists of two myosin heavy chains (MHC, primarily β -MHC in human ventricles, and α -
MHC in mouse), and four (two per head) myosin light chains (MLC): two essential light chains 
(ELC) and two regulatory light chains (RLC). The thin filament consists mainly of actin, which 
has binding sites for the myosin heads. At diastolic levels of calcium, those binding sites are 
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sterically blocked by tropomyosin. Tropomyosin is comprised of two α-helical chains arranged 
in a coiled-coil structure. These structures polymerize to form long strands that wrap around 
actin [3]. When intracellular calcium rises, the calcium binds to another thin filament associated 
protein, cardiac troponin (cTn). More specifically, it binds to cardiac troponin C (cTnC), which, 
along with cardiac troponin T (cTnT) and cardiac troponin I (cTnI), make up the trimeric protein 
cTn. The binding of calcium to cTnC begins a process that causes tropomyosin to move out of 
the myosin binding pocket on actin.  
 Once myosin binds to actin, forming a crossbridge, the myosin head undergoes a 
conformational change, generating longitudinally perceived torque, producing roughly 10-12 
pico-Newtons of force [4]. This movement is often called the powerstroke. Following this work-
producing step, myosin-bound ADP is released and replaced by ATP, which causes the myosin 
head to unbind from actin. When myosin reattaches to actin, the ATP is hydrolyzed by ATPase, 
and the process begins again [5].  
 At the end of contraction, calcium is sequestered back into the sarcoplasmic reticulum 
(by Sarco/Endoplasmic Reticulum Ca2+-ATPase, SERCA) or transported back out of the 
myocyte by NCXs and ATPase pumps. See Figure 1-1 for a schematic of cardiac contraction (in 
the figure, NCX pumps are only shown pumping calcium out of the cell, in reality they move 
calcium into and out of the cell). 
 While the stimulatory AP is all-or-nothing, the muscle contraction itself can be tightly 
regulated by a number of signaling pathways.  
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1.2 PROTEIN KINASE C CARDIAC SIGNALING 
Cardiac function can be modulated through neurohormonal stimulation. Primary 
signaling messengers such as norepinephrine, epinephrine, bradykinin, angiotensin II (Ang-II), 
endothelin I (ET-1), and others can activate protein kinase C downstream. These messengers act 
on cell surface G-protein coupled receptors (GPCRs) such as α1 adrenergic, ET-1, AT1, 
muscarinic and bradykinin receptors.  
GPCRs have seven transmembrane domains, and are involved in signaling cascades all 
over the body. These specific receptors are primarily coupled to Gq proteins (a heterotrimeric G 
protein) which in turn activate phospholipase C (PLC), which is bound to the intracellular 
portion of the Gq protein. Activated PLC acts on phosphatidylinositol 4,5-bisphosphate (PIP2), 
causing its breakdown into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 acts on IP3 
receptors located on the surface of the sarcoplasmic reticulum (SR) to release intracellular 
calcium. DAG binds to PKC to stabilize its active form and calcium increases the enzyme’s 
affinity for lipids [6, 7]. See Figure 1-2 for schematic of a PKC signaling.  
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Figure 1-2. Schematic of PKC Signaling 
 
PKC is a serine/threonine kinase and was first described by Takai et al. [8] and later 
identified in the heart by Kuo et al. [9]. There are many isoforms of PKC, categorized into three 
classes [10]: calcium sensitive, novel, and atypical. The calcium sensitive PKCs (cPKCs) have a 
calcium binding site and require activation by both DAG and calcium. There are four cPKCs: α, 
β-I, β-II, and γ. The novel PKCs (nPKCs) require only DAG activation; there are five nPKCs: δ, 
ε, η, μ, and θ. There are two atypical PKCs (aPKCs), ζ and ι/λ, and they are less well 
characterized, but have recently been implicated in sarcomeric protein phosphorylation [11].  
PKC, as a kinase will do, phosphorylates a number of intracellular proteins, including 
several myofilamental proteins. These include myosin binding protein C (MyBP-C) [12-14], 
myosin light chain 2 (MLC-2) [15, 16], cTnT [17] and cTnI. PKC-induced phosphorylation of 
cTnI is the focus of this project, and will be covered in detail. Of the isoforms discussed above, 
there is evidence that PKC α, β-I, β-II, δ and ε phosphorylate cTnI [18]. However, we are not 
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looking at the effects of a specific PKC isoform, but the phosphorylation of the sites primarily 
targeted by all PKC isoforms. 
1.3 INTRACELLULAR CALCIUM 
Intracellular calcium plays a critical role in regulating normal cardiac mechanical 
function. Although it was found that calcium rises and falls in contracting muscle more than 
forty years ago [19], there remains a great deal about its role that is still unclear. Abnormal 
calcium cycling occurs in heart failure [20-23], dilated cardiomyopathy [24, 25], ischemia-
reperfusion [26, 27], and arrhythmias [28]. There is little understanding as to why calcium 
cycling abnormalities occur, or how to correct them.  
The relationship between calcium and generated force in cardiac myocytes is often 
studied under steady-state conditions. The technique involves enzymatically “skinning” the fiber 
to remove the membrane and all intracellular structures, effectively isolating the contractile 
machinery. By changing the concentration of calcium in the bathing solution, calcium is held at a 
particular concentration and the force produced at that concentration is then measured. This 
provides a steady-state relationship between calcium and force that is referred to as the force-pCa 
relationship.  
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Figure 1-3. The Static and Dynamic Calcium-Force Relationships 
Dynamic (loops) and steady-state (sigmoid) force-calcium relationships before and after isoproterenol treatment 
from the same trabeculae muscle. From Varian K.D. et al, Am J Physiol Heart Circ Physiol, 2006 [29]. Used with 
permission. 
 
 If each force-calcium concentration pair determined from the static relationship were the 
same in the dynamic, physiologic relationship, there would be no need for further study. 
However, in dynamic measurements of intracellular free calcium, concentration reaches its 
maximum and falls to near baseline by the time developed tension reaches its peak [19, 30]. This 
implies that during dynamic conditions, maximum calcium does not produce maximum force as 
the steady-state force-pCa curve predicts (at calcium levels under saturation). Moreover, there 
are at least two force levels for a given calcium concentration, one during the rising phase and 
one during the relaxation phase, and neither are necessarily the same as the force predicted by 
the force-pCa relationship. These properties can be easily appreciated when the dynamic data are 
overlaid on the steady-state data as seen in Figure 1-3. Therefore, evaluation of the dynamic 
relationship between force and calcium, in addition to the steady-state relationship, is important 
to better understand the in vivo processes that connect them.  
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1.4 CARDIAC TNI PHOSPHORYLATION BY PKC 
One of the key elements in the physical connection between calcium and force is the 
troponin complex. The inhibitory subunit, cTnI, has gained particular prominence due the 
discovery that it is a target for phosphorylation. cTnI has been implicated in a wide array of 
myofilament property alterations.  
Cardiac TnI is a 24kD, 211 amino acid protein. It consists of 6 main regions: 1) a cardiac 
specific N-terminal extension, 2) a structural domain which binds to the C-lobe of cTnC, 3) a 
region which binds to the C-terminus of cTnT, 4) an inhibitory region which binds to actin, 5) a 
regulatory region, and 6) a second actin-binding region. Overall, cTnI has a highly conserved 
amino acid sequence (especially the inhibitory region). The human and mouse sequences differ 
in length by one amino acid at the N-terminus; the initiating methionine is present in the mouse, 
but not in the human. Amino acid positions presented here are for the mouse cTnI, but are shifted 
one lower for human (i.e., position 23 in mouse is 22 in human). See Figure 1-4 for a schematic 
of cTnI. 
Cardiac TnI it is a substrate for both protein kinase A (PKA) and PKC. The five amino 
acid residues on cTnI that can be phosphorylated by PKA and PKC are serines at positions 23, 
24, 43 and 45 and threonine at position 144. The serines nearest the N-terminus, in the cardiac 
specific N-terminal extension, (S23 and S24) are primarily phosphorylated by PKA. PKA-
induced phosphorylation has been shown to increase systolic function (i.e. reduction in peak 
developed force or pressure) [31], enhance relaxation [14, 31, 32], increase crossbridge cycling 
rate [14, 33], decrease myofilament calcium sensitivity [18, 34], alter ATPase activity [34], and 
increase length dependent activation [35, 36].  
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Figure 1-4. Schematic of cTnI 
 
It is important to acknowledge that there may be other phosphorylation sites, including 
S150 [37] and S76/T77 [38] (in human) as well as other kinases that act on cTnI, including p21-
activated kinase (PAK) [37], mammalian sterile 20-like kinase 1 (Mst1) [39], and PKD [40]. The 
impact of phosphorylation of these sites or these kinases remains unclear. 
The focus here, however, will be on PKC due to evidence that its effects are largely 
dominant over those of PKA [41]. Moreover, the effects of PKA phosphorylation are 
comparatively well-studied, while there still remains ambiguity and disagreement regarding the 
effects of PKC-induced phosphorylation of cTnI.  
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The main targets of PKC are S43, S45 and T144. The serines at position 43 and 45 reside 
in the structural domain of cTnI which binds to the C-lobe of cTnC. The threonine at 144, 
however, lies in the inhibitory, actin binding region. PKC is rather promiscuous, however, and it 
can cross phosphorylate the PKA sites [42, 43], meaning there is some affinity for PKC to 
phosphorylate S23 and S24. 
There are three primary techniques for studying the effects of PKC-mediated 
phosphorylation of cTnI: chemically or pharmacologically blocking or upregulating PKC, 
reconstituted fibers, and transgenic animals. The first method involves chemically treating the 
sample with a PKC blocker or PKC activator like ET-1 [44], propranolol [45], high calcium [46], 
or with PKC itself [47]. The difficulty with these experiments is the confounding effects that 
PKC has on other myofilament proteins, as well as its affects on L-type calcium channels [48] 
and protein expression [49].  
A cleaner experimental model involves mutating the PKC phosphorylation sites on cTnI 
directly, thereby isolating the perturbation to cTnI. This method involves reconstituting the 
sarcomere with a mutant form of the troponin (Tn) complex [50]. The mutant form is generally 
created by replacing the endogenous residue (either a serine or a threonine) with either an alanine 
(which cannot by phosphorylated) or glutamate/aspartate (both of which simulate the charge and 
steric effect of a phosphate group). The reconstitution technique involves isolating fiber bundles 
from the heart (often from papillary muscles) and then “skinning” them, removing the membrane 
by detergent treatment. The fiber is then bathed in an exchange buffer (for approximately 90 
minutes, see [51] for details) and the mutant Tn, which over time will begin to replace the 
endogenous Tn.  
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These experiments have allowed many perturbations of the phosphorylation sites, 
including: T144A (threonine at amino acid position 144 mutated to alanine) [52], S43A/S45A 
(serines at positions 43 and 45 are mutated to alanines) [52], S43A/S45A/T144A[52], 
T144E[51], S43E/S45E[51], S43E/S45E/T144E [51], and T144P (proline is the residue in the 
equivalent position in slow skeletal TnI, ssTnI) [53, 54]. The limitation of this technique is 
obvious: the muscle is already skinned, and so the type of experiments that can be performed is 
quite limited. 
The third method involves mutant cTnI expressed in a whole transgenic animal. Using 
these mice, many types of experiments are possible, including whole animal in vivo techniques 
like echocardiography. The same constructs that are used to create reconstituted fibers can be 
used to create transgenic animals, but the time and cost have limited the strains of transgenic 
mice created. The cDNA for the mutant protein is attached to a cardiac specific promoter (such 
as the α-myosin heavy chain promoter) for conditional expression. The strains of transgenic mice 
that have been created are: S23D/S24D/S43D/S45D/T144D [41], 
S23A/S24A/S43A/S45A/T144A [55], S23A/S24D/S43D/S45D (an attempt to mimic changes in 
phosphorylation during heart failure) [56], and S43A/S45A [57], and a PKC overexpressing 
mouse [58]. 
Despite, or perhaps because of, the number of experimental methods that exist, there has 
been disagreement and ambiguity regarding the effects of PKC phosphorylation of cTnI. There is 
evidence suggesting that PKC-activated phosphorylation of cTnI serines at positions 43 and 45 
has a negative ionotropic effect [41]. However, it has been shown PKC activation produces a 
positive inotropic response [45], depending on the species. Regarding relaxation, there is 
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evidence of negative [59] and positive lusitropic [53] effects as well. Previous data from our lab 
suggested negative inotropy with no change in relaxation [60].  
Based on the negative inotropic and lusitropic effects, it has been suggested that 
crossbridge cycling is decreased [51]. Given the uncertainty involving these functional effects, it 
is difficult to be certain of the state of crossbridge cycling under cTnI phosphorylation. 
Moreover, the changes in crossbridge kinetics are based on assumptions drawn from force 
kinetics – i.e., since relaxation is slower, crossbridge cycling must be slower. This conclusion 
may be correct, but the final force waveform is the end-product of several complicated processes, 
leaving open the possibility of contributions from alternative mechanisms. 
There is also disagreement over the effect on calcium sensitivity. There is evidence that 
there is no change in [61], increased [34], or decreased calcium sensitivity [51]. It has been 
suggested that the effects of PKA and PKC phosphorylation are actually opposite and meant to 
balance each other in vivo [18]; however, there are data showing decreased calcium sensitivity 
during PKA [34] and PKC-activated phosphorylation [51]. 
Intracellular calcium transients recorded from S43A/S45A mice showed increases in 
diastolic and systolic calcium [57], but only at high extracellular calcium levels (3.5 mM). The 
effects at a more physiological concentration are less clear. Some other noted effects of cTnI 
phosphorylation at the PKC sites include its role in length-dependant activation [54], response to 
afterload [56], frequency [56] and length [54] and filament sliding speed [51]. 
Overall, it is clear that there remains disagreement and ambiguity regarding the effects of 
PKC-mediated phosphorylation of cTnI. 
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1.5 MATHEMATICAL MODEL BASED ANALYSES 
Given the multifaceted, multivariate effects on the major links between calcium and force 
generation by PKC phosphorylation of cTnI, there needs to be an analysis of the data that is 
robust enough to uncover these effects. We will therefore employ a model-based analysis, where 
appropriate, which should provide stronger evidence of the specific effects of PKC-activated 
phosphorylation of cTnI on the calcium-force relationship. 
Mathematical modeling is an indispensible tool in analyzing complex systems. As put by 
Rosenblueth and Wiener in 1945 [62],  
 
“No substantial part of the universe is so simple that it can be grasped and 
controlled without abstraction. Abstraction consists in replacing the part of the 
universe under consideration by a model of similar but simpler structure. 
Models… are thus a central necessity of scientific procedure.”  
 
Like the system being studied, a mathematical model must possess a certain degree of 
unpredictability. For a mathematical model or simulation, this characteristic is called “emergent 
properties”.  
Well designed models, in general, serve three purposes: descriptive, predictive, and 
explanative. A descriptive model has adequate complexity and appropriate design so that it can 
capture the important features of an observed behavior, i.e., it can describe a system. A 
predictive model can anticipate events which have not yet occurred or experimentally cannot be 
perceived, i.e., it can predict the state of a system. An explanative model has states, structure, or 
parameters which represent actual elements in the system and so it is possible for the model to 
clarify why the system responded a certain way, i.e., it can explain system behavior. 
 14 
There are several types of mathematical models and evaluation methods: Markov models, 
Monte Carlo simulations, discrete event simulations, and others [63]. It is common to model 
biological systems as dynamic, state-based systems. Clearly, biological systems, despite overall 
homeostasis, are marked by continuous change, making them ideal dynamic systems. This means 
the model will most likely be characterized by differential equations. State-based, or 
compartment, models consist of a set of mutually exclusive and collectively exhaustive states. 
Transition from one state (i.e., State 1) to another (State 2) depends on a transition probability 
parameter and the population in State 1. This is similar to models of chemical kinetics, where the 
transition probability parameter is called a rate constant.  
Once a type of model has been chosen, the model structure needs to be formed. This will 
be guided by two things: (1) the purpose the model is intended to fulfill, which will come from 
the research question or hypothesis, and (2) knowledge of the system (either from the literature 
or experiments). Structural decisions could include selection of inputs and outputs, states to 
include, relationships between elements, and hierarchies. Along with the structure, there will be a 
number of assumptions to be identified. 
At the current pace of scientific advancement there is usually an over abundance of 
knowledge. The complexity of the model needs to match the use of the model. James 
Bassingthwaighte, a mathematical modeler, wrote, “A model… is simpler than the real thing. 
Like any simplification, it provides only a parsimonious and somewhat erroneous description” 
[64]. Given the purpose of the mathematical model, how much error between real life and the 
model is allowable? If this question is answered too conservatively, the model will be large, 
unmanageable, and probably useless. If the question is answered too liberally, the model will be 
so simple as to lack emergent properties.  
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Following the development of the model, it is necessary to validate it. Model validation 
ensures the model meets the most basic property described above: it is descriptive. The model 
needs to be compared to actual data to determine whether it can, to a reasonable degree, 
reproduce known data. 
It may be necessary to return to a previous step if the model cannot be validated. This 
may mean rearranging the structure, reassessing the assumptions, or even returning to the initial 
research question. For the model-based analysis used in this project, we have selected the four-
state model, which will be introduced, and its selection justified in Section 7.2. 
1.6 CLINICAL RELEVANCE 
Cardiovascular disease (CVD) is the number one killer in the United States and claims 
more lives each year than the next four leading causes combined [65]. Research shows that 
during end-stage heart failure, phosphorylation levels at all five sites on cTnI are abnormal [66-
70], and that PKC itself is upregulated [70, 71]. Moreover, there is evidence that cTnI may 
represent an appropriate therapeutic target for possible heart failure treatments [72]. 
Understanding the effects of increased PKC phosphorylation of cTnI will help illuminate one 
piece of a complex and multivariate disease. This research will further our understanding of the 
effects of cTnI modification, a key step towards future development of treatment targets and 
schemes.  
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2.0  SPECIFIC AIMS 
The TG-A mouse has provided valuable insights in understanding the impact of PKC 
phosphorylation of cTnI on cardiac function. It is not necessarily true that a constitutively 
phosphorylated system will behave opposite that of a non-phosphorylatable system.  
Sakthivel et al. have created a transgenic mouse model with simulated constitutive 
phosphorylation of cTnI [41]. However, both PKC and PKA sites were constitutively 
phosphorylated in their model, making it difficult to separate their individual effects. Therefore, 
we created a new transgenic mouse model (TG-E) wherein the PKC sites, S43, S45, and T144 on 
cTnI were replaced with glutamic acids to simulate constitutive phosphorylation.  
The overall research goal is to determine the effects of protein kinase C-mediated 
phosphorylation of cardiac troponin I, primarily using the TG-E transgenic mouse.  
 
Initial Characterization: The TG-E transgenic mouse will express mutant cTnI (DNA and 
protein) without changes in total cTnI expression or histology. 
 
Hypothesis 1: Increased cTnI phosphorylation at the PKC sites will result in systolic dysfunction 
and protection from ischemic contracture at the whole organ level.  
 Specific Aim 1a: Determine differences in in vivo cardiac function (echocardiography) in 
wild-type (WT, baseline) and TG-E (increased cTnI phosphorylation at the PKC sites) 
mice 
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 Specific Aim 1b: Determine differences in ex vivo whole heart function (Langendorf) in 
WT (baseline) and TG-E (increased cTnI phosphorylation at the PKC sites) mice 
 
Hypothesis 2: Increased cTnI phosphorylation at the PKC sites will result in depressed calcium-
force and ATPase-force relationships (less force per calcium or ATP hydrolyzed). 
 Specific Aim 2a: Determine differences in the dynamic calcium-force relationship in 
intact papillary muscles under increased and baseline cTnI phosphorylation at the PKC 
sites (chronic and acute phosphorylation) 
 Specific Aim 2b: Determine differences in the static calcium-force and ATPase-force 
relationships under increased and baseline cTnI phosphorylation at the PKC sites 
 
Hypothesis 3: A model-based analysis of data from Specific Aims 1 and 2 will provide an 
integrative interpretation of increased cTnI phosphorylation at the PKC sites. 
Specific Aim 3a: Determine whether the four-state model can provide unique solutions 
Specific Aim 3b: Using a model-based analysis, determine the myofilamental alterations 
caused by PKC-induced phosphorylation of cTnI   
 
 
 
 18 
3.0  ANIMAL USE 
All parts of this study were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Pittsburgh, and conform to the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). 
Animals were housed on a 12-hour light/dark cycle (7am-7pm), maintained at 68-74 ºF, 
and kept in AD Vent mouse caging (Alternative Design, Siloam Springs, AR). Animal care was 
provided by the University of Pittsburgh IACUC’s support staff, which is supervised by a 
veterinarian.  
Transgenic mice were bred and genotyped in house and wild-type FVB mice were 
purchased from Taconic (Germantown, NY). 
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4.0  EXPRESSION OF MUTANT CTNI DNA AND PROTEIN 
4.1 INTRODUCTION 
The TG-E transgenic mouse is a novel model, and this project represents the first work 
examining it. An initial characterization of the mouse at the DNA, RNA, protein, and cellular 
levels is necessary to confirm that the creation of the transgenic mouse was successful. 
Polymerase chain reaction (PCR) was used to identify positive mice. To confirm the sequence of 
the mutant cTnI, the PCR product was sequenced and compared to the original construct. To 
determine the success of the mutation at the mRNA level, reverse transcriptase PCR (RT-PCR) 
was used, but was unsuccessful because the primers were not specific enough to distinguish 
mutant cTnI mRNA from WT cTnI mRNA due to the high GC content. However, if the mutant 
protein is expressed, there must be mutant mRNA. The first attempt at protein quantification 
used the back-phosphorylation assay, which was not accurate enough to find differences. Instead, 
a phosphoprotein staining procedure was used. Overall protein expression was quantified using 
western analysis. Lastly, the histology of the S43E/S45E/T144 mice was compared to WT mice. 
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4.2 GENERATION OF TRANSGENIC MICE  
There are two strains of transgenic mice that have mutated only the PKC phosphorylation 
sites on cTnI. The first is the S43A/S45A, unphosphorylatable mouse. This transgenic mouse 
was generated several years ago and much work has been done on it. This mouse will be referred 
to as the TG-A (for transgenic, mutated to alanines) mouse. The second strain is a novel 
transgenic mouse: S43E/S45E/T144E. This mouse will be referred to as the TG-E (transgenic, 
mutated to glutamates) mouse. The TG-E mouse is the focus of this study. 
To create this mouse, the serine 43 and 45 and threonine 144 residues on cTnI were 
replaced with glutamic acid to simulate constitutive phosphorylation. The cDNA for this mutant 
cTnI was placed under the control of the cardiac specific α-myosin heavy chain promoter [73], 
using a Bluescript vector. Steps to create the transgenic mouse were similar to the creation of the 
TG-A mouse [57]. The transgene was injected into FVB (friendly virus type B) zygotes. 
Microinjected mouse embryos were then reimplanted into pseudo-pregnant FVB female mice.  
 
 
Figure 4-1. Wild type (WT) versus TG-E (TG-E) Mice Mass Comparison. 
LV, left ventricular. 
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The TG-E mice showed no differences in body mass (WT: 30.7 ± 1.6 g, TG-E: 31.3 ± 1.0 
g), left ventricular (LV) mass (WT: 102.4 ± 6.7 mg, TG-E: 103.7 ± 4.2 mg), or their ratio (WT: 
296 ± 9, TG-E: 303 ± 9), as shown in Figure 4-1. The TG-E mice also showed no external signs 
of heart failure, including lethargy or differences in feeding. 
4.3 METHODS 
4.3.1 Polymerase Chain Reaction  
PCR was performed to identify the TG-E mice. The DNA samples were isolated from tail 
clips taken from the mice at three weeks of age. The DNA was isolated using a Wizard Genomic 
DNA Purification Kit (Promega, Madison, WI) following the manufacturers published protocol. 
The two primers (Applied Biosystems, Foster City, CA) were: 5’-
CCTTGTCTTGATTAATCTTGGC-3’ (binds to the myosin heavy chain promoter) and 5’-
CTCCTGCTTCGCAATCTGCAGC-3’ (binds to cTnI sequence). PCR was run on a PCR Sprint 
Thermal Cycler (Thermo Fisher, Waltham, MA). Samples were then loaded on a 1% Agarose gel 
and run at 160 volts for 30 minutes. Gels were then imaged on a Kodak ImageStation IS2000R. 
4.3.2 Sequencing 
Three sequencing primers were used on the isolated DNA from the TG-E mice: 5’ - 
CTACTTTCGTCGCTACGC -3’ and 5’ - GCCTTCCATGCCACTCAG -3’, and an internal 
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primer: 5’ - CACCTCCCGGTTTTCCTT -3’. DNA sequencing was then carried out by the 
University of Pittsburgh genomics core. 
 
 
Figure 4-2. DNA Sequence from the TG-E Plasmid. 
The sequence above the break is the alpha myosin heavy chain promoter, and the bottom sequence is the cardiac 
troponin I sequence. The grey box is the TATA box for transcription factor binding. Notice the cTnI sequence starts 
with ATG, the methionine start codon. The double underlined sections represent the binding sequence for the PCR 
primers, and the single underlined sequences are the binding sites for the sequencing primers. The bold italicized 
triplets represent the mutation sequences (GAA is glutamate) at amino acid positions 43, 45 and 144. The primers 
were selected so that the mutation sites at 43 and 45 would be sequenced. 
 
Figure 4-2 shows the DNA sequence from the construct used to generate the mouse, and 
was utilized to develop the PCR and sequencing primers. The various primer binding locations 
are shown on the figure as underlined sections: double underlined for the PCR primers, and 
TATA AAG GGG CTG GAG CGC TGA GAG CTG TCA GAC CGA GAT TTC 
TCC ATC CCA GGT AAG AAG GAG TTT AGC GTG GGG GCT CTC CAA CCG 
CAC CAG ACC TGT CCC CAC CTA GAG GGA AAG TGT CTT CCC TGG AAG 
TGG GGC TCC TCC CAC CGG CCT GGG AAG TTC TCG GTG GCA GGA TGT 
TTC TAC TGG ATG CCC CTT CCC TTC CAC TGC CTC CTC CCT CCC TTG 
TCT TGA TTA ATC TTG GCT CTT AGT GTT CAG AAA GAT TTG CCC GGT 
GCT GTC TAC TCC ATC TGT CTC TAC TCT CTC TGC CTT GCC TTC TTG 
TGT GTT CTC CTT TTC CAC GTG TTT CTC ACT CCA CTG CCT CCC CCC 
CCC CCT TCA TTT TTA TCC TTC CTT TCT TTC TGT GTC AGA ATG CTG 
GGA ATC AAA CCC AGG GCT TCA TAC ACG TCA AGT AAG CAA TCT CCC 
AGT GAG CCA AAG CTT 
 
ATG GCT GAT GAA AGC AGC GAT GCG GCT GGG GAA CCG CAG CCT GCG 
CCT GCT CCT GTC CGA CGC CGC TCC TCT GCC AAC TAC CGA GCC TAT 
GCC ACC GAG CCA CAC GCC AAG AAA AAG TCT AAG ATC GAA GCC GAA 
AGA AAA CTT CAG TTG AAG ACT CTG ATG CTG CAG ATT GCG AAG CAG 
GAG ATG GAA CGA GAG GCA GAA GAG CGA CGT GGA GAG AAG GGG CGC 
GTT CTG AGG ACT CGT TGC CAG CCT TTG GAG TTG GAT GGG CTG GGC 
TTT GAA GAG CTT CAG GAC TTA TGC CGA CAG CTT CAC GCT CGG GTG 
GAC AAA GTG GAT GAA GAG AGA TAT GAC GTG GAA GCA AAA GTC ACC 
AAG AAC ATC ACT GAG ATT GCA GAT CTG ACC CAG AAG ATC TAT GAC 
CTC CGT GGC AAG TTT AAG CGG CCC GAA CTC CGA AGA GTG AGG ATC 
TCT GCA GAT GCC ATG ATG CAG GCG CTG CTG GGG ACC CGG GCC AAG 
GAA TCC TTG GAC CTG AGG GCC CAC CTC AAG CAG GTG AAG AAG GAG 
GAC ATT GAG AAG GAA AAC CGG GAG GTG GGA GAC TGG CGC AAG AAT 
ATC GAT GCA CTG AGT GGC ATG GAA GGC CGC AAG AAA AAG TTT GAG 
GGC TGA 
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singly underlined for the sequencing primers. The base pair mutations are shown in bold 
italicized font (the amino acid code used to incorporate glutamate into cTnI is GAA).  
4.3.3 Myofibril Isolation 
The heart was quickly excised from the mouse, and then placed in ice cold PBS, where 
the atria, as well as any other extra tissue, was removed. The ventricles were then cut into 
smaller sections, roughly eight to ten pieces, and placed in 10 mL of ice cold myofibrillar relax 
buffer (MRB) with 10 mM ethylenediaminetetraacetic acid (EDTA). The MRB consisted of: 
standard rigor buffer (SRB) plus phospocreatine (4 mM), adenosine triphosphate (ATP) (1 mM), 
2,3-butanedione monoxime (BDM, inhibits crossbridge interaction) (50 mM), dithiothreitol 
(DTT, breaks disulfide bonds) (1 mM), and phenylmethylsulphonyl fluoride (PMSF, a protease 
inhibitor) (0.1 mM). Between 2 and 4 hearts are used for each sample. The tissue was then 
homogenized using a Biohomogenizer (Biospec Products Inc., Bartlesville, OK) on the low 
setting 5 times for 12 seconds each time. The sample was then spun down on a centrifuge 
(Sorvall RC-5, Thermo Scientific, Waltham, MA) at 5,000 rpms at 4 oC for ten minutes. The 
supernatant was discarded and the pellet was resuspended in 12 mL SRB plus 1% Triton X-100 
(v/v) and allowed to sit on ice for 5 minutes. SRB consisted of: KCl (75 mM), imidazole (10 
mM), MgCl2 (2 mM), ethylene glycol tetraacetic acid (EGTA) (2 mM), and NaN3 (1 mM). The 
sample was spun down, and the pellet was resuspended in SRB plus Triton X-100 two more 
times, and SRB alone three more times. The last time, the pellet was resuspended in 1-5 mL 
(depending on the number of hearts that are being used) SRB plus protease inhibitor cocktail 
(Sigma) which contained: AEBSF (104 mM), aprotinin (80 μM), leupeptin (2.1 mM), bestatin 
(3.6 mM), pepstatin A (1.5 mM), and E-64 (1.4 mM). 
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4.3.4 Phosphoprotein Stain  
The percent replacement of endogenous cTnI with mutant cTnI in the TG-E mice was 
measured using a phosphoprotein stain. This protocol has been used to identify cardiac protein 
phosphorylation states by others [30, 69]. One set of myofibrils were treated with 20 mU PKA 
and 30 mU PKC at 37 oC for 2 hours to ensure all five phosphorylation sites in the WT mouse, 
and the remaining phosphorylation sites (two sites on the mutant cTnI and five sites on the 
endogenous cTnI) in the TG-E cTnI were maximally phosphorylated. A second set of myofibrils 
were untreated. These were then loaded on a 12.5% 8x10cm SDS-PAGE gel (1mm thickness). 
The gel was run for 60 minutes at 200V, fixed in 50% methanol and 10% acetic acid, then 
stained with Pro-Q diamond phosphoprotein stain (Invitrogen, Carlsbad, CA) [74] according to 
the manufacturer’s protocol. The gel was visualized with a custom gel scanner with an excitation 
filter of 560 nm and an emission filter of 590 nm. The gel was subsequently stained with SYPRO 
ruby total protein stain (Invitrogen) to control for differences in loaded protein. Once the gel was 
stained and rinsed according to the manufacturer, the gel was excited with UV illumination and 
visualized with a 600 nm emission filter. Band intensity was quantified using densitometry with 
ImageJ software (National Institutes of Health, Bethesda, MD). 
4.3.5 Phosphoprotein Data analysis  
There were two goals in the analysis of the measured band intensity from the 
phosphoprotein stain. The first was the determination of the percent replacement in the TG-E 
mouse, and the second was the identification of the basal phosphorylation state of the WT and 
TG-E mice. 
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Let n = total number of cTnI molecules, assumed to be the same for wild-type (WT) or 
TG-E mice; fM: fraction of mutant cTnI protein in TG-E mice; XWT and XTG: basal degree of cTnI 
phosphorylation for WT and TG-E mice, respectively (0: no phosphorylation, 1: full (maximal) 
phosphorylation); APWT and APTG: actual cTnI phosphorylation for WT and TG-E mice, 
respectively; TPWT and TPTG: total (= actual + pseudo) cTnI phosphorylation for WT and TG-E 
mice, respectively (note: for WT mice, TPWT = APWT). 
The phosphoprotein stain does not recognize pseudo-phosphorylation and therefore 
quantifies actual phosphorylation only. Actual cTnI phosphorylation under basal conditions for 
WT (APWT_base) and TG-E (APTG_base) mice can be written as: 
 WTbaseWT nXAP 5_ =  (4.1) 
 ( ) ( ) TGmTGmTGmbaseTG nXfXnfXfnAP 35215_ −=+−=  (4.2) 
Thus, actual cTnI phosphorylation under full (maximal) phosphorylation conditions (i.e., 
XWT = XTG = 1), for the two groups can be written as: 
 nAPWT 5max_ =  (4.3) 
 ( )nfAP mTG 35max_ −=  (4.4) 
Dividing Equation 4.4 by Equation 4.3, the fraction of mutant cTnI prtotein (fm) can be 
written as (Ractual_max 
max_
max_
WT
TG
AP
AP
= ): 
 [ ]max_13
5
actualm Rf −=  (4.5) 
Dividing Equation 4.2 by Equation 4.1, the ratio of actual phosphorylation under basal 
conditions, Ractual_base (
baseWT
baseTG
AP
AP
_
_= ), can be written as: 
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5
35
_
−
=  (4.6) 
Substituting fm from Equation 4.5, Equation 4.6 can be rewritten to express 
WT
TG
X
X
 in 
terms of measured quantities (Ractual_max and Ractual_base) as:  
 
max_
_
actual
baseactual
WT
TG
R
R
X
X
=  (4.7) 
Total cTnI phosphorylation levels (actual + pseudo) under basal conditions for the two 
groups are given by: 
 WTbaseWT nXTP 5_ =  (4.8) 
 ( ) mTGmbaseTG nfnXfTP 335_ +−=  (4.9) 
Dividing Equation 4.8 by Equation 4.9, the ratio of total phosphorylation, Rtotal_base can 
be written as: 
 (4.10) 
 
This analysis makes two key assumptions. The first is assumption is there are only five 
phosphorylation sites on cTnI. This is most likely false (see Section 1.4 ), but is still a safe 
assumption because it is conservative. If you assume that there are six phosphorylation sites, 
instead of five, the fractional coefficient on Equation 4.5 becomes 6/3 instead of 5/3, leading to a 
larger estimation of fm. Therefore, the more phosphorylation sites there are, the larger the percent 
replacement estimate. 
The second assumption is more difficult. The cTnI was treated with high doses of PKA 
and PKC, and assumed that it was fully phosphorylated. It may be very difficult or nearly 
impossible, however, to fully phosphorylate cTnI. In order to test this possibility, we needed to 
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collaborate with an outside group, as we did not have the capabilities here. These data and 
analyses is shown in Section 4.4. 
4.3.6 Western Blots 
Immunoblotting (Western blots) was performed on cellular lysate and myofibrillar 
samples to quantify total cTnI protein and its myofilamental stoichiometry. The myofibrilar 
isolation protocol was slightly altered from Section 4.2.3 . To prepare samples, the ventricular 
tissue was isolated from the excised heart and then homogenized in homogenizing buffer (75 
mmol/L KCl, 10 mmol/L imidazole (pH 7.2), 2 mmol/L MgCl2, 2 mmol/L EGTA, 1 mmol/L 
NaN3, 4 mmol/L creatine phosphate, 1 mmol/L ATP, 50 mmol/L BDM, 1 mmol/L DTT, 0.1 
mmol/L PMSF, 10 mmol/L EDTA) [75]. This was centrifuged and resuspended in standard rigor 
buffer plus 1% Triton X-100 (v/v) multiple times. The isolated pellet was the myofibrils, and the 
supernatant was the cell lysate. Myofibril and cell lysate samples were separated by SDS-PAGE 
(10% separating gel, Bio-Rad Laboratories, Hercules, CA). Separated proteins were then 
transferred to a nitrocellulose membrane (Bio-Rad), at 4 ºC at 90V for 90 minutes. The 
membrane was then placed in blocking buffer (Odyssey, LI-COR Biosciences Lincoln, NE) for 1 
hour at room temperature. WT and TG-E myofibrils were treated with mouse monoclonal cTnI 
antibody (clone 19C7, Fitzgerald, Concord, MA) and mouse monoclonal β-actin antibody 
(Abcam, Cambridge, MA, USA). The entire cellular content (myofibrils plus supernatant) from 
the WT and TG-E mice were treated with mouse monoclonal cTnI antibody and mouse 
monoclonal GAPDH (glyceraldehyde 3-phosphate dehydrogenase) antibody (AbD Serotec, 
Raleigh, NC). Primary antibodies were visualized with IR-Dye 800 donkey anti-mouse 
secondary antibody (Rockland Immunochemicals, Gilbertsville, PA). All proteins were 
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visualized using an infrared western blot imaging system (Odyssey). Band intensity was 
quantified using densitometry using ImageJ software. 
4.3.7 Hemotoxylin and Eosin Staining  
Left ventricular tissue from wild-type (WT) and transgenic (TG-E) mice was fixed with 
2% paraformaldehyde PBS at 4 °C for four hours, and then cryoprotected in 30% sucrose in PBS 
at 4 °C for at least 24 hours. The samples were submerged in OCT (Optimal Cutting 
Temperature) compound and frozen in isopentane over liquid N2, and then sliced into 6 μm 
sections and placed on glass slides. Samples were then stored at -80 °C until they could be 
stained.  
The samples were stained with 0.1% Mayers Hematoxylin solution (Sigma) and 0.5% 
alcoholic Eosin Y solution. After each stain, the sample was washed with ethanol. Samples were 
mounted and coversliped with Cytoseal XYL mounting medium (Fisher). Samples were 
visualized on a fluorescence microscope (Nikon Instruments Inc, Melville, NY). Analysis of 
images to determine myocyte size and number was done using MetaMorph software (Molecular 
Devices Corporation, Downington, PA). 
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4.4 RESULTS 
4.4.1 PCR Results 
PCR was run on every TG-E mouse that descended from the original founder mouse. The 
original plasmid was run on every gel as a positive control. Gels were run in duplicate. If there 
was any ambiguity, such as an unclear band, the sample was run a third or fourth time until two 
subsequent gels yielded clear results. Mice were only subjected to experiments if they were 
confirmed positive by two PCR runs. 
 
 
Figure 4-3. Representative PCR Gel 
 
Figure 4 -3 shows a representative agarose gel of PCR results. Since the primers only 
bind to the mutant DNA sequence, the presence of a band indicates the presence of the mutant 
DNA. The first lane on the left is the negative control, containing only loading buffer and PCR 
cocktail. The next two lanes were confirmed positive transgenic mice, the next two confirmed 
negative mice. The right lane is the plasmid for positive control.  
 30 
4.4.2 DNA Sequencing Results 
While the PCR data were intended to confirm the presence of the mutant cTnI DNA in 
the transgenic mice, it was important to confirm that the sequence of this DNA contained the 
specific point mutations at positions 43, 45 and 144.  
Figure 4-4 and Figure 4-5 compare the DNA from a transgenic mouse and the plasmid 
for the α-MHC promoter and cTnI, respectively. There is a high degree of homology (97% for 
the α-MHC promoter and 99% cTnI) between the plasmid and transgenic mouse sequences, 
indicating the presence of mutant DNA in the transgenic mice. 
 
 
Figure 4-4. α-MHC Plasmid Sequence Versus Sequence from TG-E Mouse 
The top sequence is from a PCR-confirmed positive TG-E mouse, and the bottom sequence is from the plasmid used 
to generate the mouse. There is greater than 97% agreement between the two sequences. If the nucleotide could not 
be reliably identified, the position was marked with an ‘N’ in the sample sequence.. 
 
More specifically, the TG-E mouse possesses the base pair sequence GAA, indicating 
glutamates, at sites 43 and 45 (indicated by the underlined sections in Figure 4 -5), indicating 
that the point mutations are expressed in the transgenic mouse’s DNA. The third site, 144, was 
Sample  TCNTCCATCTGTNNCTACTCTCTCTGCCTTGCCTTCTTGTGTGTTCTCCTTTTCCACGTG 
        :  :::::::::  :::::::::::::::::::::::::::::::::::::::::::::: 
Plasmid TACTCCATCTGTCTCTACTCTCTCTGCCTTGCCTTCTTGTGTGTTCTCCTTTTCCACGTG 
 
Sample  TTTCTCACTCCACTGCCTCCCCCCCCCC-TTCATTTTTATCCTTCCTTTCTTTCTGTGTC 
        :::::::::::::::::::::::::::: ::::::::::::::::::::::::::::::: 
Plasmid TTTCTCACTCCACTGCCTCCCCCCCCCCCTTCATTTTTATCCTTCCTTTCTTTCTGTGTC 
 
Sample  ANAATGCTGGGAATCAAACCCAGGGCTTCATACACGTCAAGTAAGCAATCTCCCAGTGAG 
        : :::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Plasmid AGAATGCTGGGAATCAAACCCAGGGCTTCATACACGTCAAGTAAGCAATCTCCCAGTGAG 
 
Sample  CCAAAGCTT 
        :::::::::                                                    
Plasmid CCAAAGCTT 
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too far downstream to confirm its presence by sequencing, and so we remain uncertain that it 
was mutated. However, it is unlikely that only two of the three mutated sites were expressed.  
 
 
Figure 4-5. cTnI Sequence from Plasmid Versus TG-E mouse 
The top sequence is from a PCR-confirmed positive TG-E mouse. It shows greater than 99% agreement with the 
plasmid sequence below it. The underlined sections (in the third line) represent the cTnI positions 43 and 45, which 
were mutated from serines to glutamates (GAA). The underlined sections show that the sample did incorporate the 
base pair changes. 
4.4.3 Phosphoprotein Stain 
Phosphorylation levels of maximally phosphorylated cTnI (PKA and PKC-treated) were 
used to calculate the fraction (fM) of endogenous cTnI that has been replaced with the mutant 
form. First, the ratio of the intensity of the cTnI phosphoprotein stain to total cTnI protein stain 
for the WT (RWT) and transgenic (RTG) mice was calculated (Figure 4-6).  
 
Sample  -----------------ATGGCTGATGAAAGCAGCGATGCGGCTGGGGAACCGCAGCCTG 
                         ::::::::::::::::::::::::::::::::::::::::::: 
Plasmid -----------------ATGGCTGATGAAAGCAGCGATGCGGCTGGGGAACCGCAGCCTG 
 
Sample  CGCCTGCTCCTGTCCGACGCCGCTCCTCTGCCAACTACCGAGCCTATGCCACCGAGCCAC 
        :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Plasmid CGCCTGCTCCTGTCCGACGCCGCTCCTCTGCCAACTACCGAGCCTATGCCACCGAGCCAC 
 
Sample  ACNCCAAGAAAAAGTCTAAGATCGAAGCCGAAAGAAAACTTCAGTTGAAGACTCTGATGC 
        :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Plasmid ACGCCAAGAAAAAGTCTAAGATCGAAGCCGAAAGAAAACTTCAGTTGAAGACTCTGATGC 
 
Sample  TGCAGATTGCGAAGCAGGAGA 
        ::::::::::::::::::::: 
Plasmid TGCAGATTGCGAAGCAGGAGA 
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Figure 4-6. Phosphoprotein Assay on PKA and PKC Treated Samples 
SDS-PAGE gel stained with Pro-Q Diamond phosphoprotein stain (top panel) and subsequently with SYPRO Ruby 
total protein stain (bottom panel). The arrow shows the cTnI bands in the WT, TG and hcTnI (human cardiac 
troponin I) lanes. Image was cropped to remove irrelevant lanes from same gel. WT and TG samples were treated 
with PKA and PKC. Band intensity of phosphoprotein stain (A.U.): WT = 113, TG-E = 144, and total protein stain: 
WT = 1047, TG-E = 1666. This yielded RWT = 0.108, RTG = 0.087, and thus a Ractual_max = 0.80, suggesting that there 
is 20% less phosphorylation in the TG-E sample. 
 
The ratio of these two numbers (Ractual_max = RTG/RWT) is the relative level of maximal 
phosphorylation of cTnI in the TG-E mice as a fraction of the maximal phosphorylation level of 
the cTnI in WT mice. Based on the measured value of Ractual_max (0.79 ± 0.02, n = 4) and 
Equation 4.5, the replacement of endogenous cTnI with mutant cTnI was 35.6 ± 3.7%. 
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Figure 4-7. Phosphoprotein Assay on Untreated Samples 
The procedure was also performed on untreated samples; the top panel is the phosphoprotein stain and the bottom 
panel is the total protein stain. Band intensity of the phosphoprotein stain (A.U.): WT = 30.5, TG-E = 21.0, and total 
protein stain: WT = 101, TG-E = 97. This yielded RWT = 0.300, and RTG = 0.216, and thus Ractual_base = 0.721, 
suggesting 27% less phosphorylation in the TG sample. 
 
The phosphoprotein assay was used on a second set of myofibrils not treated with PKA 
or PKC to quantify the relative level of actual phosphorylation under the baseline condition in 
the TG-E mouse (Figure 4-7). The value of Ractual_base for the untreated samples was 0.75 ± 0.02 
(n = 3). Given that Ractual_base (0.75 ± 0.02, n = 3) is not statistically different from Ractual_max (0.79 
± 0.02, n = 4), Equation 4.7 shows that the basal degree of cTnI phosphorylation for WT and 
TG-E mice is equal. Thus, Equation 4.10 can be simplified to yield: 
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Where TPWT_base and TPTG_base are total (= actual + pseudo) cTnI phosphorylation for WT 
and TG-E mice, respectively. It can be seen that Rtotal_base is greater than one (since 10 ≤≤ WTX  
and 10 ≤≤ mf  by definition). This suggests that the TG-E mice have greater total 
phosphorylation than the WT mice. 
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4.4.4 Western Blots 
While it has been shown that the physiological stoichiometry of myofilament proteins is 
maintained in other troponin mutants [76], it is important to examine cTnI expression due to the 
addition of the transgene in this mouse. A representative gel is shown in Figure 4-8. 
 
 
Figure 4-8. Western blot of TG-E versus WT samples 
Western blot on myofibrils (top panel) and total cellular lysate (bottom panel), using monoclonal antibodies anti β-
actin, anti cTnI (cardiac troponin I) and anti GAPDH (glyceraldehyde 3-phosphate dehydrogenase). 
 
In the TG-E mouse, Western blots revealed that there were no differences in the ratio of 
the intensity of the cTnI and β-actin bands (WT: 1.54 ± 0.07, TG-E: 1.47 ± 0.19, n = 2, P = 
0.65), or the cTnI to GAPDH bands (WT: 1.59 ± 0.17, TG-E: 1.43 ± 0.16, n = 2, P = 0.43), 
indicating that the mutant cTnI was incorporated into the myofilament in such a way that native 
stoichiometry was maintained. 
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4.4.5 Histology 
The hematoxylin and eosin stained LV sections from WT (Figure 4 -9A) and TG-E 
samples (Figure 4-9B) showed similar cell area as a percent of total image area (WT: 81.5 ± 1.6 
%, n = 2 animals,  TG-E: 78.4 ± 0.4 %, n = 2 animals, P = NS) and a similar number of nuclei 
(WT: 111 ± 11, n = 2, TG-E: 111 ± 8, n = 2 animals, P = NS) in a 100 x 100 pixel segment of the 
image.  
 
Figure 4-9. H&E Stained Sections from WT and TG-E mice 
Hematoxylin and eosin stained sections from WT (panel A) and TG-E (panel B) mice. Magnification: 20X. 
Numerical analysis of cell area and number of nuclei showed no statistical differences. 
 
These numerical data suggest that there are no histological abnormalities in the TG-E 
mice. Furthermore, the images show no obvious differences in cell shape or orientation. 
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4.5 2D-DIGE 
The 2D-DIGE (Difference In Gel Electrophoresis) was done in collaboration with Dr. R. 
John Solaro, Chad Warren and the University of Illinois at Chicago Proteomics Core. 
4.5.1 Methods 
Two sets of samples were sent to University of Illinois at Chicago for analysis. The first 
set were WT myofibrils treated with PKA and PKC as described in Section 4.2.4. The second set 
were WT and TG-E liquid nitrogen frozen mouse tissue.  
For the PKA and PKC treated myofibrils, samples were randomly labeled with 
fluorescent cyanine dyes (Cy2, Cy3, and Cy5) from GE Healthcare (Piscataway, NJ) to control 
for any dye differences. Protein samples were labeled by adding 100 pmoles of CyDye to 50 μg 
of protein and then quenched with 10 mM L-lysine [77]. The gel’s first dimension was focused 
using the Protean IEF cell (BioRad, Hercules, CA) with pH 4-7 or 7-11 IPG strips. The samples 
were actively rehydrated at 50 V in 18 cm IPG strips pH 4-7, or 7-11NL 10-16 hrs with 80-120 
μg of total protein (40 μg/channel). The focusing in the first dimension was achieved using a 
preset linear program: 250 V rapid ramping for 15 min, 10,000 V linear ramping for 3 hours, 
10,000 V rapid ramping until 60,000 V•hours [78]. The strips were equilibrated and laid onto 
12% SDS-PAGE gels [77, 79]. Gels were imaged with a Typhoon 9410 scanned at 100 µm and 
analyzed with PDQuest software (v7.1, BioRad, Hercules, CA). 
In the case of the frozen mouse tissue samples, the liquid nitrogen frozen mouse tissue 
was homogenized twice in standard relax buffer (10 mmol/L Imidazole pH 7.2, 75 mmol/L KCL, 
2 mmol/L MgCl2, 2 mmol/L EDTA, and 1 mmol/L NaN3) with 1% (v/v) Triton X-100 [75]. For 
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the untreated samples, the pellet was solubilized in UTC buffer (8 mol/L urea, 2 mol/L thiourea, 
and 4% (w/v) CHAPS). The phosphatase treated samples were washed twice in phosphatase 
buffer (25 mmol/L Tris-HCl pH7.0, 0.2 mmol/L MnCl2, 0.1 mmol/L EDTA, 5 mmol/L DTT and 
mammalian protease inhibitors from Sigma 1:100) then resuspended in 50 μL phosphatase buffer 
plus PP1A (10 units) and PP2A1 (0.1 unit) (Calbiochem). The samples were then allowed to 
incubate for 4 hrs at 37°C to completely de-phosphorylate the cTnI. After the incubation period, 
myofibrils were spun down and the supernatant was removed. The pellet was resuspended in 
UTC buffer. Protein (in UTC buffer) concentration was determined with an RC-DC assay kit 
(BioRad, Hercules, CA). Samples in UTC buffer (100 μg) were cleaned up with GE Healthcare’s 
2D clean-up kit (Piscataway, NJ) and then re-suspended in UTC buffer. 
These samples were then labeled and run on 2D gels as described for the first set of 
samples; gels were then transferred on polyvinylidene fluoride (PVDF) membrane and analyzed 
as previously described [80]. The primary antibody used for cTnI was a pan monoclonal C5 
1:5000 (Fitzgerald) and the secondary antibody was an anti-mouse-IgG (FAB) specific 1:100000 
(Sigma). 
4.5.2 Results 
Two sets of samples were subjected to 2D-DIGE. The first samples were those run on the 
phosphoprotein stain, in order to determine the accuracy of our assumption that cTnI had been 
fully phosphorylated by the PKA and PKC treatment. The PKA and PKC treated samples (n=3) 
were never fully phosphorylated, and never reduced the unphosphorylated species to zero. A 
representative 2D-DIGE gel is shown in Figure 4-10. One of the key assumptions in the analysis 
of the phosphoprotein data is proven incorrect, and another analysis was needed.  
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Significantly increasing the dose of PKA and PKC treatment was unrealistic due to cost 
issues. One possible method was to treat the heart tissue with PKA and PKC activators before 
creating the myofibrils. However, given the success with 2D-DIGE, we decided to perform our 
analysis using this technique. 
 
 
Figure 4-10. 2D-DIGE of PKA and PKC WT Myofibrils 
Representative 2D-DIGE gel of myofibrils treated with PKA and PKC. P-cTnI: phosphorylated forms of cTnI, U: 
unphosphorylated form of cTnI. 
 
Proteins from WT and TG-E myofibrils were separated using 2D-DIGE (Figure 4-11A). 
The 2D-DIGE gels were capable of separating the individual phospho-species of cTnI (U: 
unphosphorylated cTnI, P1: phosphorylated at one site, P2: two, P3: three, P4: four, P5: five 
sites). In TG-E samples, there was an additional spot near P3, indicated by an asterisk in Figure 
4-11A, which was not present in the WT samples. We postulated that this spot represented 
mutant cTnI, given the mutant cTnI is pseudo-phosphorylated at three sites. 
To confirm that this spot was constitutively pseudo-phosphorylated mutant cTnI, we 
treated WT and TG-E myofibrils with PP1A and PP2A1 to de-phosphorylate cTnI (Figure 4 -
11B). The WT cTnI spot profile was reduced to only the U (unphosphorylated) spot, indicating 
complete dephosphorylation. In the phosphatase-treated TG-E samples, there were two spots: U 
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and mutant cTnI (indicated by an asterisk in Figure 4 -11B). The ratio of the intensity of the 
mutant cTnI spot to the total intensity (i.e., sum of unphosphorylated (U) and mutant spots) 
represents the percent replacement, which was 7.2 ± 0.5% (n = 9, P < 0.001 versus no change, 
Table 1). 
To verify the protein identity of the spots, membrane transfers of the 2D-DIGE gels were 
probed with a specific pan cTnI antibody. Figure 4 -11C illustrates multiple spots in the 
untreated samples whereas only one spot is visible in the phosphatase-treated sample, a pattern 
similar to that in the 2D-DIGE gels (Figures 4-11A and Figure 4-11B, second panels). All six 
spots are not seen in this example due to low abundance of P4 and P5. The mutant cTnI spot was 
also confirmed by Western analysis (data not shown). 
There were no differences in the relative spot intensities (U, P1-P5) of cTnI in the WT 
and TG-E samples, except the presence of the mutant cTnI spot (Figure 4 -11A and Table 1 ). 
This indicates that the basal actual phosphorylation of cTnI was unchanged in the transgenic 
mouse. Moreover, there were no differences in the phosphorylation levels of cardiac troponin T 
(cTnT), tropomyosin (Tm), myosin regulatory light chain (RLC), or myosin binding protein C 
(MyBP-C) (Figure 4-11D and Table 1; n: WT = 4, TG-E = 4) . 
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Figure 4-11. 2D-DIGE Data from WT and TG-E Samples 
Analysis of cardiac troponin I (cTnI) by 2D-DIGE. *, mutant cTnI; Px, phosphorylated spot (where x = number of 
sites phosphorylated); U, un-phosphorylated spot. pH values indicate the strip that was used for the first dimension. 
Samples were labeled separately with different CyDyes and mixed to run in the same 2D gel. (A) Representative 
image of untreated WT and TG-E samples run on a 2D-DIGE gel that was utilized to determine phosphorylation 
levels of cTnI. Notice the mutant cTnI near the P3 spot. (B) Phosphatase treated (PP1A and PP2A1) WT and TG-E 
samples and a non-treated TG-E sample. Percent replacement was 7.2 ± 0.5% expressed as mean ± S.E.M. (n=9). 
(C) Western blot analysis to verify cTnI spots and the complete de-phosphorylation of cTnI by PP1A and PP2A1. 
Note: P4 and P5 are not shown due to low abundance, however with longer exposure time we positively identified 
these spots, but the others were saturated. (D) Representative 2D-DIGE gel (only one channel shown) utilized to 
determine phosphorylation levels of the sarcomeric proteins (n = 4). TM, tropomyosin; RLC, regulatory light chain; 
TnT3or4, troponin T isoform 3 or 4; MyBP-C 1-11, myosin binding protein C spots labeled arbitrarily; and ELC, 
essential light chain. 
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Table 1. Quantification of Percent Replacement and Protein Phosphorylation 
 
Values are expressed as mean ± S.E.M.. TM-P: phosphorylated tropomyosin, RLC-P: phosphorylated myosin 
regulatory light chain, cTnT-P: phosphorylated troponin T, cTnI-P – cTnI-P5: phosphorylated cTnI (at 1 – 5 sites), 
S1-S11-MyBP-C: myosin binding protein-C. Quantification of percent phosphorylation of the total indicated by P 
(n=4). The percent replacement of the mutant troponin I is labeled as replacement (n=9).  The percent of myosin 
binding protein C spot of the total myosin binding protein C spots labeled as S1 through S11 n=4.  Note: There were 
no significant differences between WT and TG-E. 
 
WT TG-E
REPLACEMENT N/A 7.2 ±0.5%
TM-P 46.3±7.0% 36.5±4.7
RLC-P 19.5±1.2% 21.3±1.4%
cTnT-P 56.9±0.9% 56.3±0.6%
cTnI-P1 27.6±1.3% 27.3±1.6%
cTnI-P2 12.5±1.0% 13.2±0.9%
cTnI-P3 20.0±1.6% 19.2±1.4%
cTnI-P4 9.9±0.8% 10.1±0.5%
cTnI-P5 3.9±1.3% 4.1±0.5%
S1-MyBP-C/TOTAL 6.7±0.8% 6.2±0.4%
S2-MyBP-C/TOTAL 8.3±0.7% 7.3±0.9%
S3-MyBP-C/TOTAL 11.7±1.6% 11.5±1.3%
S4-MyBP-C/TOTAL 13.3±0.4% 12.8±0.7%
S5-MyBP-C/TOTAL 9.6±2.3% 11.8±1.7%
S6-MyBP-C/TOTAL 6.2±1.8% 4.7±1.6%
S7-MyBP-C/TOTAL 14.3±0.9% 13.9±0.6%
S8-MyBP-C/TOTAL 6.6±1.2% 6.1±1.1%
S9-MyBP-C/TOTAL 7.0±1.4% 8.4±0.8%
S10-MyBP-C/TOTAL 10.3±1.3% 11.0±1.5%
S11-MyBP-C/TOTAL 5.9±1.1% 6.4±0.7%
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4.6 SUMMARY 
It was confirmed that the TG-E mice successfully incorporated the mutant DNA. 
The analysis of the phosphoprotein stain was not a reliable assay for determining percent 
replacement of endogenous cTnI in the TG-E mouse. With the assistance of the University of 
Illinois at Chicago Proteomics core, we were able to determine the percent replacement using 
2D-DIGE. The TG-E mice had 7.2 ± 0.5% replacement of endogenous cTnI with the mutant 
form. 
Moreover, there were no differences in overall cTnI expression, phosphorylation of other 
myofilamental proteins, or histology. Overall, the mutant mouse was confirmed as a useful 
research tool, although the low expression of mutant cTnI may be of concern.  
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5.0  WHOLE ORGAN STUDIES 
5.1 INTRODUCTION 
Hypothesis 1:  Increased cTnI phosphorylation at the PKC sites will result in systolic 
dysfunction and protection from ischemic contracture at the whole organ level.  
 
 Specific Aim 1a: Determine differences in in vivo cardiac function (echocardiography) in 
WT (baseline) and TG-E (increased cTnI phosphorylation at the PKC sites) mice 
 Specific Aim 1b: Determine differences in ex vivo whole heart function (Langendorf) in 
WT (baseline) and TG-E (increased cTnI phosphorylation at the PKC sites) mice 
 
Non-invasive procedures allow the collection of data while minimizing the impact on the 
system. Imaging, such as echocardiography, can be used to determine function in the intact in 
vivo system, without possible artifacts from an artificial experimental condition. However, a 
minimally invasive procedure such as this does not isolate a single system, which can make it 
difficult to determine the nature of the observed functional effects. 
The perfused isolated heart preparation was performed by Oscar Langendorf in 1897 
(who lends his name to the procedure), and is still useful today [81]. Langendorf preparation 
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experiments have been done in the TG-A mouse [57, 60]. Those results will be discussed and 
compared to the results from the TG-E mouse.  
5.2 METHODS 
5.2.1 Echocardiography 
The mice were anesthetized with isoflurane (1.5% isoflurane induction and maintenance 
with 100% oxygen) via nose cone. The depth of anesthesia was monitored by toe reflex 
(extension of limbs, supine positioning). Isoflurane was selected because it is a quickly 
reversible anesthetic; once administration is completed, the animal recovers quickly. 
Once the plane of anesthesia was established, the animal was placed in a supine position 
on a warmed pad. The hair on the chest was removed using Nair® Lotion (Church & Dwight 
Co., Inc., Princeton, NJ) and prepared for echocardiographic examination. Echocardiography 
was used to take measurements of left ventricular dimensions (M-mode), pulmonary artery flow 
right above the pulmonary valve, and aortic flow just above the aortic valve (via Doppler 
imaging). Data were collected via a 13 MHz linear array probe (model 15L8, Acuson, Mountain 
View CA). Hemodynamic measurements were performed once on mice ranging from 4-6 months 
of age.  
Upon completion of the echocardiographic examination, the chest was cleaned and wiped 
dry, and the animal was maintained on the warming pad until it had recovered. Then the animal 
was returned to its box and checked after ten minutes to confirm they were unaffected by the 
procedure.  
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5.2.2 Echocardiography: Data Analysis 
The echocardiographic data were analyzed using Access Point (version 2.0, Freeland, 
LLC., Boulder, CO). Data were collected for three subsequent beats, and then averaged to obtain 
a single value per animal.  
 Measured variables from the M-mode 1-D data included: septal wall end-systolic 
thickness (SWESt), left ventricular end-systolic diameter (LVESd), posterior wall end-systolic 
thickness (PWESt), septal wall end-diastolic thickness (SWEDt), ventricular end-diastolic 
diameter (LVEDd), and posterior wall end-diastolic thickness (PWEDt). Fractional shortening 
(FS) was calculated from the measured M-mode data by Equation 5.1. 
 FS(%) = �LVEDd-LVESdLVEDd � × 100 (5.1) 
Measured variables from Doppler data included: cycle length (CL), systolic time, and 
time to peak. Peak to diastolic time was calculated on a beat to beat basis as systolic time minus 
time to peak.  
 Reading echocardiographic images is subjective, especially in mice where the structures 
of interest are quite small. In order to correct for subjectivity when reading the images, a second 
person (trained in reading echocardiography images) also analyzed a subset of the data (4 total, 
picked randomly: 2 WT and 2 TG-E), and was blinded to genotype. The error between the two 
readings, the intra-observer error [82], was calculated as the percent difference between the 
original reading and the second reading, as shown in Table 2.  
 There was very high intra-observer error in the septal wall thickness measurements 
during systole (74%) and diastole (60%), as well as posterior wall thickness during systole (19%) 
and diastole (22%). These measurements were only an order of magnitude greater than the 
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resolution of the images, and so it is of little surprise that the error was large. These 
measurements were removed from further analysis. The other measurements had low intra-
observer errors (LVESd, LVEDd, cycle length, systolic time and diastolic time), and statistical 
analysis was performed on these. 
 
Table 2. Echocardiographic Intra-Observer Error 
 
Values are mean ± S.E.M.. Top table shows intra-observer errors for all measured parameters. Bottom table shows 
error for parameters that had error ≤ 10%, which were included for statistical analysis. 
 
Error (n = 4)
M-Mode
Systole
  Septal Wall Thickness (%) 74 ± 64
  Ventricular Diameter (%) 5 ± 4
  Posterior Wall Thickness (%) 19 ± 14
Diastole
  Septal Wall Thickness (%) 60 ± 70
  Ventricular Diameter (%) 3 ± 2
  Posterior Wall Thickness (%) 22 ± 10
Pulmonary Flow
  Cycle Length (%) 2 ± 1
  Systolic Time (%) 6 ± 4
  Time to Peak (%) 10 ± 5
Error (n = 4)
M-Mode
   LVESd (%) 5 ± 4
   LVEDd (%) 3 ± 2
Pulmonary Flow
   Cycle Length (%) 2 ± 1
   Systolic Time (%) 6 ± 4
   Time to Peak (%) 10 ± 5
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 The top section in Table 2 shows the error in all measured parameters, while the bottom 
section indicates the error in the measured parameters that had acceptable levels of intra-observer 
error. 
5.2.3 Isolated Heart 
Isolated heart preparations were similar to those we have done in the past [83]. Male WT 
FVB and TG-E mice of similar age (121 – 140 days) were used. The mice were anesthetized 
with an intraperitoneal injection of Avertin (2,2,2-tribromoethanol, 250 mg/kg body weight). 
Animals were then anticoagulated using 100 units of heparin. Once the heart was excised from 
the animal, the aorta was quickly cannulated, and the atria were removed. The heart was perfused 
in retrograde fashion at a constant pressure of 70-80 mmHg. Tissue culture medium (Media 199, 
Invitrogen, Carlsbad, CA) was used as the perfusate (1.8 mmol/L [Ca]). To this solution the 
following were added: creatine (5.0 mmol/L), taurine (4.8 mmol/L), carnitine (6.0 mmol/L), 
sodium pyruvate (2.5 mmol/L), insulin (8 µmol/L), and metoprolol (5.0 µmol/L, to eliminate 
pacing-induced catecholamine release). The solution was oxygenated with 95% O2 and 5% CO2, 
pH adjusted to 7.4, and temperature maintained at 37 oC. A balloon made from high density 
polyethylene (HDPE) was placed in the left ventricle through the mitral valve and secured with a 
suture though the left ventricular apex. A catheter-tip pressure transducer (MPC-500, Millar 
Instruments, Houston, TX) was used to measure left ventricular pressure. The balloon volume 
was altered using a thumb-screw controlled 100 µL micro-syringe (Hamilton Gas Tight, Reno, 
NV). Platinum pacing electrodes were placed on the heart, which was then paced at 4 Hz using a 
stimulator (Harvard Apparatus, Holliston, MA). Pressure data were digitized on-line at 500 Hz 
for later offline analysis. 
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When the experiment was complete, the heart was removed from the apparatus. The left 
and right ventricles were separated, blotted dry, and then weighed (see Section 1.7 for results). 
5.2.4 Isolated Heart: Protocols 
A Frank Starling protocol was performed on all of the isolated hearts. A reference LV 
volume (Vref, typically 10–12 µl) was set by adjusting the balloon volume to yield a LV end 
diastolic pressure of 5 mmHg. Pressure data were continuously recorded over a 2 minute period. 
The first 20 seconds corresponded to data at the reference volume, followed by a period wherein 
LV volume was increased in 2 µl increments to the point when developed pressure had reached 
its maximum value (Vmax, Figure 5-1). The Frank Starling protocol alone was performed on one 
subset of experiments (WT: n = 6, transgenic, TG-E: n = 6).  
 
 
Figure 5-1. Frank Starling Protocol 
Typical 2-minute recording of left ventricular (LV) pressure before, during, and after increase in LV volume. LV 
pressure increased with increments in LV volume. There was no change in pressure when LV volume was held 
constant at the highest value for 80 s. Used from [83] with permission. 
 
In a second subset of the experiments (WT: n = 11, TG-E: n = 9), the Frank Starling 
protocol was performed, and then hearts were perfused as described above for a baseline period 
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of five minutes, after which retrograde aortic perfusion was halted for fifteen minutes, inducing 
global no-flow ischemia. Flow was then restored for twenty minutes which was called the 
reperfusion period. Pressure data were digitized at 100 Hz for the forty minute baseline-
ischemia-reperfusion period. 
In a third subset of the experiments (WT: n = 6, TG-E: n = 6), the Frank Starling protocol 
was performed, and then isolated hearts were treated with 1 μmol/L isoproterenol for ten 
minutes. A second Frank-Starling protocol was conducted on the heart post isoproterenol 
treatment.  
5.2.5 Isolated Heart: Data analysis  
In isolated heart experiments, individual cardiac cycles were first identified by using the 
spike in the pacer signal. Signal averaging over the cardiac cycle was then performed to reduce 
high-frequency random noise. Pressure data from five to seven steady state contractions at a 
given LV volume were averaged to yield a representative cycle. LV pressure waveforms were 
characterized by several amplitude and rate indices. Amplitude indices included end diastolic 
pressure (Ped), peak systolic pressure (Psys), and developed pressure (Pdev = Psys – Pdia). Rate 
indices included maximal rate of rise (dP/dtmax), maximal rate of fall (dP/dtmin), rise time (Trise), 
and relaxation time (Trelax). Trelax was defined as the time taken for developed pressure to decay 
from 75% to 25% of its maximum value. Similarly, Trise was defined as the time taken for 
pressure to rise from 25% to 75% of its maximum value. Calculations of Trelax and Trise were 
performed after the diastolic value of the pressure waveform was subtracted, such that each 
waveform rose from and declined to zero.  
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Wall stress (σ) was estimated using a thick-walled spherical model from Equation 5.2 
[84], 
 𝜎𝜎 = 𝑃𝑃
�1+𝑀𝑀
𝜌𝜌𝜌𝜌
�
23−1 (5.2) 
where P is pressure, M is the mass of the left ventricle, ρ is the density of muscle, which was 
assumed to be 1.05 g/ml, and V is the volume of the ventricle. Equation 5.2 was used to 
calculate σdev, σed, dσ/dtmax, and dσ/dtmin by using Pdev, Ped, dP/dtmax and dP/dtmin in place of P, 
respectively. 
5.2.6 Isolated Heart: Statistical Analysis  
For the isolated heart data, regression analysis with dummy variables was used to identify 
differences in various relationships between wild-type and transgenic groups: σdev–volume, 
dσ/dtmax–volume, Trelax–volume, dσ/dtmin–volume. Data were fit to the following linear regression 
model: 
 𝒀𝒀 = 𝒃𝒃𝟎𝟎 + 𝒃𝒃𝟏𝟏𝑿𝑿 + 𝒃𝒃𝟎𝟎𝟎𝟎𝑫𝑫 + 𝒃𝒃𝟏𝟏𝟎𝟎𝑿𝑿𝑫𝑫 (5.3) 
where Y is the response variable (σdev, dσ/dtmax, etc.), X is the predictor variable (volume), and D 
is the dummy variable, which differentiates between the control (WT: D = 0) and the treatment 
(TG-E: D = 1) groups, b0 is the intercept and b1 is the slope. If the values of b0X and b1X are 
statistically different from zero, the mutation had an effect on either the intercept (b0X) or slope 
(b1X) of the relationship [85].  
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5.3 RESULTS 
5.3.1 Echocardiography 
Sample images from the echocardiography studies are shown in Figure 5-2. The TG-E 
mice exhibited a decrease in fractional shortening (FS, WT: 50.7 ± 5.3, n=10, TG-E: 46.0 ± 5.6, 
n=10, see Table 3), but it was not statistically significant (P = 0.07). This decrease was not the 
result of diastolic dysfunction, as there were no differences in left ventricular end-diastolic 
diameter. The TG-E mice did show decreased contractility, however, evidenced by a greater left 
ventricular end-systolic diameter (WT: 1.66 ± 0.19, TG-E: 1.85 ± 0.25), which, like FS, was on 
the verge of statistical significance (P = 0.06). While the P-values for the differences in LVESd 
and EF are non-significant, their proximity to the threshold of significance is close.  
The lack of differences in LVEDd also indicates that the mutation in TG-E did not lead to 
any detectable enlargement of the left ventricle, suggesting no cardiac hypertrophy. However, we 
cannot be certain since we were unable to accurately measure wall thickness. 
The TG-E mice showed significantly increased cycle length and decreased heart rate 
(WT: 461 ± 31 bpm, TG-E; 426 ± 29 bpm, P = 0.02, Table 3). The increased cycle time came 
with an increased systolic time (WT: 65 ± 3 ms, TG-E: 68 ± 3 ms, P = 0.04). These changes 
were not due to the time to peak, or rise time, since that was actually shorter in the 
S43E/S45E/T144 mice. However, the peak to diastolic, relax time was longer in the TG-E mice 
(WT: 46 ± 3 ms, TG-E: 52 ± 4 ms, P = 0.001, Table 3).  
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Figure 5-2. Echocardiographic Images from WT and TG-E mice 
Representative images from WT (Panels A and C), and TG-E (Panels B and D) mice. Images are from 1-D M-mode 
of the left ventricle (Panels A and B) and Doppler of pulmonary arterial flow just outside the pulmonary valve 
(Panels C and D). The white horizontal bar represents 100 ms.  
 
Table 3. Echocardiographic Indices from WT and TG-E Mice 
 
Data are mean ± S.E.M.. LVESd: left ventricular end-systolic diameter, LVEDd: left ventricular end-diastolic 
diameter, FS: fractional shortening, HR: heart rate.  
  
WT (n = 10) TG-E (n = 10) P -value
M-Mode
   LVESd (mm) 1.66 ± 0.19 1.85 ± 0.25 0.06
   LVEDd (mm) 3.37 ± 0.22 3.42 ± 0.22 0.56
   FS (%) 50.7 ± 5.3 46.0 ± 5.6 0.07
Pulmonary Flow
   Cycle Length (ms) 131 ± 9 141 ± 9 0.02
   HR (bpm) 461 ± 31 426 ± 29 0.02
   Systolic Time (ms) 65 ± 3 68 ± 3 0.04
   Time to Peak (ms) 19 ± 2 16 ± 2 0.02
   Peak to Diastolic (ms) 46 ± 3 52 ± 4 0.001
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5.3.2 Isolated Heart 
5.3.2.1 Frank Starling Protocol 
Pressure waveforms are shown for the Frank Starling protocol from a representative 
individual WT (Figure 5-3A) and TG-E (Figure 5-3B) animal. Pdev and Ped were compiled for 
all animals (Figure 5-4). 
The TG-E mice showed no differences passive or diastolic properties compared to WT 
mice. There were no statistical differences in Ped (Figure 5-4, triangles) or σed (data not shown) 
over the entire range of volumes studied. 
 
 
Figure 5-3. WT and TG-E Frank Starling Raw Data 
Left ventricular (LV) pressure recordings for WT (A) and TG-E (B) mice as volume is increased from 12μL to Vmax. 
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Figure 5-4. Compiled Developed and Diastolic Indices 
Developed (circles) and diastolic (triangles) pressures for WT (closed) and TG-E (open) mice. Values are means ± 
S.E.M.. 
 
 
Figure 5-5. Stress-Volume Relationships for WT and TG-E Mice 
Effects of altered LV volume on σdev (developed stress) (A), dσ/dtmax (maximum time-derivative of stress) (B) in 
WT (closed) and TG-E (open) mice. The data were fitted to a linear trendline (WT: solid line, TG-E: dashed line). 
The slopes of the σdev – volume, and dσ/dtmax – volume relationships for the TG-E mice were significantly lower 
(P<0.05) than in the WT data.  
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The TG-E mice exhibited reduced systolic function. The slope of the σdev – volume 
relationship was reduced in TG-E mice (WT: 2.9 ± 0.1 mmHg•µl-1, n = 6, TG-E: 2.5 ± 0.1 
mmHg•µl-1, n = 6, P = 0.02), with no change in the intercept, indicating a 13% reduction in LV 
contractile state over all lengths (Figure 5-5A). Additionally, there was a decrease in the slope of 
the dσ/dtmax – volume relationship (WT: 0.084 ± 0.004 mmHg•ms-1•µl-1, n = 6, TG-E: 0.074 ± 
0.003 mmHg•ms-1•µl-1, n = 6, P = 0.03), with no change in the intercept, indicating a 12% 
decrease in the kinetic aspects of contraction (Figure 5-5B).  
 
 
Figure 5-6. Relaxation Indices for WT and TG-E Mice 
Effects of altered LV volume on Trelax (relaxation time from 75% to 25% peak developed pressure) (A), and dσ/dtmin 
(minimum time-derivative of stress) (B) in WT (closed) and TG-E (open) mice. The data were fitted to a linear 
trendline (WT: solid line, TG-E: dashed line). The intercept of the Trelax – volume relationship for the TG-E mice 
was significantly greater (P<0.05) than for the WT data. The magnitude of the slope of the dσ/dtmin – volume 
relationship for the TG-E mice was significantly lower (P<0.05) than for the WT data. 
 
The TG-E mice exhibited slowed relaxation as evidenced by a parallel, upward shift of 
the Trelax – volume relationship (intercept values: WT: 24 ± 1 ms, n = 6, TG-E: 30 ± 2 ms, n = 6, 
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P = 0.005), with no change in the slope, indicating a 20% increase in the time for the LV to relax 
(Figure 5-6A). Moreover, there was a decrease in the magnitude of the slope of the dσ/dtmin – 
volume relationship (WT: -0.067 ± 0.003 mmHg•ms-1•µl-1, n = 6, TG-E: -0.056 ± 0.003 
mmHg•s-1•µl-1, n = 6, P = 0.03), with no change in the intercept, indicating a 16% reduction in 
the kinetic aspects of relaxation (Figure 5-6B). 
5.3.2.2 Ischemia-Reperfusion Protocol 
TG-E mice showed no differences in systolic (Figure 5-7A) or diastolic (Figure 5-7B) 
pressure with respect to WT mice during the entire time course of the ischemia-reperfusion 
experiments. Of particular interest are the similar increases in diastolic pressure immediately 
following reperfusion (Figure 5-7B, 2nd vertical line), as this represents the degree of diastolic 
contracture (fold increase in diastolic pressure from baseline to reperfusion, WT: 4.6 ± 0.8, n = 9, 
TG-E: 3.9 ± 0.5, n = 11, P = 0.32).  
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Figure 5-7. Data from Ischemia-Reperfusion Experiments 
LV pressure from WT and TG-E mice during ischemia and reperfusion. At five minutes (first vertical line), coronary 
flow is reduced to zero and ischemia begins. At twenty minutes (second vertical line), flow is restored and 
reperfusion begins. Protocol lasts 40 minutes total. (A) Systolic pressures have been normalized to baseline values 
prior to ischemia. There were no statistical differences between WT (black) and TG-E (white) pressures. (B) 
Diastolic pressures have been normalized to baseline values prior to ischemia. The TG-E (white) mice showed no 
significant protection from diastolic contracture compared to WT (black). Data are mean ± S.E.M.. 
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5.3.2.3 Isoproterenol Protocol 
Treatment with 1 µM isoproterenol increased developed pressures to the same degree in 
both WT and TG-E mice (Table 4). The developed pressures after isoproterenol treatment, while 
not significantly different (P = 0.053), trended towards higher pressures in the WT (Pdev = 78 ± 6 
mmHg) than in TG-E (Pdev = 62 ± 4 mmHg). Isoproterenol also shortened rise and relaxation 
times to the same degree in WT and TG-E animals (see Table 4).  
 
Table 4. Effects of Isoproterenol Treatment 
 
Data represent index value post-isoproterenol treatment minus pre-isoproterenol treatment. There were no 
significant differences between the WT and TG-E responses to isoproterenol treatment. Data are mean ± S.E.M.. 
5.4 INADVERTENTLY INDUCED HYPOXIA 
Given that our perfusion medium (supplemented Media 199, see Section 5.2.3) has lower 
oxygen carrying capacity than blood, one needs to consider potentially confounding effects of 
hypoxia, especially at high LV volumes. In order to be certain we were not inducing ischemic 
effects in isolated hearts at high left ventricular volumes (at or near Vmax), we performed an 
isolated mouse heart experiment wherein LV volume was fixed at a high level (end-diastolic 
pressure ~30 mmHg) and perfusate O2 tension was measured with an ABL-5 Blood Gas 
WT (n = 7) TG-E (n = 7)
ΔPdev (mmHg) 28 ± 2 29 ± 3
Δ(dP/dtmax) (mmHg•ms
-1) 3.37 ± 0.35 3.20 ± 0.21
ΔTrise (ms) -14 ± 1 -14 ± 1
ΔTrelax (ms) -68 ± 13 -56 ± 12
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Analyzer (Radiometer, Copenhagen, Denmark) and reduced in stepwise fashion (controlled 
mixing of fully oxygenated and deoxygenated perfusate).  
Raw LV pressure data at each of the oxygenation conditions from the experiment are 
illustrated in Figure 5-8A; the first recording is for the fully oxygenated condition (pO2 = 921 
mmHg). Developed (Figure 5-8B) and end-diastolic (Figure 5-8C) pressures are plotted as a 
function of pO2. The initial 20% decrease in pO2 from the baseline level (i.e., from 921 to 736) 
caused only a small (1.5%) drop in developed pressure.  
Thus, it is unlikely that our baseline perfusate oxygenation status is on the verge of being 
a limiting factor for LV contractility. Furthermore, ischemia caused a significant rise in end-
diastolic pressure (see Section 5.3.2.2 ). We did not observe similar increases in end-diastolic 
pressure at a fixed volume in the isolated heart experiments. 
Moreover, while blood would be a better perfusion medium (efficient carrier and delivery 
of oxygen) than that used in this project, blood perfused mouse hearts showed values similar to 
ours [86]. In summary, we do not believe that ischemia was a confounding factor in our studies. 
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Figure 5-8. Effects of Reduced Oxygenation in an Isolated Heart 
Isolated mouse heart data (LV pressure at fixed LV volume) obtained at various perfusate oxygenation levels. (A) 
Segments of raw pressure data at each perfusate oxygenation level. (B) Values of developed pressure at each pO2. 
(C) Values of end-diastolic pressure at each pO2 studied. This is data from one mouse, but several experiments 
confirmed these results. 
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5.5 SUMMARY 
Hypothesis 1 : Increased cTnI phosphorylation at the PKC sites will result in systolic 
dysfunction and protection from ischemic contracture at the whole organ level.  
Compared to wild-type control mice, TG-E mice exhibited decreased systolic function in 
echocardiography studies (decreased fractional shortening, P=0.07) and isolated whole heart 
experiments (decreased developed pressure, P=0.02), with no evidence of diastolic dysfunction. 
Moreover, the TG-E mice exhibited slowed relaxation under echocardiography (increased peak 
to diastolic time, P=0.001) and isolated hearts (increased relaxation time, P=0.005). Compared to 
WT mice, the transgenic mice did not exhibit any additional protection from ischemic 
contracture.  
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6.0  FORCE-CALCIUM RELATIONSHIPS 
6.1 INTRODUCTION 
Hypothesis 2: Increased cTnI phosphorylation at the PKC sites will result in depressed  calcium-
force and ATP-force relationships (less force per calcium or ATP hydrolyzed). 
 
 Specific Aim 2a: Determine differences in the dynamic calcium-force relationship in 
intact papillary muscles under increased and baseline cTnI phosphorylation at the PKC 
sites (chronic and acute phosphorylation) 
 Specific Aim 2b: Determine differences in the static calcium-force and ATP-force 
relationships under increased and baseline cTnI phosphorylation at the PKC sites 
  
The goal of Specific Aims 1a and 1b was to determine the functional effects of PKC 
phosphorylation of cTnI. The goal of Specific Aims 2a and 2b is to determine if these functional 
effects are mediated through changes in calcium handling, the myofilament response to calcium, 
or energetics. 
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6.1.1 Myofibrilar ATPase Measurement 
In order to determine ATPase activity, we first used a myofibrilar ATPase assay. Myofibrils 
used in the ATPase assay were suspended in standard rigor buffer to a concentration of 
approximately 100µg/ml, and maximal Ca2+-activated actomyosin ATPase activity was measured 
as described by Liou and Fuchs [87]. The reaction was initiated by the addition of 1mM MgATP 
and terminated after 10min by the addition of an equal volume of 2% SDS [88]. Samples were 
then measured for inorganic phosphate content [89]. 
The myofibrilar maximal ATPase activity assay showed no differences between the WT 
and TG-E samples (WT = 172.3 ± 11.2 nmol•mg-1•min-1, n= 12, TG-E: 171.6 ± 6 nmol• 
mg-1•min-1, n=12, see Figure 6-1).  
 
 
Figure 6-1. Myofibrilar Maximal ATPase Activity 
Maximal calcium-activated ATPase activity for WT (black) and TG-E (white) myofibrils. No differences were seen 
in maximal ATPase activity in WT (172.3 ± 11.2 nmol mg-1 min-1) versus TG (171.6 ± 6.0 nmol mg-1 min-1) mice. 
Data are mean ± S.E.M.. 
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 Subsequent to this experiment, however, it was decided to directly compare ATPase 
activity to skinned fiber force generation. In order to make this comparison, the force and 
ATPase data needed to be collected simultaneously in the same fiber. Thus, this procedure was 
replaced with the skinned fiber ATPase assay described in Section 6.2.4.  
6.2 METHODS 
6.2.1 Isolated Papillary Muscle 
Male FVB mice of similar age and body mass were anesthetized with inhaled isoflurane, 
and then cervically dislocated. The heart was quickly excised and placed in modified Krebs-
Henseleit (KH) solution containing 30 mmol/L 2,3-butadione monoxime (BDM). The KH 
solution contained NaCl (141 mmol/L), Dextrose (50 mmol/L), NaHCO3 (25 mmol/L), HEPES 
(5 mmol/L), KCl (5 mmol/L), NaH2PO4 (1.2 mmol/L), MgSO4 (1 mmol/L) and CaCl2 (2.0 
mmol/L), pH adjusted to 7.35, and bubbled with 95% O2, 5% CO2. Thin papillary muscle strips 
of similar shape and size were dissected from the right ventricle and mounted by suturing the 
valve and ventricular tissue to a force transducer (Aurora Scientific Inc., Aurora, Ontario, 
Canada) and motor arm (Aurora Scientific Inc., Aurora, Ontario, Canada). The muscle was 
lowered into a constantly perfused bath containing KH solution and maintained at 37 oC, and 
paced at 2 Hz. Stimulation voltage and muscle length (Lmax) were adjusted to obtain maximum 
developed force. The muscle was allowed to equilibrate for at least 30 minutes before 
performing the experimental protocol. Muscle diameter was recorded using a digital video 
 65 
microscopy system (Ionoptix, Milton, MA), and cross-sectional area (mm2) was calculated 
assuming cylindrical geometry.  
 
 
Figure 6-2. Schematic of Intracellular Calcium Imaging Setup 
Schematic of the experimental setup used to collect simultaneous force and calcium fluorescence in isolated 
papillary muscles. The system starts with a xenon white light lamp (lower right hand corner of the schematic), which 
generates a wide frequency spectrum of excitation light. This light is passed to the Ionoptix Hyperswitch which 
rapidly switches the light pathway into two filters, a 340 nm wavelength and a 380 nm wavelength filter. These two 
alternating filtered wavelengths of light are then focused on the surface of the sample papillary muscle. The muscle 
is mounted between a force transducer and a length controller motor arm. The fluorescent dye loaded in the muscle, 
when excited, emits light at a wavelength of 510 nm. This light passes through a 510 nm filter and into a 
photomultiplier tube (PMT). The PMT passes a voltage signal (which is proportional to the amount of light that it 
detects) to the computer. The computer is also connected to the Hyperswitch, so it is able to differentiate between 
light emitted when the muscle is excited by 340 nm light versus 380 nm light. The computer also simultaneously 
measures the output signal from the force transducer. 
 
Calcium measurements using fura-5F AM required a system capable of dual excitation, 
single emission measurements. An IonOptix Hyperswitch (Ionoptix) alternated between 
excitation frequencies of 340 and 380 nm at 1000 Hz. The setup also included an inverted 
microscope, a filter, and a pair of photomultiplier tubes (see Figure 6-2). The fluorescence was 
gathered from a small section from the center of the muscle with a 40X magnification objective 
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lens (LD Plan-NEOFLUA, Carl Zeiss MicroImaging, Inc., Thornwood, NY). Background 
fluorescence was recorded before dye loading. Fura-5F AM (50 μg) was dissolved in 25 μL 
dimethyl sulfoxide (DMSO) and 25 μL Pluronic. To this solution, 2.755 mL KH solution, 4.3 
mg/L TPEN, and 5.0 mg/L cremophor were added. The muscle was diffusionally loaded by 
bathing the muscle with this solution for 30 minutes. The ratio of fluorescence emission from 
340 nm excitation and 380 nm excitation, R, was calculated after subtracting background 
fluorescence. 
Fluorescence calibration was performed after the experiment was complete. The first step 
was to end all metabolic activity in the muscle, so that calcium was no longer being actively 
transported. The muscle was bathed in a poisoning solution [90] for 10 minutes which 
completely removed its ability to generate force. The poisoning solution contained: KCl (140 
mmol/L), HEPES (25 mmol/L), MgCl2 (0.75 mmol/L), NaCN (2mmol/L), iodoacetic acid (0.5 
mmol/L). After 10 minutes, the muscle was bathed in the saturating calcium calibration solution, 
which contained 1 mg of the calcium ionophore 4-BrA23187 (TefLabs, Austin, TX) dissolved in 
50 μL DMSO added to 100 mL modified KH solution with 4 mM CaCl2. The muscle was left in 
the saturating calcium calibration for ten minutes and then fluorescence was measured. The two 
fluorescence signals were: Sb-340 and Sb-380. Their ratio, Sb-340/Sb-380 is Rmax. The muscle was then 
bathed in zero calcium calibration solution, which contained modified KH solution with 0 mM 
Ca, and 1 mM EGTA. After ten minutes, fluorescence was measured. The two fluorescence 
signals were Sf-340 and Sf-380. Their ratio, Sf-340/Sf-380 is Rmin. These calibration coefficients were 
then used to calibrate calcium using Equation 6.1 [91]. See Appendix E.  
 [𝐶𝐶𝐶𝐶2+]𝑖𝑖 =  𝐾𝐾𝑑𝑑 �𝑆𝑆𝑓𝑓−380𝑆𝑆𝑏𝑏−380� �𝑅𝑅−𝑅𝑅𝑚𝑚𝑖𝑖𝑚𝑚𝑅𝑅𝑚𝑚𝐶𝐶𝑚𝑚 −𝑅𝑅� (6.1) 
where Kd is the dissociation constant for the fluorescent dye calcium binding. For fura-5F Kd is 
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assumed to be 400 nM, as indicated by the manufacturer [92], but can be determined 
experimentally [93, 94]. 
6.2.2 Isolated Papillary Muscle: Protocols 
Muscle length was set to several values less than Lmax by the computer controlled length 
controller. The complete length protocol included (as a percentage of Lmax, and alternating with 
100% Lmax), 75%, 80%, 85%, 90%, 92%, 94%, 96%, 98%, 100%. Muscle length was normalized 
to Lmax and 75% Lmax, representing the full range of force producing lengths (sarcomere lengths 
of 2.4 µm and 1.7 µm). 
The acute treatment protocol was performed at room temperature to decrease the 
possibility of muscle degradation during the chemical treatment. Moreover, calcium transients 
were not measured during this protocol – the length of time required to load the fluorescent dye 
and chemically treat the muscle was too long to yield reliable data by the end of the protocol. 
After the muscle equilibrating period, 1 μM propranolol (Sigma) was added to the papillary 
superperfusate solution, and the muscle was treated for 15 minutes. Following the first treatment, 
the muscle was superperfused with 1 μM propranolol plus 30 μM phenylephrine (Sigma) for 15 
minutes. 
We did not verify that this treatment increased PKC phosphorylation of cTnI. The 
concentration used here were taken directly from a previous study on mouse RV papillary 
muscles, in which it was shown that this treatment resulted in increased cTnI phosphorylation at 
the PKC sites [95].  
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6.2.3 Isolated Papillary Muscle: Data Analysis  
In isolated papillary experiments, individual cycles were first identified by using the 
spike in the pacer signal. Signal averaging over the cycle was then performed to reduce high-
frequency random noise. Force and fluorescence data from five to seven steady state contractions 
at a given length were averaged to yield a representative cycle. Force waveforms were 
characterized by several amplitude and rate indices. Amplitude indices included end diastolic 
force (Fed), peak systolic force (Fsys), and developed force (Fdev = Fsys – Fdia). Rate indices 
included maximal rate of rise (dF/dtmax), and maximal rate of fall (dF/dtmin). The calcium 
transient was characterized in terms of R/Red (Red: fluorescence ratio at end-diastole), Rsys/Red 
(Rsys: peak systolic fluorescence) and dR/dtmin. 
The effects of phenylephrine were determined by comparing force waveforms after 
propranolol treatment and after phenylephrine plus propranolol treatment. 
6.2.4 Isolated Papillary Muscle: Statistical Analysis  
For the papillary muscle data, regression analysis with dummy variables was used to 
identify differences in various relationships between the WT and TG-E groups: Fdev–length, 
dF/dtmin–length, R/Red–length, and dR/dtmin–length (see Section 5.2.6).  
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6.2.5 Skinned Fiber 
The skinned fiber protocols were performed in collaboration with Dr. Murali Chandra 
(and his graduate student: Ranganath Mamidi) in the Department of Veterinary and Comparative 
Anatomy, Pharmacology and Physiology (VCAPP) at Washington State University. 
Both the WT and TG-E mice were anesthetized with pentobarbital sodium (50 mg/kg 
body wt), and hearts were rapidly excised and immediately placed into ice-cold high relaxing 
(HR) solution containing (in mM) 20 MOPS, 53 KCl, 10 EGTA, 6.81 MgCl2, 5.35 Na2ATP, and 
1.0 DTT. The pH was adjusted to 7.0 with KOH and a fresh cocktail of protease inhibitors (in 
μM: 4 benzamidine-HCl, 5 bestatin, 2 E-64, 10 leupeptin, 1 pepstatin, and 200 PMSF) were 
added to the fresh ice-cold buffered solutions. Papillary muscle fiber bundles were then carefully 
cut from the wall of the left ventricles of WT and TG-E mouse hearts. Thin muscle fiber bundles 
(~200 μm in width and ~2.0 mm in length) were dissected and were detergent skinned overnight 
using HR solution with 1% TritonX-100 to chemically permeabilize the muscle fiber 
preparations [96].  
The detergent-skinned muscle fiber bundles were attached to the arm of a displacement 
motor (model 308B, Aurora Scientific Inc) on one end and to a force transducer (AE 801, Sensor 
One Technologies Corporation) on the other end using aluminum T-clips (Kem-Mil Co, 
Hayward, CA). The elliptical cross-sectional area of the muscle fiber was determined by 
measuring the width and thickness at three points along the length of the muscle fiber bundle. 
The muscle fiber bundle was immersed in a 15-μL bath containing activating solutions with 
different pCa (–log10([Ca2+])). Activating solution in the bath was constantly stirred by means of 
a motor-driven vibration of a membrane positioned on the underside of the bath. Maximum 
activating solution (pCa 4.3) contained (in mM) 31 potassium propionate, 5.95 Na2ATP, 6.61 
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MgCl2, 10 EGTA, 10.11 CaCl2, 50 BES (pH 7.0), 10 NaN3, 0.9 NADH, and 10 
phosphoenolpyruvate as well as 4 mg/ml pyruvate kinase (500 U/mg), 0.24 mg/ml lactate 
dehydrogenase (870 U/mg), and 20 μM A2P5, and a cocktail of protease inhibitors.  
Isometric tension and ATPase activity were simultaneously measured at 20°C as 
described previously [97, 98]. Briefly, the tension developed at steady-state was measured by the 
force transducer and recorded using LabView software (National Instruments, Austin, TX). 
ATPase activity of the detergent-skinned muscle fiber bundles was measured by projecting near 
UV light through the muscle chamber. Light was split via a beam splitter (50/50) and intensities 
measured at 340 nm (sensitive to changes in NADH concentration) and at 410 nm (insensitive to 
changes in NADH concentration), which served as a reference signal. An analog divider and a 
log amplifier produced a signal proportional to the amount of ATP consumed in the muscle 
chamber solution. ATP regeneration from ADP was enzymatically coupled to the breakdown of 
phosphoenolpyruvate (PEP) by pyruvate kinase to pyruvate with a concomitant regeneration of 
ATP from ADP. This reaction is coupled to the synthesis of lactate from pyruvate catalyzed by 
lactate dehydrogenase during which process NADH is converted to NAD+. The consumption of 
NADH is proportional to the amount of ATP consumed and was measured online by UV 
absorbance at 340 nm [98]. 
6.2.6 Skinned Fiber: Protocols  
The sarcomere length of the muscle fiber bundle was adjusted to 2.2 μm using a He-Ne 
laser diffraction system [97]. The sarcomere length was readjusted to 2.2 μm after two cycles of 
full activation and relaxation to stabilize the resting sarcomere length throughout the later stages 
of the experiment [98]. 
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The Ca2+ concentration of the activating solution was changed to produce steady-state 
force-generating activations at pCa 4.3, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, and 9.0 [99]. 
6.2.7 Skinned Fiber: Data Analysis  
For skinned fiber experiments, normalized force or ATPase activity was calculated as the 
ratio of the measured quantity at a given pCa and the maximally activated value (i.e., at pCa = 
4.33). Normalized force-pCa and ATPase-pCa data were fitted to a modified Hill equation 
(Equation 6.2) using a nonlinear regression algorithm (SigmaPlot, Systat Software Inc., San 
Jose, CA):  
 
𝑋𝑋
𝑋𝑋𝑚𝑚𝐶𝐶𝑚𝑚
=  11+10𝑚𝑚𝐻𝐻 (𝑝𝑝𝐶𝐶𝐶𝐶 50− 𝑝𝑝𝐶𝐶𝐶𝐶 ) (6.2) 
where X is a measured quantity (either force or ATPase activity) at a given pCa and Xmax is the 
maximally activated value (i.e., at pCa = 4.33). Two parameters were estimated from normalized 
force-pCa data for each fiber: pCa50 (pCa required to produce normalized value of 50%) and the 
Hill coefficient (nH, a measure of the steepness of the normalized force-pCa or ATPase-pCa 
curve, which characterizes the cooperative phenomena). 
6.2.8 Skinned Fiber: Statistical Analysis 
The force-pCa and ATPase-pCa data were analyzed using a standard t-test comparing 
Fmax, ATPasemax, and the pCa50 and nH values for both relationships.  
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6.3 RESULTS 
6.3.1 Papillary Muscle: Results 
6.3.1.1 Muscle Length Protocol 
Representative raw fluorescence count data are shown for 340 nm excitation (Figure 6-
3A), 380 nm excitation (Figure 6-3B) and their online calculated ratio (Figure 6-3C). 
 
 
Figure 6-3. Raw Fluorescence Data from a WT Papillary Muscle 
Raw fluorescence counts at excitation wavelengths of (A) 340 nm and (B) 380 nm. Also shown is the online 
calculated ratio of the two signals, 340/380. From one WT RV papillary muscle. 
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The raw fluorescence data are then averaged on a beat to beat basis (10-20 cycles). 
Figure 6-4 shows representative force and calcium data from one WT and one TG-E experiment. 
The TG-E mice exhibited decreased force production, indicated by a downward shift of the 
developed force (Fdev) – length relationship (intercept values: WT: 1.88 ± 1.22 mN•mm-2, n = 5, 
TG-E: -0.51 ± 0.35 mN•mm-2, n = 6, P = 0.04, Figure 6-5A and Table 5).  
 
 
Figure 6-4. Raw Force and Calcium from WT and TG-E Papillary Muscles 
Representative force (top) and calcium (bottom) data for WT (solid line) and TG-E (dashed line) mice at three 
lengths (100%, 96% and 92% of Lmax). 
 
Compared to the WT mice, there was slowed relaxation in the TG-E mice as evidenced 
by an upward shift in the dF/dtmin – length relationship (intercept values: WT: -55 ± 16 mN• 
mm-2•s-1, TG-E: 5 ± 8 mN•mm-2•s-1, P < 0.001, Figure 6-5B and Table 5).  
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Figure 6-5. Force - Length Relationships in WT and TG-E Papillary Muscles 
Force data from isolated papillary muscles. Effects of altered muscle length on developed force (Fdev) (A), dF/dtmin 
(relaxation) (B) in WT (black circles) and TG-E (gray triangles) mice. The raw data were fitted to a linear trendline 
(WT: solid line, TG-E: dotted line). Compared to the WT data, the intercept of the Fdev – length relationship was 
significantly lower (P<0.05) and the intercept of the dF/dtmin –length relationship was significantly higher (P<0.05) 
in the TG-E mice. 
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Figure 6-6. Calcium - Length Relationships in WT and TG-E Papillary Muscles 
Intracellular calcium concentration [Ca]i data from isolated papillary muscles. [Ca]i is expressed as R (R = [emission 
fluorescence340]/[emission fluorescence380]) and is normalized by the end-diastolic value of R (Red). Effects of 
altered muscle length on Rsys (peak systolic R) normalized by Red (end-diastolic R) (A) and dR/dtmin (calcium 
relaxation) (B) in WT (black circles) and TG-E (gray triangles) mice. The raw data were fitted to a linear trendline 
(WT: solid line, TG-E: dashed line). There were no differences in the intercept or slope of the Rsys/Red – length, or 
dR/dtmin – length relationships between WT and TG-E. 
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In contrast, intracellular calcium concentration transients ([Ca]i) were unaltered in TG-E 
mice, exhibiting no changes in the slope or intercept of the [Ca]i amplitude (as quantified by 
Rsys/Red) – length relationship (P-value: for slope = 0.53, for intercept = 0.83; Figure 6-6A and 
Table 5), or the relaxation (as quantified by dR/dtmin) – length relationship (P-value: for slope = 
0.23, for intercept = 0.28; Figure 6-6B and Table 5).  
If the slope of the length-parameter relationship is statistically different from zero, then 
length has an effect on that parameter. The WT and TG-E mice showed an effect of length on 
Fdev and dF/dtmin (increasing Fdev with increasing length, and increasing magnitude, i.e., more 
negative, of dF/dtmin with increasing length). However, there was no effect of length on Rsys/Red 
or dR/dtmin in the WT or TG-E mice. This is in agreement with our past findings ([83] and 
Appendix A), that length changes do not affect the calcium transient in mice. 
 
Table 5. Slope and Intercept Values for Various Relationships in Papillary Muscles 
 
 
WT TG-E P -value
Fdev - Length n = 40 n= 48
   Slope 7.7 ± 1.7 4.9 ± 0.5 0.0858
   Intercept 1.9 ± 1.2 -0.5 ± 0.3 0.0447
dF/dtmin - Length n = 40 n = 48
   Slope -96.4 ± 22.6 -90.0 ± 11.5 0.793
   Intercept -55.1 ± 16.5 5.0 ± 8.4 0.001
R sys/R ed - Length n = 28 n = 34
   Slope 0.09 ± 0.12 -0.13 ± 0.30 0.5361
   Intercept 1.5 ± 0.1 1.6 ± 0.3 0.828
dR /dtmin - Length n = 28 n = 34
   Slope -28.8 ± 39.4 71.2 ± 67.0 0.2276
   Intercept -64.2 ± 33.1 -139.3 ± 56.3 0.2807
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We did perform the standard calibration measurements after every papillary muscle 
experiment; however, we found that in approximately half of the experiments, the measured 
calibration values did not make physical sense (e.g., Rmin measured at the end of the experiment 
below the background value measured at the beginning of the experiment or Rmax measured at 
the end of the experiment close to some of the peak R values measured during the experiment). 
Therefore, we decided to report our calcium measurements in terms of uncalibrated fluorescence 
ratios, which should be valid for relative comparisons, if not for absolute values of calcium 
[100]. In about half of the experiments, the calibration values did make sense (n: WT = 3, TG-E 
= 3). Upon reviewing these subset of data, we found no significant difference in diastolic 
calcium between the WT and TG-E groups (WT= 401 ± 142 nM, TG-E = 524 ± 152 nM, P = 
0.58). These values are similar to calibrated calcium levels reported in the past [57, 101]. 
6.3.1.2 Acute cTnI Phosphorylation Protocol 
Figure 6-7 shows representative data from before and after phenylephrine treatment for a 
WT (Figure 6-7A and B) and TG-E (Figure 6-7C and D) mouse.  
In the WT mice, treatment with 30 μM phenylephrine in the presence of 1 μM 
propranolol resulted in a decrease in Fdev (-22.2 ± 6.4%) compared to Fdev with 1 μM propranolol 
treatment alone (Figure 6-8A). There was also an increase in Trelax after phenylephrine treatment 
(15.9 ± 7.4%) compared to propranolol treatment (Figure 6-8B).  
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Figure 6-7. Representative Prop./PE Treatment Data 
Comparison of developed force (panels A and C) and normalized force (panels B and D) after 1 μM propranolol 
(prop.) treatment (solid line) and after 1 μM propranolol plus 30 μM phenylephrine (PE) treatment (dashed line). 
Panels A and B are from a single WT mouse, and Panels C and D are from a single TG-E mouse. Both showed a 
decrease in developed force and an increase in relaxation time with PE treatment. 
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Figure 6-8. Effect of Phenylephrine Treatment 
Percent change in Fdev (A) and Trelax (B) in WT (black) and TG-E (gray) mice after treatment of papillary muscle 
with phenylephrine in the presence of propranolol, compared to baseline (treatment with propranolol alone). Data 
are mean ± S.E.M.. 
 
The TG-E mice exhibited similar responses, showing a decrease in Fdev (-28.7 ± 10%, 
Figure 6 -8A) and an increase in Trelax (16.4 ± 10.2%) after phenylephrine and propranolol 
treatment, compared to propranolol treatment alone.  
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There were no differences between the WT and TG-E mice in the response to 
phenylephrine in the presence of propranolol, either in Fdev (P-value = 0.60) or Trelax (P-value = 
0.97). 
 
 
Figure 6-9. Calcium from Prop./PE Treatment Experiment 
Intracellular calcium after 15 minutes of 1 μM propranolol (prop.) treatment (solid line) and after 5 minutes of 1 μM 
propranolol plus 30 μM phenylephrine (PE) treatment (dashed line). 
 
 In general, due to the length of the protocol, it was not possible to record calcium and 
force simultaneously under propranolol and phenylephrine conditions. However, in a few of the 
experiments, we were able to record calcium, so there is anecdotal evidence of no effect on the 
intracellular calcium transient with phenylephrine treatment, as can be seen in Figure 6-9. In this 
example, force has been reduced, with no change in intracellular calcium. The ability to record 
force and calcium simultaneously in these experiments was rare, so statistical evidence cannot be 
provided.  
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6.3.2 Skinned Fiber 
 
Figure 6-10. Data from WT and TG-E Skinned Fibers 
Mechanical and energetic characteristics in skinned fibers from WT (closed circles) and TG-E (open circles) mice. 
(A) Absolute force data (mN•mm-2) showing WT mice have significantly higher Fmax than TG-E mice. (B) Relative 
force data (%Fmax) showing that there is no difference in pCa50 (calcium sensitivity) or Hill coefficient 
(cooperativity) between the WT and TG-E mice. (C) Absolute ATPase activity (pmol•mm-3•sec-1) shows that WT 
mice have a higher, but not statistically significant maximal value. (D) Relative ATPase activity (%Max) shows no 
differences in pCa50 or nH values between the WT and TG-E mice. 
 
There was a 14% significant decrease in maximally activated force (Fmax) in the TG-E 
mice (Figure 6-10A and Table 6). While there was a similar decrease (9%) in maximal ATPase 
activity (Figure 6-10C and Table 6), it was not statistically significant. The skinned fiber data 
were fit to the modified Hill equation (Equation 6.1 ). There were no differences in pCa50 
 82 
(calcium sensitivity) or Hill coefficient (nH, cooperativity) for either the force-pCa (Figure 6-
10B and Table 6) or ATPase-pCa relationships (Figure 6-10D and Table 6).  
 
 
Figure 6-11. Tension Cost for WT and TG-E Skinned Fibers 
There was no difference in the slope of the fitted linear regression, representing tension cost, between the two 
groups. 
 
The force-ATPase activity relationship is a linear one, and its slope (when fit to linear 
regression) is defined as tension cost. There were no differences in tension cost between the WT 
(7.33 ± 0.13, R2 = 0.97) and TG-E (7.41 ± 0.10, R2 = 0.98) mice (Figure 6-11 and Table 6). 
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Table 6. Summary of Data from Skinned Fiber Protocol 
 
Values are mean ± S.E.M.. Fmax: maximally activated force; nH: Hill coefficient. * P<0.05 versus WT.  
6.4 SUMMARY 
Hypothesis 2 : Increased cTnI phosphorylation at the PKC sites will result in depressed 
calcium-force and ATP-force relationships (less force per calcium or ATP usage). 
In isolated papillary muscle experiments over a range of muscle lengths, the TG-E mouse 
(increased cTnI phosphorylation at the PKC sites) exhibited decreased Fdev and dF/dtmin, 
indicating negative inotropy and negative (slower) relaxation. There were no changes in the 
calcium transient amplitude (Rsys/Red) or relaxation (dR/dtmin) in the TG-E mouse, compared to 
the WT mouse.  
Acute phosphorylation of cTnI using phenylephrine in the presence of propranolol had a 
negative inotropic and lusitropic effect in the WT mice. The TG-E mice showed a similar 
pattern. Due to the length of the protocol, it was not possible to perform chemical treatments in 
and measure intracellular calcium transients the same papillary muscle. However, anecdotal 
evidence shows there is no effect on the calcium transient. 
WT (n=10) TG-E (n=10)
Force - pCa
   Fmax (mN•mm
-2) 65.7 ± 1.6 56.6 ± 2.5 *
   pCa50 5.74 ± 0.01 5.76 ± 0.01
   nH 2.98 ± 0.13 2.84 ± 0.11
MgATPase - pCa
   Max (pmol•mm-3•sec-1) 477 ± 23 434 ± 23
   pCa50 5.77 ± 0.02 5.75 ± 0.01
   nH 2.60 ± 0.13 2.56 ± 0.07
Tension Cost 7.33 ± 0.13 7.41 ± 0.10
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In skinned fiber data, the TG-E mouse showed a decrease in maximal developed force, 
with no change in pCa50 or Hill coefficient. There was no change in pCa50 or Hill coefficient for 
the pCa – ATPase relationship. There was no change in the tension cost between the TG-E and 
WT mice. 
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7.0  MODEL-BASED ANALYSIS 
7.1 INTRODUCTION 
Hypothesis 3: A Model-based analysis of data from Specific Aims 1 and 2 will provide an 
integrative interpretation of increased cTnI phosphorylation at the PKC sites. 
 
Specific Aim 3a: Determine whether the four-state model can provide unique solutions 
Specific Aim 3b: Using a model-based analysis, determine the myofilamental alterations 
caused by PKC-induced phosphorylation of cTnI   
 
The experimental evidence from Specific Aims 1a, 1b, 2a and 2b provide an extensive 
catalogue of functional effects of PKC-induced phosphorylation of cTnI. The goal here is to 
identify the underlying changes in myofilamental processes that can simultaneously explain all 
of our results. To do this, we require the use of a mathematical model-based analysis to integrate 
and interpret the experimental results. Before we can use the model in this way, however, we 
must provide evidence that the model is identifiable based on our input(s) and output(s). 
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7.2 METHODS 
7.2.1 Model Selection 
In lieu of developing an entirely new mathematical model, we set out first to determine if 
an existing model could meet our needs. The four-state model of myofilament activation was 
found to be a suitable model because its inputs and outputs matched our data, and it met the three 
criteria of a well-posed model set forth in Section 1.5: descriptive, predictive, and explanative. 
The four-state model is descriptive because it has adequate complexity and appropriate design to 
capture the important features of an observed behavior [102, 103]; predictive because after 
careful validation it can anticipate behavior that has not been observed [104]; and explanative 
because, being based upon actual elements in the physiological pathway, the model is capable of 
illuminating the causes of the behavior [105].  
We have also used this model-based analysis for calcium and pressure data in WT mouse 
isolated hearts previously, see Appendix A and [83]. It has the appropriate design and level of 
complexity. For these reasons, we have selected this model for our data analysis. 
7.2.2 Four-State Model 
During diastole, actin and myosin are unbound and the muscle is relaxed (see Section 
1.1). During systole, an action potential stimulates cardiac myocytes to allow extracellular 
calcium to enter the cell, which stimulates a huge secondary release of calcium from the 
sarcoplasmic reticulum. Calcium then binds to cardiac TnC and triggers a cascade that allows 
actin and myosin to form a crossbridge, the force generating unit of muscle.  
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Figure 7-1. Schematic of the Four-State Model 
The four –state model is a compartment model describing two non-force-generating states (States 1 and 2) and two 
force-generating states (States 3 and 4), and five individual species: actin, [A]; myosin [M]; calcium-bound actin 
[Ca-A]; calcium-bound crossbridge, [Ca-A-M]; calcium-free crossbridge, [A-M]. There are seven rate constants: k1, 
k2, k3, k4, f, g, and d. 
 
This pathway of cardiac contraction is described in the four-state model and is shown in 
Figure 7-1. In State 1, calcium ([Ca]), actin ([A]) and myosin ([M]) are all in their unbound 
(diastolic) states. In State 2, calcium is bound to troponin on the thin filament ([Ca-A]), but actin 
and myosin have not formed a crossbridge. Movement between State 1 and State 2 is regulated 
by the parameters k1 and k3, representing the rate constants of calcium binding and release, 
respectively. State 3 is a force-generating state (converting from diastole to systole), and has 
calcium bound, and the strong crossbridge is formed ([Ca-A-M]). The classical f and g rate 
constants represent the binding and unbinding of actin and myosin, or the forming and breaking 
of the strongly bound crossbridge. State 4 ([A-M]) is a second force-generating state, in which 
calcium is dissociated from troponin (controlled by k4) in the presence of a strongly bound 
crossbridge. Calcium can bind to TnC in State 4 (by rate constant k2) to return to State 3. State 4 
can convert to State 1 though the unbinding of actin and myosin and dissolution of the force-
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generating crossbridge, described by rate constant d. There is no pathway directly from State 1 to 
State 4. A differential equation can be written for each species, yielding Equations 7.1 – 7.5. 
 𝑑𝑑[𝐴𝐴](𝑡𝑡)
𝑑𝑑𝑡𝑡
=  −𝑘𝑘1[Ca](𝑡𝑡)[𝐴𝐴](𝑡𝑡) + 𝑘𝑘3[Ca-𝐴𝐴](𝑡𝑡) + 𝑑𝑑[𝐴𝐴-𝑀𝑀](𝑡𝑡) (7.1) 
 𝑑𝑑[𝑀𝑀](𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑[𝐴𝐴-𝑀𝑀](𝑡𝑡) − 𝑓𝑓[Ca-𝐴𝐴](𝑡𝑡)[𝑀𝑀](𝑡𝑡) + 𝑔𝑔[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) (7.2) 
 𝑑𝑑[Ca-𝐴𝐴](𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑘𝑘1[Ca](𝑡𝑡)[𝐴𝐴](𝑡𝑡) − 𝑘𝑘3[Ca-𝐴𝐴](𝑡𝑡) − 𝑓𝑓[Ca-𝐴𝐴](𝑡𝑡)[𝑀𝑀](𝑡𝑡)+  𝑔𝑔[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) (7.3) 
 𝑑𝑑[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡)
𝑑𝑑𝑡𝑡
=  𝑓𝑓[Ca-𝐴𝐴](𝑡𝑡)[𝑀𝑀](𝑡𝑡) + 𝑘𝑘2[Ca](𝑡𝑡)[𝐴𝐴-𝑀𝑀](𝑡𝑡) 
−𝑔𝑔[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) − 𝑘𝑘4[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) (7.4) 
 𝑑𝑑[𝐴𝐴-𝑀𝑀](𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑘𝑘4[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) −  𝑑𝑑[𝐴𝐴-𝑀𝑀](𝑡𝑡) − 𝑘𝑘2[Ca](𝑡𝑡)[𝐴𝐴-𝑀𝑀](𝑡𝑡) (7.5) 
 The model simulates cooperativity through a feedback mechanism of force generating 
crossbridges (State 3 and 4) on to the rate constants k1 and f. This feedback is shown by the gray 
arrows in Figure 7-1. There are also two algebraic feedback equations, described by: 
 𝑘𝑘1(𝑡𝑡) = 𝛼𝛼1�[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) + [𝐴𝐴-𝑀𝑀](𝑡𝑡)�𝛾𝛾1 + 𝛽𝛽1 (7.6) 
 𝑓𝑓(𝑡𝑡) = 𝛼𝛼𝑓𝑓�[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) + [𝐴𝐴-𝑀𝑀](𝑡𝑡)�𝛾𝛾𝑓𝑓 + 𝛽𝛽𝑓𝑓  (7.7) 
The model output is force, and is the sum of the two force-generating states (Equation 
7.4 and Equation 7.5) times a scaling factor, and is shown in Equation 7.8: 
 𝐹𝐹(𝑡𝑡) = 𝛾𝛾�[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) + [𝐴𝐴-𝑀𝑀](𝑡𝑡)� (7.8) 
Initial conditions represent the concentrations (per unit volume of sarcoplasm) at t=0 of 
each state prior to introduction of free calcium [102, 106]: [A]t=0 = 70 μM, [M]t=0 = 20 μM,  
[Ca-A]t=0 = 0 μM, [Ca-A-M]t=0 = 0 μM, [A-M]t=0 = 0 μM.  
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We experimentally measured ATPase activity and estimated the tension cost. We adapted 
the four-state model to provide these data. Equation 7.8  was used to calculate ATPase activity 
from the model predicted steady-state data.  
 ATPase = 𝑔𝑔 ∗ [Ca-A-M] + 𝑑𝑑 ∗ [A-M] (7.8) 
The parameter d has very little effect on the value of ATPase (see Appendix D), 
however, as the [A-M] state is much less populated than the [Ca-A-M] state. Thus, g is the 
primary effector of ATPase activity. The tension cost is calculated as the slope of the linear 
trendline associated with the steady-state force – ATPase relationship. 
7.2.3 A Priori Identifiability 
First we will define what an identifiable model is. We assume the model is defined by a 
system of differential equations: 
 𝑑𝑑𝑚𝑚𝑚𝑚 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑓𝑓�𝑚𝑚𝑚𝑚(𝑡𝑡),𝑝𝑝𝑖𝑖 ,𝑢𝑢𝑚𝑚 (𝑡𝑡)� (7.9) 
where xn is an n-dimensional state variable, pi is an i-dimensional parameter array, and um is an 
m-dimensional input vector. We also assume there is at least one output equation: 
  𝑦𝑦𝑗𝑗 (𝑡𝑡) = 𝑔𝑔�𝑚𝑚𝑚𝑚(𝑡𝑡),𝑝𝑝𝑖𝑖 ,𝑢𝑢𝑚𝑚 (𝑡𝑡)� (7.10) 
where yj is a j-dimensional output vector. We assume that there is some true, experimental output 
array of dimension j, Yj. If the model is identifiable, there exists a unique, parameter set of 
dimension i, Pi. Thus, the goal of model optimization is to minimize Yj – yj by altering pi until it 
is equal to Pi. If this is possible, the model is identifiable.  
Differential algebra allows the use of classical algebra techniques on a system with 
derivatives [107]. The system (1) is reduced using Ritt’s pseudodivision algorithm into a 
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characteristic set. To reduce the system, the variables are first ranked, with the state variables 
and their derivatives ranked highest. When the system is being reduced, the highest ranked 
elements are preferentially eliminated from the equation set. When the set can no longer be 
reduced, it is called autoreduced. One of the equations in this characteristic set should contain 
only inputs, outputs and parameters:  
 𝑓𝑓�𝑦𝑦𝑗𝑗 ,𝑦𝑦?̇?𝑗 ,𝑦𝑦?̈?𝑗 , … ,𝑢𝑢𝑚𝑚 , 𝑢𝑢?̇?𝑚 ,𝑢𝑢?̈?𝑚 , … ,𝑝𝑝𝑖𝑖� = 0 (7.11) 
which is in a state-space form and represents the input-output relationships. The parameters are 
therefore a function of only the model inputs, outputs, and their derivatives, all known elements. 
The coefficients of Equation 7.11 are extracted, and represent the exhaustive summary. The 
Buchberger algorithm is applied to the exhaustive summary, to obtain the Gröbner set [108]. 
This is analogous to finding the solution of a linear system using Gaussian elimination. If the 
parameters are uniquely identifiable then the model is a priori globally identifiable. If there are a 
finite number of possible parameter sets then the model is locally identifiable, and if there are an 
infinite number of parameter sets, the model is nonidentifiable. 
This analysis assumes a fixed input function, noise-free input and output, and a given 
model structure.  
7.2.3.1 Model Identifiability Using Differential Algebra: An Example  
 The details of this analysis are explained elsewhere [109, 110]. The use of differential 
algebra to determine whether a model is globally identifiable is easiest to describe through use of 
a simple example.  
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Figure 7-2. Schematic of Example Model 
 
Consider a two compartment model (see Figure 7.2), with an input u(t) into state 1 (x1), a 
transition rate constant of k1 to state 2 (x2) and rate constant of k2 to a sink from state 2. The 
model output, y, is state 2, x2. The model is described by the following two differential equations 
and one output equation. 
 𝑑𝑑𝑚𝑚1(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑚𝑚1̇(𝑡𝑡) = 𝑢𝑢(𝑡𝑡) − 𝑘𝑘1𝑚𝑚1 (7.12) 
 𝑑𝑑𝑚𝑚2(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑚𝑚2̇(𝑡𝑡) = 𝑘𝑘1𝑚𝑚1 − 𝑘𝑘2𝑚𝑚2 (7.13) 
 𝑦𝑦 = 𝑚𝑚2 (7.14) 
We will assign the following ranking system, which ranks the state variables highest, 
because our goal is to eliminate them first. 
 𝑢𝑢 < 𝑦𝑦 < ?̇?𝑦 < ?̈?𝑦 < 𝑚𝑚1 < 𝑚𝑚2 < 𝑚𝑚1̇ < 𝑚𝑚2̇ (7.15) 
The two differential equations and output equation are then ranked according to the 
highest input, output, or state variable in each equation. This yields: 
 −𝑚𝑚2 + 𝑦𝑦     leader x2 (7.16) 
 𝑚𝑚1̇ − 𝑢𝑢 + 𝑘𝑘1𝑚𝑚1     leader ẋ1 (7.17) 
 𝑚𝑚2̇ − 𝑘𝑘1𝑚𝑚1 + 𝑘𝑘2𝑚𝑚2     leader ẋ2 (7.18) 
The first step is to reduce the highest ordered equation, Equation 7.18. We will do this 
by using Equation 7.16 and its derivative. When we do this, Equation 7.18 becomes: 
 −𝑘𝑘1𝑚𝑚1 + ?̇?𝑦 + 𝑘𝑘2𝑦𝑦     leader x1 (7.19) 
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The system is now: 
 ?̇?𝑦 − 𝑘𝑘1𝑚𝑚1 + 𝑘𝑘2𝑦𝑦     leader x1 (7.20) 
 𝑚𝑚2 + 𝑦𝑦     leader x2 (7.21) 
 𝑚𝑚1̇ − 𝑢𝑢 + 𝑘𝑘1𝑚𝑚1     leader ẋ1 (7.22) 
The same technique is used, where Equation 7.20 and its derivative are used to replace 
x1 in Equation 7.22. When this is done, Equation 7.22 becomes: 
 ?̈?𝑦 + (𝑘𝑘1 + 𝑘𝑘2)?̇?𝑦 + 𝑘𝑘2𝑦𝑦 − 𝑘𝑘1𝑢𝑢     leader ?̈?𝑦 (7.23) 
 The system is now: 
 ?̈?𝑦 + (𝑘𝑘1 + 𝑘𝑘2)?̇?𝑦 + 𝑘𝑘1𝑘𝑘2𝑦𝑦 − 𝑘𝑘1𝑢𝑢     leader ?̈?𝑦 (7.24) 
 −𝑘𝑘1𝑚𝑚1 + ?̇?𝑦 + 𝑘𝑘2𝑦𝑦     leader x1 (7.25) 
 𝑚𝑚2 + 𝑦𝑦     leader x2 (7.26) 
This system can no longer be further reduced, and is said to be autoreduced. This is 
known at the model’s characteristic set. Equation 7.24 contains no state variables, and 
represents the model’s input-output relationship. The coefficients of Equation 7.24 are 
extracted, and represent the exhaustive summary. 
 𝑘𝑘1 + 𝑘𝑘2          𝑘𝑘1𝑘𝑘2          𝑘𝑘1  (7.27) 
The next step is to determine if k1 and k2 be uniquely identified from the exhaustive 
summary. The Buchberger algorithm is applied to the exhaustive summary to obtain the Gröbner 
set. For this simple example, it is possible to do this analysis by hand. First, we assume that the 
true, unique value for k1 is α and for k2 is β, which provides the following: 
  𝑘𝑘1 + 𝑘𝑘2 − 𝛼𝛼 − 𝛽𝛽 = 0 (7.28) 
 𝑘𝑘1𝑘𝑘2 − 𝛼𝛼𝛽𝛽 = 0 (7.29) 
 𝑘𝑘1 − 𝛼𝛼 = 0 (7.30) 
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Clearly, it is possible to solve this system for k1 = α and k2 = β. This technique has been 
automated in a program known as DAISY (Differential Algebra for Identifiability of SYstems).  
DAISY (version 1.4) was written by G.Bellu, M.P.Saccomani, S.Audoly and L.D'Angio, 
and is copyrighted by University of Cagliari and University of Padova, Italy. We have received 
permission from the authors to use it here. The program runs in Reduce, an algebraic computer 
program (version 3.8, Konrad-Zuse-Zentrum für Informationstechnik Berlin (ZIB), Berlin, 
Germany).  
Obtaining the Gröbner set can be extremely computationally intensive, making it difficult 
or impossible to solve. Moreover, this analysis becomes significantly more computationally 
intensive with even minor increases in complexity. In order to assuage this problem DAISY uses 
a set of pseudo-randomly selected values for each parameter, to simplify the symbolic algebra. 
So in the above example, the program may select k1 = 25 and k2 = 27. The system is solved, and 
the Gröbner set is obtained, showing uniquely identified parameters. Therefore, for this example, 
DAISY would report that it is globally identifiable.  
DAISY was used to determine the a priori identifiability of other models of cardiac 
function, as shown in Appendix B. 
7.2.3.2 DAISY and the Four-State Model 
DAISY was used to determine the a priori identifiability of the four-state model. The 
model first must be in its most reduced form, which it is not as described above. The five 
differential equations can be reduced to the following three differential equations and one output 
equation. 
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 𝑑𝑑[𝐴𝐴](𝑡𝑡)
𝑑𝑑𝑡𝑡
=  −𝑘𝑘1[Ca](𝑡𝑡)[𝐴𝐴](𝑡𝑡) + 𝑘𝑘3(−[𝐴𝐴](𝑡𝑡) + [𝐴𝐴-𝑀𝑀](𝑡𝑡) + 50)+ 𝑑𝑑(−[𝑀𝑀](𝑡𝑡) − [Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) + 20) (7.31) 
 𝑑𝑑[𝑀𝑀](𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑(−[𝑀𝑀](𝑡𝑡) − [Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) + 20) − 𝑓𝑓(−[𝐴𝐴](𝑡𝑡) + [𝐴𝐴-𝑀𝑀](𝑡𝑡) + 50)[𝑀𝑀](𝑡𝑡)
+ 𝑔𝑔[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) (7.32) 
 𝑑𝑑[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡)
𝑑𝑑𝑡𝑡
=  𝑓𝑓(−[𝐴𝐴](𝑡𝑡) + [𝐴𝐴-𝑀𝑀](𝑡𝑡) + 50)[𝑀𝑀](𝑡𝑡)+ 𝑘𝑘2[Ca](𝑡𝑡)(−[𝑀𝑀](𝑡𝑡) − [Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) + 20) − 𝑔𝑔[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡)
− 𝑘𝑘4[Ca-𝐴𝐴-𝑀𝑀](𝑡𝑡) 
(7.33) 
 𝐹𝐹(𝑡𝑡) = 𝛾𝛾(−[𝑀𝑀](𝑡𝑡) + 20) (7.34) 
The model input is [Ca](t), and the model output is F(t). The exponents on the feedback 
equations (Equation 7.6 and 7.7), γ1 and γf, are not estimated, and their values are assumed to 
obtain appropriate cooperativity, and have previously been assigned values of 0.5 and 2, 
respectively [102]. Here we use values of 1.25 and 1 (Section 7.3.3), because they resulted in nH 
values that closely matched our experimental data. There are nine free parameters to estimate: α1, 
β1, k2, k3, k4, αf, βf, d, and g. The scaling factor γ is not included as a free parameter.  
DAISY cannot handle exponent values which are not whole numbers, so there is an issue 
with Equation 7.6 if γ1 is 0.5, or 1.25. We tested the instance when γ1 is 0.5, and in this case, we 
made the following substitution for the feedback variable: 
 𝑘𝑘1(𝑡𝑡) = 𝛼𝛼1𝑚𝑚4(𝑡𝑡) + 𝛽𝛽1 (7.35) 
Where x4(t) is the new model output, and introduced in: 
 [𝑀𝑀](𝑡𝑡) = 𝑚𝑚42(𝑡𝑡) + 20 (7.36) 
We have performed identifiability analysis with and without the feedback equations (in 
which case there are seven free parameters). 
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7.2.4 Automated Optimization 
Automated parameter estimation was performed using built-in Matlab functions (version 
2009a, The Mathworks, Natick, MA). These included lsqcurvefit (which uses the Levenberg-
Marquadt and Newton methods) and the Genetic Algorithm. Each parameter was bounded by 
zero as a minimum, but was given no maximum bound. 
7.3 RESULTS 
7.3.1 A Priori Identifiability 
The identifiability analysis of the four-state model turned out to be computationally 
expensive. Each variation took hours to run, and the exhaustive summary for the most 
complicated model was over 150,000 characters long. 
 
Table 7. Results of Identifiability Analysis 
 
Each variation was both algebraically observable and globally identifiable.  
Model # State Var. # Outputs # Paramters Observable Identifiable
4-state Model
     Without Feedback 3 1 7  Globally
     Linear Feedback 3 1 9  Globally
     γ1 = 0.5, γf = 2 3 1 9  Globally
-----------------------------------------------------------------------------
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7.3.2 Automated Optimization 
Automated optimization was unable to calculate parameters with reasonable standard 
errors. A representative optimized parameter set is shown in Table 8. The R2 for the fit is high; 
however, the standard error of each parameter exceeds the actual value estimated for that 
parameter. The ± standard error values in Table 8 (and Table 9) are the 5% confidence limits of 
estimation calculated from the Jacobian matrix (not to confuse them with S.E.M. from 
experimental observations). The P-value compares the parameter to zero, and no parameter was 
significantly different from zero. 
 
Table 8. Parameter Estimates from Levenberg-Marquadt Algorithm 
 
 
 This was a typical result, and indicates that automated optimization cannot reliably 
identify the unique solution, despite the identifiability analysis indicating that the four-state 
model was a priori globally identifiable (see Section 7.3.1). It is a bit of a misnomer to refer to it 
as “identifiability analysis”, however, since it does not determine if the unique parameter set is 
Parameter Value P  - value
k 2 99.0 ± 299 N.S.
k 3 5.70 ± 319 N.S.
k 4 407 ± 687 N.S.
g 434 ± 4210 N.S.
d 137 ± 394 N.S.
α1 1.58 ± 4.24 N.S.
β1 0.145 ± 0.344 N.S.
αf 0 .00 ± 5.16 N.S.
βf 35.2 ± 107 N.S.
R 2 0.995
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identifiable. Instead, identifiability analysis determines whether a unique parameter set exists for 
a given input-output pair and model structure [111]. It is an important analysis to do, even if the 
model is not being used for the inverse problem. In this case, that unique parameter set was not 
attainable using a variety of automated procedures. 
 Why was the model theoretically identifiable but not practically identifiable by 
automated optimization procedures? There are many challenges in numerical parameter 
optimization (see Section 8.7.1), but a sensitivity analysis of the four-state model (see Appendix 
D) revealed some important details. A number of the model parameters had only a small effect 
on the time-varying data. However, when the model was used to simulate steady-state force-pCa 
data, these parameters had a larger effect (Table 21).  
 In order to further explore this idea, we used the four-state model to generate synthetic 
dynamic data using a known parameter set, and applied automated optimization to determine 
whether it was possible to recover the parameter set from this synthetic data. 
One of the assumptions made by the DAISY differential algebra analysis is a noise free 
data set. Intracellular calcium transients are associated with a fair amount of noise due to the 
nature of the measuring technique. Even signal averaging can only reduce the noise, not 
eliminate it. Therefore, we used a model to approximate the time-varying calcium transient. The 
model input is described by Equation 7.37: 
 [𝐶𝐶𝐶𝐶]𝑖𝑖(𝑡𝑡) = 𝐴𝐴(1 − 𝑒𝑒−𝐵𝐵𝑡𝑡)(𝑒𝑒−𝐶𝐶𝑡𝑡) (7.37) 
where A = 1.739 µM, B = 205.89 s-1, and C = 30.52 s-1.  
 Parameter optimization on the synthetic dynamic data alone showed that the parameters 
associated with largest sensitivity for the dynamic data (k3, g, and d: see Table 2 1) were 
accurately estimated, and associated with reasonable standard error values (Table 9 , see values 
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highlighted in gray), while those associated with low sensitivity were less accurately estimated 
and associated with large standard errors. Nonetheless, the overall model fit was very good (R2 > 
0.99, Table 9 and Figure 7-3). 
 
Table 9. Values for Parameter Estimation on Synthetic Data 
 
 
We then generated synthetic steady-state data using the same parameter set used to create 
the synthetic dynamic data. For the steady state data, constant levels of calcium were used as 
input. Automated parameter optimization was used to fit both dynamic and steady-state data 
simultaneously, which resulted in accurate estimation of all model parameters and standard error 
values several orders of magnitude smaller than those associated with parameters fit to only the 
dynamic data (Table 9). The overall model fit using the combined data was excellent (R2 > 0.99, 
Table 9 and Figure 7-3).  
These findings indicated that the difficulty in using parameter estimation on the 
experimental data arose because the input/output pair for the twitch contraction lacked the 
necessary informational content. To compensate for this, the model should be fit to dynamic and 
Parameter
Synthetic       
Data
Fit to Dyamic        
Synthetic Data
Fit to Dynamic + Steady 
State Synthetic Data
k 2 25 3.42 ± 144 24.6 ± 0.044
k 3 84 93.3 ± 13.3 86.2 ± 0.176
k 4 84 80.0 ± 55.9 82.9 ± 0.147
g 205.3 201 ± 76.3 206 ± 0.349
d 44.6 42.5 ± 4.07 44.0 ± 0.067
α1 2 1.50 ± 15.9 2.04 ± 0.003
β1 3 2.63 ± 15.0 3.05 ± 0.003
αf 0.15 0.130 ± 1.18 0.150 ± 0.001
βf 0.7 0.839 ± 4.78 0.705 ± 0.001
R 2 N/A > 0.99 > 0.99
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steady-state data simultaneously. However, dynamic and steady-state experimental data were not 
collected under the same conditions and so they could not be paired. Therefore, another form of 
model-based analysis was required.  
 
 
Figure 7-3. Synthetic and Model-Fit Pressure Waveform 
Pressure waveforms (arbitrary units) for model-generated synthetic data (solid line) and model-based fits (parameter 
optimization) to dynamic data only (dotted line) or dynamic and steady-state data simultaneously (dashed line).  
7.3.3 Model-Based Interpretation of Experimental Data 
Instead of trying to fit the whole raw data set, we attempted to simulate the dynamic and 
steady-state functional differences between the WT and TG-E mice identified here (see Section 
5 and Section 6 ). The goal was to first identify a “baseline” parameter set that created data 
similar to the WT mice, and then determine the minimum number of parameters required to 
simultaneously recapitulate all of the differences in the TG-E mouse. In order to do this, we 
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wrote a Matlab program which could simultaneously calculate time-varying and steady-state data 
(see Appendix C). 
We identified three changes in the TG-E mouse that we wished to recreate: a decrease in 
peak developed force/pressure (see Section 5. 3.2.1 and Section 6.3. 1.1), an increase in 
relaxation time (see Section 5.3.2.1  and Section 6.3.1.1 ), and a decrease in Fmax (see Section 
6.3.2). There were also three indices that should not be significantly altered between the groups: 
pCa50, the Hill coefficient, and the tension cost (see Section 6.3.2).  
We also simplified the system by determining if any parameters could be estimated from 
our experimental data. The slope of the force–ATPase activity relationship is an estimate of the 
tension cost, and represents the rate constant of cross-bridge detachment (g) [112, 113]. The  
TG-E mice exhibited no change in tension cost compared to WT mice (see Section 6.3 .2), 
implying unaltered g in the TG-E mouse. 
The relationship between g and tension cost as defined by Brenner [112] applies to the 
two state model used in that paper. In the four-state model used here, tension cost and g are not 
synonymous. As discussed above, model parameter d also affects steady-state ATPase; but its 
contribution relative to the effects of g is small (7.8% (average over all activation levels) of the 
total ATPase rate calculation, see Sensitivity Analysis in Appendix D). 
Since there were no differences in the intracellular calcium transients in the WT and  
TG-E mice (see Section 6.3.1.1), we used the same simulated transient as the input for both.  
The first step was to identify a baseline parameter set. We used estimated parameters 
from past work with the four-state model [83, 102-105], making slight alterations to match the 
WT data. The following parameters were used for the baseline: α1 (µM-2•s-1) = 2.0, β1  
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(µM-1•s-1) = 3, αf (µM-2•s-1) = 0.15, βf (µM-1•s-1) = 0.7, k2 (µM-1•s-1) = 25, k3 (s-1) = 84, k4 (s-1) = 
84, g (s-1) = 205.3, d (s-1) = 44.6, γ1 = 1.25, and γf = 1.  
Decreasing the value of f (23%) predicted the observed decrease in maximum twitch 
force and Fmax but no change in relaxation time under twitching conditions. However, we 
experimentally observed an increase in relaxation time. There must be a parameter (or set of 
parameters), altered simultaneously with f, that would produce decreased magnitude of 
contraction (both under twitching and steady-state conditions), increased relaxation time, and no 
change in calcium sensitivity or tension cost. We focused on parameters that would maintain the 
activation state: (1) increased calcium binding (i.e., increase k1), and (2) decreased crossbridge 
dissolution in the absence of cTnC-bound calcium (i.e., decreased d). Although the first 
perturbation can produce slowed relaxation, it was unable to reconcile all of the experimental 
observations.  
The second perturbation (a decrease in f by 23% and a decrease in d by 35%) was able to 
reproduce the time-varying experiment observations (see Figure 7-4), the steady state 
experiment observations (see Figure 7 -5) and the tension cost estimate (see Figure 7 -6). The 
magnitude of these changes closely mirrored the results observed in the isolated heart (14% 
negative inotropy, 20% negative lusitropy) and skinned fiber (14% decrease in Fmax, less than 2% 
change in pCa50, nH, and tension cost).  
These magnitudes acted as a guide. The goal here was not to identify exact parameter 
values, but identify a plausible solution which explained the major findings of our experiments. 
It is necessary to point out that there is no mathematical proof that this is a unique solution. 
However, we systematically varied all model parameters and found only one solution. Moreover, 
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there is some experimental evidence to corroborate changes in these parameters (see Section 
8.7).  
 
 
Figure 7-4. Experimental and Model Calculated Pressure Waveforms 
Experimental (A,B) and Model (C, D) derived pressure data, shown as absolute values (A, C) and normalized values 
(B, D) from WT/BL (baseline) (solid) and TG-E/Pert. (perturbation) (dashed) data. Percent change between the 
WT/BL and TG/Pert. indices shown below the legend in appropriate panels. 
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Figure 7-5. Experimental and Model Calculated pCa-Force Plots 
Experimental (A,B) and Model (C, D) derived stead-state data, shown as absolute values (A, C) and normalized 
values (B, D) from WT/BL (baseline) (solid) and TG-E/Pert. (perturbation) (dashed) data. Percent change between 
the WT/BL and TG/Pert. indices shown below the legend in appropriate panels. 
 
 104 
 
Figure 7-6. Experimental and Model Calculated Force-ATPase Relationships 
Experimental (A) and Model (B) derived tension cost, from WT/BL (baseline) (solid) and TG-E/Pert. (perturbation) 
(dashed) data. Percent change between the WT/BL and TG/Pert. indices shown below the legend in appropriate 
panels. 
 
We chose to model the isolated heart data for three reasons: (1) the isolated heart 
experiment represents more physiological conditions compared to the isolated papillary muscle 
experiment, (2) there was a great deal of variability in the papillary muscle data, and (3) data 
from isolated heart and skinned fiber preparations were quantitatively consistent (e.g., 
magnitudes of ΔPdev at Vmax and ΔFmax were similar). 
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The experimental data and the model-based analysis suggest that the TG-E mouse has 
two altered myofilament processes: decreased f and a calcium-independent persistence of the 
active state.  
7.4 SUMMARY 
The differential algebra tool DAISY found the four-state model to be a priori globally 
identifiable, although automated optimization proved to be unreliable. We decided to conduct in 
silico experiments to identify what parameters would recreate our experimental observations. 
The model-based analysis revealed that the experimental observations in TG-E mice 
could be reproduced by two simultaneous perturbations: a decrease in the rate constant of 
crossbridge dissolution (f) and an increase in calcium-independent persistence of the 
myofilament active state (d).  
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8.0  DISCUSSION 
8.1 HYPOTHESES 
Hypothesis 1 : Increased cTnI phosphorylation at the PKC sites will result in systolic 
dysfunction and protection from ischemic contracture at the whole organ level 
The results presented in Section 5.3.1  and Section 5.3.2.1  show that the TG-E mice 
exhibited systolic dysfunction, evidenced by an increased LVESd in echocardiographic data, and 
a decreased peak developed pressure in isolated heart data. The results of the ischemia-
reperfusion experiments (Section 5.3.2.2) indicated that the TG-E mice have no added protection 
from ischemic contracture, compared to WT mice.  
Part of hypothesis 1 is supported by our results: increased cTnI phosphorylation at the 
PKC sites does result in systolic dysfunction. However, the second half of the thesis has been 
disproven: increased cTnI phosphorylation at the PKC sites does not result in protection from 
ischemic contracture at the whole organ level. 
Hypothesis 2 : Increased cTnI phosphorylation at the PKC sites will result in depressed 
calcium-force and ATP-force relationships (less force per calcium or ATP hydrolyzed).  
In Section 6.3.1.1  the TG-E mice had decreased developed force, with no change in 
intracellular calcium, indicating less twitch force per unit calcium compared to WT mice. The 
results in Section 6.3.2 showed that there was a reduction in Fmax for fixed calcium levels, also 
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indicating depressed calcium-force relationship. In this same section, there was no change in the 
ATPase-force relationship (the tension cost) between the WT and TG-E mice. Protocol length 
restricted our ability to record intracellular calcium during acute phosphorylation experiments.  
Our results support the first part of hypothesis 2, indicating that increased cTnI 
phosphorylation at the PKC sites does result in depressed calcium-force relationship. However, 
we have found that there is no change in the ATPase-force relationship. 
Hypothesis 3: A model-based analysis of data from Specific Aims 1 and 2 will provide 
an integrative interpretation of increased cTnI phosphorylation at the PKC sites. 
The results of the identifiability analysis (Section 7.3.1) indicate that the four-state model 
we selected for the model-based analysis is capable of providing unique solutions from the data. 
The model-based analysis was able to recreate the negative inotropy, negative lusitropy, decrease 
in Fmax with no change in pCa50 or the tension cost that were experimentally observed in the  
TG-E mice (Section 7.3.2 ). All of these results were recreated with two model parameter 
perturbations.  
Thus, a model-based analysis of data from Specific Aims 1 and 2 did provide an 
integrative interpretation of increased cTnI phosphorylation at the PKC sites. 
8.2 INITIAL CHARACTERIZATION 
The TG-E mouse showed a 7.2% replacement of endogenous cTnI with mutant cTnI. 
There were no differences in the level of other phosphorylated species of cTnI 
(unphosphorylated and one through five sites phosphorylated). Therefore, there is an increase in 
total phosphorylation of cTnI at the PKC sites: the summation of basal phosphorylation 
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(unchanged in TG-E mice) and pseudo-phosphorylation (increased by 7.2% in TG-E mice). 
Recent evidence indicates that basal in vivo cTnI phosphorylation at the PKC sites is very low 
[38, 114]. Thus, the percent replacement in our TG mice, although small, may represent a 
physiologically relevant level of increased PKC cTnI phosphorylation. 
The other mouse model, TG-A (serine 43 and 45 mutated to alanine), showed a ~50% 
replacement of endogenous cTnI by the mutant cTnI [61]. Thus, the TG-E and TG-A mice 
represent cTnI phosphorylation changes in opposite directions and of differing magnitudes. 
However, given the low basal phosphorylation state, a higher replacement of non-
phosphorylatable sites would be required to observe functional effects. 
There were also no alterations in phosphorylation of Tm, TnT, ELC or MyBP-C, 
indicating that the observed effects were from cTnI PKC phosphorylation alone. 
Transgenic mouse models are not a panacea; there can be some limitations associated 
with these models. For example, it is important to verify that the observed functional effects are 
due to changes made in the transgene (i.e., PKC phosphorylation of cTnI in our case), and not an 
unintentional side-effect of inserting the transgene. It is possible that when the mutant cTnI 
transgene randomly inserted into the genome it split the coding region for another protein, 
changing the transgenic animal in an unforeseen and unpredictable manner. Usually, this 
possibility is eliminated by studying multiple lines, where the transgene would have randomly 
inserted into different locations in each line. Unfortunately, we only had one line for our 
transgenic mouse. This is a limitation of the study, which we partially addressed by examining 
the phosphorylation status of other key myofilamental proteins (see Section 4.5.2) and 
performing acute phosphorylation experiments (see Section 6.3.1.2 ). While not a replacement 
for multiple transgenic lines, since we cannot completely eliminate the possibility that the 
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transgene altered or eliminated an important gene during its incorporation, the results of these 
two experiments provide reasonable evidence that the functional effects we observed were most 
likely due to the mutation (i.e., increased PKC phosphorylation of cTnI), and not a side effect of 
the creation of the transgenic mouse.  
8.3 CONTRACTION AND RELAXATION 
There was evidence of reduced contraction in the TG-E mice compared to WT mice at all 
levels studied: (1) echocardiographic studies revealed decreased LVESd, (2) isolated heart 
studies showed depressed developed pressures over the entire volume range, (3) intact papillary 
muscles exhibited lower developed force over the entire set of lengths, and (4) skinned fibers 
showed significantly lower Fmax. In reconstituted fibers where cTnI PKC phosphorylation sites 
were rendered constitutively pseudo-phosphorylated, a decrease in Fmax was also seen [51]. The 
TG-A mouse model showed an increase in developed pressures at high extracellular calcium 
levels (3.5 mmol/L [Ca]) [60]. Together with previous data, the new transgenic model supports 
the hypothesis that phosphorylation of cTnI by PKC lowers the ability of the myocardium to 
generate active force, under both dynamic and steady-state activations.  
In echocardiographic, isolated heart and intact papillary experiments, TG-E mice also 
showed negative lusitropy when compared to control mice. This is consistent with the results of 
Pi et al., who treated wild-type mice with the PKC activator ET-1 and observed an increase in 
relaxation time (negative lusitropy) [55]. Furthermore, in their transgenic animal, in which all 5 
cTnI phosphorylation sites were replaced with alanines, the effects of ET-1 were severely 
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blunted. These results, combined with the results presented here, suggest that phosphorylation of 
the PKC sites on cTnI has a negative lusitropic effect.  
By that same logic, the TG-A mouse would be expected to exhibit positive lusitropy. 
Contrary to this, however, our own work in isolated hearts provides no evidence of change [60]. 
In the TG-A mouse, the T144 is not mutated to an unphosphorylatable alanine, leaving its 
phosphorylation level near baseline levels. It is possible that phosphorylation at position T144 on 
cTnI is primarily responsible for PKC-induced slowing of relaxation. If this were true, then it 
follows that the TG-A mouse may not show differences compared to WT mice.  
8.4 ISOLATED HEART AND ECHOCARDIOGRAPHY 
8.4.1 Heart Rate 
Echocardiographic data showed that the TG-E mice had a lower heart rate (mild 
bradycardia) compared to the WT mice (see Section 5.3.1 ). Given the interplay between heart 
rate and heart failure [115], there was a concern that the mutation resulted solely in a depressed 
heart rate, and all other functional effects were a long-term consequence of this reduced heart 
rate. When WT mice were subjected to acute phosphorylation treatment, the functional changes 
mimicked those seen in the TG-E mouse (see Section 6.3.1.2 ). The WT mice, however, had 
never been exposed to reduced heart rates, making it unlikely that our observations in the TG-E 
mouse were a response to chronic bradycardia. 
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8.4.2 Response to Ischemia  
TG-A mice have shown increased susceptibility to ischemic contracture [57]. This was 
based on a significant increase in diastolic pressures compared to WT mice during the ischemic 
and reperfusion periods in isolated hearts, as shown in Figure 8-1. Based on these results, we 
expected that constitutive phosphorylation of these sites might confer protection from ischemic 
contracture. However, our data did not support this expectation (see Figure 5-7, Section 5.3.2.2).  
We did not treat either WT or TG-E mice with anything to control phosphorylation. 
Therefore the WT myocardium was free to respond to stresses as it would under normal 
conditions. In the case of ischemia/reperfusion injury, it would attempt to protect itself by 
upregulating PKC [116]. Because the WT and TG-E mice had similar responses to 
ischemia/reperfusion, we hypothesized that the phosphorylation state of cTnI in the two strains 
may have been similar as well.  
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Figure 8-1. WT vs. TG-A Response to Ischemia-Reperfusion 
LV pressure from WT and TG-A mice during ischemia and reperfusion, modified from [57]. At five minutes (first 
vertical line), coronary flow is reduced to zero and ischemia begins. At twenty minutes (second vertical line), flow is 
restored and reperfusion begins. Protocol lasts 40 minutes total. (A) Systolic pressures. There were no statistical 
differences between WT (black) and TG-A (white) pressures. (B) Diastolic pressures. The TG-A (white) mice 
showed significant susceptibility to diastolic contracture compared to WT (black). Data are mean ± S.E.M.. 
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8.4.3 Response to β-adrenergic Stimulation  
The TG-E and WT mice responded similarly to isoproterenol (1µmol/L) infusion: an 
increase in developed pressure and a decrease in rise and relaxation times. β-adrenergic 
stimulation acts through cAMP mediated activation of PKA-activated pathways. Specifically, 
PKA phosphorylates specific sites on cTnI (S23 and S24) and cellular calcium handling proteins 
(e.g., sarcoplasmic reticulum ATPase pump, L-type calcium channels), which result in positive 
inotropy and faster relaxation [31, 33, 117]. These results show that the mutation we introduced 
in cTnI did not affect these PKA-dependent pathways, suggesting that β- and α- adrenergic 
stimulation of cTnI are distinct, and may not have any interaction in their effects on cardiac 
function. 
8.5 ISOLATED PAPILLARY MUSCLE 
8.5.1 Intracellular Calcium Transients 
There were no differences in intracellular calcium amplitude or relaxation between the 
WT and TG-E mice, or with PKC activation through phenylephrine treatment. We have 
previously seen in the TG-A mice that there were also no differences in intracellular calcium at 
normal extracellular calcium levels [57]. Others have also shown that there are no changes in 
intracellular calcium with PKC phosphorylation of cTnI [55, 58].  
There are several limitations in the methodology of measuring intracellular calcium 
transients. An intact papillary muscle is a live system, and it is difficult to reliably measure an 
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intracellular process without disrupting the system. In order to detect intracellular calcium, fura 
must bind to it, which it does because fura is derived from the calcium chelator BAPTA [91]. 
The problem is that intracellular calcium buffering can occur, specifically with fura-2 [118], 
which has a high binding affinity for calcium (kd = 224 nM). Moreover, the high binding affinity 
can slow its dissociation from calcium during the relaxation (descending) phase of the calcium 
transient, leading to a perceived increase in relaxation times compared to measurements using 
other calcium indicators [119]. In order to reduce the impact of these limitations, we used an 
alternate form of fura-2, fura-5F, which has a higher kd value (400 nM), and thus dissociates 
from calcium more readily. 
Another limitation is compartmentalization, which arises from the loading method used 
here. We used the acetoxymethylester (AM) form of fura, which is cell-permeant and can diffuse 
across membranes. Once the dye is in the cytoplasm, nonspecific esterases hydrolyze the AM 
form, removing its ability to move across the membrane and activating the calcium sensitive dye. 
However, it is possible for the dye to enter other intracellular organelles before it is activated, 
removing its ability to measure cytoplasmic calcium. It is estimated that up to 29% of fura-2 
could be compartmentalized [120], particularly in the mitochondria [121]. This makes it difficult 
to determine absolute levels of intracellular calcium (see Section 6.1.1.1), but should not affect 
our ability to compare intracellular calcium transients that were collected under identical 
experimental conditions. 
 Lastly, this is a measurement of intracellular free calcium, not calcium bound to troponin 
C. We assume that the free calcium and TnC-bound calcium follow the same time path, but it is 
not necessarily true. Suppose we observe an increase in relaxation time of the free calcium 
transient and assume this means elongation of bound TnC calcium; this is a legitimate 
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assumption, but the observation could also indicate faster dissociation of calcium from TnC, thus 
increasing the free form of calcium. In fact, there are many intracellular pathways that can 
increase or decrease free calcium concentration. There is currently no way to definitively 
measure the calcium which activates the myofilament, and so care must be taken while analyzing 
data from intracellular free calcium transients. 
8.5.2 Acute Phosphorylation 
The goal of the acute cTnI phosphorylation experiments was to extend the results of 
Montgomery et al. [95]. In that study, right ventricular papillary muscles from WT FVB and  
TG-A mice were treated with 30 μM phenylephrine in the presence of 1 μM propranolol. They 
found that there was a 62% reduction in peak twitch force in the WT mice, and only a 45% 
reduction in the TG-A mice. They attribute this blunted response to the inability of PKC to 
phosphorylate the alanines on the mutant cTnI expressed in the TG-A mice. 
We decided to use phenylephrine with propranolol as well, due to its common usage as 
an α1-adrenergic stimulator in mice [122-124]. We observed a negative inotropic response in the 
WT mice, as well as a negative lustropic response. While we had hypothesized that the TG-E 
mouse would have a blunted response to α1-adrenergic stimulation, the mice responded similarly 
to the WT mice, showing negative inotropy and lusitropy of comparable magnitude. 
The difference in response between the TG-A and TG-E mice compared to the WT mice 
is likely due to the large difference in expression of the transgenic cTnI. The TG-A mice 
exhibited approximately 50% replacement of endogenous cTnI with the mutant cTnI [61]. Thus, 
the alanines on the mutant cTnI would be fairly effective at blocking the PKC phosphorylation 
activated by the α1-adrenergic stimulation. 
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 However, the TG-E mice have only 7.2% replacement of endogenous cTnI (see Section 
4.4.2). While the glutamates that replaced the serines are just as effective as the alanines at 
blocking phosphorylation, there are not nearly as many of them. In fact, almost 93% of the PKC 
phosphorylation sites are free to be phosphorylated. Thus, it is unlikely there would be a 
significant difference between the WT and TG-E mice in their response to α1-adrenergic 
stimulation.  
 The response itself fits in well with our other findings. In the echocardiographic, isolated 
heart, and isolated papillary data, we found that the TG-E mice had decreased force production 
and slowed relaxation compared to the WT mice. It is important to verify that these effects arise 
from actual PKC phosphorylation of cTnI, and not from another possible source arising from the 
formation of the transgenic mice. The fact that the acute treatment resulted in these same 
responses provides this evidence.  
 The limitation of this study stems from PKC’s ability to phosphorylate other 
myofilamental proteins (see Section 1.2 ), and so the effects observed may be due to 
phosphorylation of proteins other than cTnI. However, this seems unlikely given the agreement 
of these data with the transgenic data. 
8.6 SKINNED FIBERS 
8.6.1 Calcium Sensitivity 
The TG-E mice did not exhibit differences in calcium sensitivity compared to WT mice. 
Burkart et al. conducted experiments on detergent-extracted cardiac fibers reconstituted with 
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three forms of mutant cTnI that were pseudo phosphorylated at the PKC sites: S43E/S45E, 
S43E/S45E/T144E, and T144E [51]. They showed that S43E/S45E and S43E/S45E/T144E fibers 
exhibited similar decreases in calcium sensitivity. However, there was no change in calcium 
sensitivity in T144E fibers, suggesting that phosphorylation at this site plays no role. This is 
inconsistent with data from Wang et al. in which chemical phosphorylation of T144 by PKC-βΙΙ 
resulted in increased calcium sensitivity [125].  
The reconstituted fibers studied by Burkart et al. showed a much higher replacement of 
endogenous cTnI with the mutant form (70-97%) than was present in our TG-E mouse. Wang et 
al. found that PKC-βΙΙ caused a 20-50% incorporation of radiolabeled phosphate, which was 
much closer to the level of phosphorylation simulated by our mutant cTnI. This suggests calcium 
sensitivity may be affected differently at very high, possibly non-physiologic, levels of PKC 
phosphorylation of cTnI.  
Since our model simulates phosphorylation at all three PKC sites, it is possible there are 
two offsetting effects on calcium sensitivity; a decrease in calcium sensitivity due to the 
(pseudo)phosphorylation at S43/S45 and an increase in calcium sensitivity in response to the 
(pseudo)phosphorylation at T144. This possibility raises the question: if PKC phosphorylates all 
three positions, what is the purpose of mutually offsetting effects at the different sites? One 
possibility is that certain PKC isoforms only phosphorylate or preferentially phosphorylate a 
given residue, resulting in unequal phosphorylation on the three sites. For example, PKC-βΙΙ 
[125] and tyrosine-phosphorylated PKCδ [126] preferentially phosphorylate T144. 
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8.6.2 ATPase Activity 
We observed a decrease in maximal ATPase activity of approximately 9%, although this 
was not quite statistically significant. Pyle et al. saw a decrease in ATPase activity and Fmax, 
leading to no change in tension cost in WT papillary muscles treated with phenylephrine plus 
propranolol [61].  
8.7 INTEGRATIVE AND MODEL-BASED INTERPRETATION 
8.7.1 Parameter Identifiability Challenges 
Analysis with DAISY revealed that the four-state model is globally identifiable, but there 
are many obstacles when identifying the unique parameter set in practice. In the case of the four-
state model, we discovered the issue involved the informational content of our input/output pair. 
However, in general, additional difficulties can arise from the complexity of the solution space. 
If the solution space is discontinuous, an automated optimization algorithm may generate errors 
when it attempts to find solutions in these areas. More complicated procedures, like Genetic 
Algorithms, however, can avoid this problem because they search for multiple solutions at the 
same time.  
The solution space may also contain many local minima and basins of attraction. These 
can lead an optimization algorithm to find a solution which does not represent the global minima. 
In order to find the true global minima, much iteration may be required to be certain that the best 
solution has actually been found. 
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If the experimental data the model is trying to fit involves multiple processes with 
varying time constants, the error function may not produce reasonable values. The pressure 
waveform from an isolated heart has a fast decay period followed by a relatively steady-state 
diastolic period. The method of calculation of the error between the model and experimental data 
becomes very important. Assume the error is represented by the vertical difference (in the y-
direction) between the waveforms. In this case, if the fast decay period is shifted by only a small 
degree in the x-direction, the error value would be very large, considering only a small parameter 
change may be necessary to improve the fit. However, if the error is represented by the 
horizontal difference (in the x-direction) between the waveforms, a small difference during the 
diastolic period would results in very large errors. It is very difficult to accurately represent the 
error between the data and the model in situations like this. 
8.7.2 Site Specificity 
While the experimental data were explained by a simultaneous decrease in model 
parameters g and d, it is possible to model the effects of each change independently. The four-
state model indicated that an independent decrease in d was associated with an increase in 
calcium sensitivity and slowed relaxation. As discussed earlier, experimental data suggest that 
T144 phosphorylation causes an increase in calcium sensitivity [125] and is primarily 
responsible for slowed relaxation (see Section 8.3). Burkart et al. [51] found that reconstituted 
detergent-extracted cardiac fibers mutating S43/S45 and S43/S45/T144 to glutamates caused a 
depression in maximal force, but mutating only T144 resulted in no significant change in Fmax. 
There was even a slight, though non-significant, increase in maximal force in the T144E mutant, 
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which we saw in the model when only d was altered. For these reasons, it is tempting to attribute 
the decrease in d to T144 phosphorylation.  
Likewise, the model indicated that an independent decrease in f was associated with a 
decrease in calcium sensitivity, no change in relaxation, negative inotropy, and decreased 
maximal ATPase activity. Experimental data suggest that phosphorylation of S43 and S45 results 
in decreased calcium sensitivity [51], no change in relaxation [60], and negative inotropy [60]. 
Thus, it is possible that the decrease in f is a result of S43 and S45 phosphorylation.  
This is also supported by a recent paper by Mathur et al. [127], in which they studied the 
effects of three mutant cTnI’s (S45E, S43E/S45E and S43E/S45E/T144E) expressed in an 
isolated actin/myosin system. They found that the S45E mutation alone was sufficient to lower 
the ATPase rate, which is consistent with phosphorylation at S43/S45 resulting in a decrease in f. 
This also supports the hypothesis that T144 phosphorylation causes the change in d, which has 
little affect on the ATPase rate.  
8.7.3 Biophysical Basis for Model-Based Interpretations 
There is evidence that the introduction of negative charges at S43 and S45 stabilizes the 
N-terminus region and increases the interaction of the inhibitory region with actin [128]. This 
leads to a stabilization of the inactive form of actin [127]. If the phosphorylation of cTnI at the 
PKC sites stabilized the inactive form of actin, when myosin binds to it, it is less likely to 
hydrolyze ATP and generate force. In the four-state model, there is no pathway for inactive actin 
and so it is possible that a stabilization of inactive actin could be manifested in the model as a 
decrease in f.  
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There is also evidence that T144, but not S43 or S45, phosphorylation alters the 
interaction of cTnI with cTnC at the Ca2+ binding site [129]. Our model-based hypothesis is that 
T144 phosphorylation is responsible for a calcium-independent persistence of the myofilament 
active state. This could be mediated through altered interaction with cTnC and its interaction 
with calcium binding. While this is a tenuous connection, it provides a plausible explanation for 
our theory. Unfortunately, however, there is a paucity of work done on the T144 site.  
We had assumed that f, g, and d represent the kinetic rate constants for formation and 
dissolution of force-generating crossbridges. However, this is a simplification of reality. The 
parameters f, g, and d are actually a mean field approximation of spatially distributed and 
interacting individual contractile units, the totality of which manifest as the “mean” rate 
constants of crossbridge formation and dissolution. It is likely that the overall (mean) values of f, 
g, and d. are determined by spatial distribution, organization, and interaction of these individual 
units, in addition to the kinetic rate constants of the individual units. One can imagine a situation 
where two mice have identical overall expression of a mutant myofilament protein, but different 
spatial distribution. It is possible that these two mice would have different values of f, g, or d.  
In the end, the precise biophysical basis for the altered myofilament properties remains 
unknown. Although, given that the model parameters represent several biochemical processes 
lumped together, there exist many possible explanations for the model-based findings. 
8.7.4 Functional “Gain” 
The low level of mutant cTnI expression (7-8%, see Section 4.5.2) was unexpected, but 
resulted in significant functional effects. If the myofilament is visualized as many force-
generating units working in parallel and series, it is difficult to envision how a change in 8% of 
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these units could result in the overall phenotype we observed. However, there are several 
possible explanations for the high functional “gain” of PKC phosphorylation of cTnI. 
The first possibility is that the mutant cTnI had differential transmural expression. There 
is evidence that myosin isoforms are differentially expressed through the ventricular wall [130], 
so it is possible that the mutant cTnI was expressed at higher levels in either the endocardium or 
epicardium. This would result in a higher than 8% expression in a specific location and could 
produce large global functional effects. 
It is also possible that a minority of mutant cTnI affect a much larger area by influencing 
neighboring functional units arranged in series or parallel. In skeletal muscle, it has been 
suggested that cooperative interaction can be sensed along the entire length of the thin filament 
[131]. It is also possible that the mutant cTnI may have changed the myofilament lattice spacing, 
altering the crossbridge kinetics (a mechanism observed for MyBP-C [132]) in an area 
surrounding a single mutant cTnI. 
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9.0  CONCLUSIONS 
9.1 TAKE HOME MESSAGES 
• Despite low integration of mutant protein, TG mice show significant functional changes, 
indicating high sensitivity of cardiac contraction to PKC cTnI phosphorylation.  
• Increased PKC phosphorylation of cTnI resulted in decreased magnitude of contraction 
(decreased fractional shortening in echocardiographic data, decreased developed pressure 
in isolated hearts, decreased developed force in isolated papillary muscles, and decreased 
maximally activated force in skinned fibers).  
• Increased PKC phosphorylation of cTnI resulted in slowed relaxation (longer peak to 
diastolic time in echocardiographic data, longer relaxation time in isolated hearts, and 
decreased magnitude of dF/dtmin in isolated papillary muscles).  
• Increased PKC phosphorylation of cTnI resulted in no changes in calcium sensitivity, 
cooperativity, tension cost, or intracellular calcium transient (magnitude or relaxation).  
• Identifiability analysis on the four-state model found it to be a priori globally 
identifiable; however, automated optimization was not effective. 
• The model-based analysis revealed that the experimental observations in TG-E mice 
could be reproduced by two simultaneous perturbations: a decrease in f and an increase in 
calcium-independent persistence of the myofilament active state.  
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• Based on our data and data from the literature, we speculate that the effects of PKC-
mediated cTnI phopshorylation are site-specific (S43/S45 vs. T144). 
9.2 CLINICAL IMPLICATIONS 
As covered in Section 1.6 , PKC phosphorylation of cTnI may be involved in heart 
failure, either as a cause, a consequence, or compensation. The work done here shows several 
effects which depress cardiac function in a transgenic animal with increased phosphorylation of 
cTnI at the PKC sites. Nonetheless, the mouse did not appear to degenerate into heart failure, 
showing no cardiac hypertrophy (evidenced by no change in LVEDd, see Section 5.3.1 ) or 
external signs of depressed cardiac function such as lethargy or differences in eating patterns. 
This suggests that an ~8% increase in PKC phosphorylation of cTnI does not cause heart failure. 
Therefore, if PKC over-phosphorylation of cTnI is a cause or stimulating event for heart failure, 
it is at higher levels.  
There may be utility in blocking PKC phosphorylation of cTnI in humans during heart 
failure as a treatment scheme [72, 133, 134]. Cardiac TnI is a useful target for therapy because of 
specificity of its expression in cardiac tissues, as evidenced by its use as a diagnostic marker for 
myocardial ischemia. As we have shown here, increased PKC phosphorylation of cTnI is 
associated with many negative effects, and blocking this pathway would help to assuage these. 
Moreover, there is high “gain” on the functional effect of phosphorylation at these sites.  
The effects of PKC phosphorylation of cTnI are not all bad; there are beneficial effects as 
well. For example, PKC phosphorylation of cTnI exerts cardioprotective effects during ischemia-
reperfusion injury (see Section 5.3.2.2), most likely through a decrease in myofilament ATPase 
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[135] (see Section 6.3.2). Thus, non-specific blocking of PKC phosphorylation of cTnI may not 
be a clinically viable strategy. More work is required to determine whether the positive and 
negative effects of PKC phosphorylation of cTnI follow different signaling pathways and if so, 
whether it is possible to selectively block pathways that produce negative effects. 
9.3 FUTURE WORK 
The quanitification of mutant mRNA in the transgenic mouse was unsuccessful in our 
earlier attempts. While we proved that the mutant protein was expressed (see Section 4.5.2 ), 
quantifying the mutant mRNA might help identify the cause of the low mutant protein 
expression. We originally used primers that would bind to the mutant cTnI sequence, but not the 
endogenous one, by targeting the mutated sites (S43, S45 or T144). However, it is possible to 
take advantage of the untranslated 3’ region or introns to differentiate between the mutant and 
endogenous protein. Thus, the two ends of the endogenous cTnI sequence could be used to 
generate primers, and the RT-PCR products differentiated by weight.  
While we performed acute phosphorylation experiments in papillary muscles (see 
Section 6.2.2 ), it would also be useful to treat skinned fibers with a PKC activator. Then it is 
possible to compare the change in Fmax in the acute phosphorylation treatment fibers (if there is 
one) to the observed change in the transgenic fibers.  
One of the findings of the modeling portion of this work is that the four-state model, 
while a prior globally identifiable, requires an information-rich data set (see Section 7.3.2). It is 
possible to increase the information content of the data set by providing paired dynamic and 
steady-state data. There are two experiments that could provide these data: skinned fibers with 
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caged calcium (dynamic response to activation level) and skinned fibers with length 
perturbations (dynamic response to length changes). Both of these experiments could be done on 
skinned fibers that had already produced steady-state (force-pCa and ATPase-pCa) data. 
Caged calcium allows calcium to be near-instantly mobilized or chelated through flash 
photolysis [136, 137]. By nearly instantaneously decreasing or increasing the concentration of 
calcium available to the myofilament, we generate “step-inputs” into the system. Analyzing 
“step-input” responses can provide dynamic data that are simple to interpret. Length 
perturbations are made to a skinned fiber by stretching or shortening the fiber by a small amount 
(~1% total length), which creates a spike in force production, a return to a value near baseline, 
and then an approach to a new steady-state value [138]. This type of dynamic data comes at a 
trade-off, however, since muscle length would have to be incorporated into the model, which 
would increase its complexity.  
One of the conjectures put forth here is the site specificity between S43/S45 and T144. It 
would be helpful to create additional transgenic mice expressing each of the mutant cTnIs used 
by Burkart et al. [51]. Experiments on these mice could help to clarify these issues.  
There are also a number of hypotheses generated by this work that may be possible to test 
experimentally, but were outside the purview of this project. The first deals with the 
phosphorylation status of cTnI during ischemia/reperfusion. Since there was no difference 
between the WT and TG-E mice, we hypothesized that their phosphorylation status was similar. 
Flash freezing the heart in liquid nitrogen and then using 2D-DIGE to check the level of 
phosphorylation (see Section 4.4) could confirm this hypothesis.  
 The model-based hypotheses would also be useful to test. Specifically, investigating the 
biophysical basis for these effects – how does cTnI phosphorylation result in the effects in 
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crossbridge cycling that the model-based interpretation identified? Possible avenues of research 
including examining lattice spacing [35] and structural dynamics using FRET [139]. They are 
difficult to test, and few reliable techniques currently exist. In the future, new techniques may be 
available to test these hypotheses. 
 Given the utility of this transgenic mouse in understanding heart failure, it would be 
interesting to cross this mouse with a true heart failure model, and compare the phenotypes of the 
TG-E + heart failure mouse, TG-E mouse, heart failure mouse, and WT mouse. Does the 
increase in PKC phosphorylation of cTnI exacerbate the heart failure phenotype or is it more 
complicated than that? It would also be interesting to cross the heart failure mouse with a 
transgenic mouse in which the PKC phosphorylation sites on cTnI were unphosphorylatable. 
There is no doubt of the utility of the mouse model for studying cardiac physiology and 
disease [140], but, obviously, a mouse is not a man. Care must be exercised when applying 
findings from a mouse to human cardiovascular function and disease [141]. One can question the 
extrapolation of mouse studies to humans, so future studies could focus on larger mammals.  
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APPENDIX A 
PRESSURE-CALCIUM RELATIONSHIPS IN PERFUSED MOUSE HEARTS 
While not directly related to the overall goals of this project, we were interested in the 
pressure-calcium relationships in WT mouse hearts. The following text and figures are modified 
from [83], and used here with permission.  
The mouse heart has several distinguishing features compared to larger mammals, 
including an in-vivo heart rate of approximately 600 beats per minute [141]. Consequently, 
calcium handling in the mouse myocardium is also different from mammals with longer cardiac 
cycles. There exists an almost complete dependence on the sarcoplasmic reticulum to provide the 
calcium for myocyte contraction [1, 142]. Gao et al. [94] have characterized calcium cycling and 
contractile activation in mouse myocardium. They described a positive force-frequency 
relationship in isolated mouse myocardium, though the increase in force was greater than that 
expected from the underlying increase in intracellular free calcium, suggesting “frequency 
dependent sensitization” of the myofilaments. Their findings also showed that mouse 
myofilament had decreased calcium sensitivity and increased cooperativity under steady-state 
activation relative to other species.  
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Length-dependent activation in the mouse may have unique features as well. Typically, 
there are two components of length-dependent activation that are distinguishable from their 
temporal patterns of responses [143, 144]. The fast-acting early component is due to increased 
calcium sensitivity of the myofilament, and is the basis for the Frank-Starling relationship. The 
slow-acting late component is due to an increase in the calcium transient. Reyes et al. [145] have 
studied in-vivo hemodynamics in the anesthetized mouse using a conductance catheter to obtain 
pressure-volume loops. They demonstrated that increasing end-diastolic volume by aortic 
constriction resulted in an immediate increase in contractility. However, there was no further 
augmentation in contractility up to 7 minutes after the increase in load, suggesting that the late 
component of length-dependent activation was not operative in the mouse. Calcium transients 
were not measured in this study, and therefore the potential role of intracellular free calcium in 
the absence of the late component remains speculative. 
The purpose of this study was to characterize the relationship between pressure and 
intracellular free calcium in the perfused mouse heart. Specifically, we were interested in the 
following questions: (1) Can peak developed pressure change significantly with a minimal 
change in the peak systolic intracellular free calcium?, (2) Is the late component of length-
dependent activation absent?, and (3) What are the determinants of pressure relaxation? Two 
perturbations were used to alter pressure: changes in ventricular volume at a fixed stimulation 
interval (Frank-Starling protocol) and single-beat changes in stimulation interval at a fixed 
ventricular volume (mechanical restitution protocol). We used the isolated perfused mouse heart 
preparation and the calcium-sensitive fluorescent dye rhod-2 to record pairs of left ventricular 
(LV) pressure and intracellular free calcium concentration ([Ca]i). This allowed us a more 
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physiological assessment of murine myocardium compared to isolated tissue studies, as well as 
measurements of [Ca]i that are not possible with in vivo studies.  
 
METHODS 
Isolated perfused hearts experiments were performed as described in Section 5.2.3 . The 
Frank-Starling protocol was performed as described in Section 5.2.4. 
Fluorescence measurements. Methods to measure intracellular free calcium from the 
perfused mouse heart using the calcium sensitive fluorescent dye rhod-2 have previously been 
described in detail [146, 147]. In this study, several equipment modifications from the original 
descriptions have been made, which include use of a spectrofluorometer equipped with a 150 
watt Xenon light source and 2 photomultiplier units (Photon Technology International, 
Lawrenceville, NJ). The heart was situated in a water-jacketed chamber kept at 37 oC, and placed 
against the optical window. Heart motion was prevented by an anterior-to-posterior stabilizer as 
well as two lateral stabilizers. Three light guides (3 mm core) were coupled to the surface of the 
mouse heart by placing them within 1 mm of a glass window of the heart warming chamber: one 
for excitation light, one to collect fluorescence emission, and one to collect reflected light that 
was used in the calibration of the fluorescence signal. The excitation and fluorescence emission 
light guides were placed in a horizontal plane and at 30o and 70o, respectively, with respect to the 
plane of the glass window. The light guide for reflected light was placed 45o above the horizontal 
plane and at 70o with respect to the glass window.  
After baseline measurements, 100 μg of rhod-2 was loaded through the coronary 
perfusate, and after 20 minutes, fluorescence and absorbance measurements were taken. 
Fluorescence time-based scans were performed with excitation at 524 nm and emission at 589 
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nm, and a long pass filter (550 nm) placed in the emission light pathway. Fluorescence data were 
digitized on-line at 500 Hz for later off-line analysis. To account for dye washout, absorbance 
was calculated from a reflectance scan at 500 – 600 nm taken after each time-based fluorescence 
scan. At the end of the experiment the heart was tetanized with a bolus of 20 mM CaCl2 with 10 
μM cyclopiazonic acid (Sigma Chemical Co., St. Louis, MO) to determine the maximum 
fluorescence (Fmax).  
Quantification of the relative amount of rhod-2 in the heart was done by taking the ratio 
of reflectance at 524 nm (R524, rhod-2 sensitive) to 589 nm (R589, rhod-2 insensitive). Rhod-2 
absorbance (A) was calculated according to the following formula [146, 148]: 
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where subscripts “0” and “rhod2” indicate the reflectance ratio before and after dye loading, 
respectively. Intracellular free calcium was calculated using the following formula: 
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where Kd is the dissociation constant for rhod-2 and calcium (710 nM), Ft and At are 
fluorescence and dye absorbance at time t, F0 is the fluorescence before dye loading, and Fmax 
and Amax are maximal fluorescence obtained from the tetanized heart and dye absorbance just 
prior to tetanizing the heart, respectively. 
Mechanical restitution protocol. All measurements were obtained in this protocol with 
LV volume set at Vmax (identified in the Frank-Starling protocol). Pressure and fluorescence data 
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were recorded for steady-state contractions at the control pacing interval of 240 ms (i.e., control 
pulse interval, CPI) and for a test contraction with a single-beat perturbation of the pacing 
interval (i.e., test pulse interval, TPI). To achieve a range of pressure and calcium pairs, data 
were collected at four values of TPI (200, 400, 600, and 800 ms) and with the test contraction 
deployed in three ways: after a steady-state contraction (Figure 9-1A), after one extra-systole at 
100 ms (Figure 9-1B), and after two extra-systoles at 100 and 200 ms (Figure 9-1C). Each 
experimental condition (i.e., a combination of TPI value and mode of deployment) was repeated 
4 – 5 times. 
 
Figure 9-1. Example of Mechanical Restitution Protocol 
Examples of fluorescence and left ventricular (LV) pressure data obtained during mechanical restitution protocols. 
A, B, and C correspond to protocol 1 (test pulse interval = 600 ms, no extra systole), protocol 2 (test pulse interval = 
600 ms, 1 extra-systole indicated by arrow), and protocol 3 (test pulse interval = 600 ms, 2 extra-stimuli indicated by 
arrows), respectively. Following a prolonged test pulse interval there was potentiation of both LV pressure and 
systolic calcium with respect to the steady-state contractions. 
 
Data analysis. Individual cardiac cycles were first identified using the spike in the pacer 
signal. Signal averaging over the cardiac cycle was then performed to reduce high-frequency 
random noise, especially in the calcium fluorescence signal. For the Frank-Starling protocol, 
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pressure and fluorescence data from 5-7 steady-state contractions at a given LV volume were 
averaged to yield a representative cycle. For the mechanical restitution protocol, up to 5 of the 
repeated measurements of each experimental condition were averaged to yield one representative 
cycle each for control and test contractions. LV pressure and calcium waveforms were 
characterized by several amplitude and rate indices. Amplitude indices included diastolic 
pressure (Pdia) and calcium ([Ca]i-dia), peak systolic pressure (Psys) and calcium ([Ca]i-sys), and 
developed pressure (Pdev= Psys – Pdia) and calcium ([Ca]i-dev = [Ca]i-sys – [Ca]i-dia). Rate indices 
included maximal rate of rise (dP/dtmax, d[Ca]i/dtmax), maximal rate of fall (dP/dtmin, d[Ca]i/dtmin), 
rise time (Trise-P, Trise-Ca), and relaxation time (Trelax-P, Trelax-Ca). Trelax was defined as the time 
taken for developed pressure (or calcium) to decay from 75% to 25% of its maximum value. 
Similarly, Trise was defined as the time taken for pressure (or calcium) to rise from 25% to 75% 
of its maximum value. Finally, the calcium area ([Ca]i-area) was calculated as the area under the 
calcium transient. Calculations of Trelax, Trise, and [Ca]i-area were performed after subtracting the 
diastolic value of pressure (or calcium) waveform, such that each waveform rose from and 
declined to zero.  
Data are expressed as mean ± S.E.M.. Repeated measures analysis of variance and 
Tukey’s HSD post hoc test were used to evaluate the effects of acute changes in LV volume 
loading on pressure and calcium variables, the effects of time on these variables, and the effects 
of stimulus interval in the mechanical restitution data. To relate percentage changes from 
baseline values in two variables, linear regression analysis was performed with the constraint of 
zero intercept. 
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RESULTS 
Frank-Starling protocol. An example of the Frank-Starling protocol data from one heart 
is illustrated in Figure 9-2, showing marked changes in pressure with little change in the calcium 
transient. In 8 hearts, Psys increased from 62.3 ± 5.5 mmHg to 120.2 ± 9.0 when LV volume was 
raised from 16.5±0.3 μL to 30.6±0.3 μL.  
 
 
Figure 9-2. Example Pressure and Calcium Waveforms 
Examples of averaged LV pressure and intracellular free calcium transient ([Ca]i) data during a cardiac cycle from 
the Frank-Starling (A) and mechanical restitution (B) protocols. A: As LV volume was increased, there were 
significant changes in the LV pressure without any accompanying changes in [Ca]i. B: During single-beat alterations 
in pacing interval at a fixed volume, both LV pressure and [Ca]i changed. 
 
As illustrated in Figure 9-3, Pdia, Pdev (9-3A), (dP/dt)max, and (dP/dt)min significantly 
increased (all P<0.05) and Trelax-P or Trise-P (9-3B) were unchanged with increments in LV 
volume. Thus, changes in LV volume simply scaled the developed pressure waveform, without 
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any significant alterations in its morphology. In contrast, there were no significant changes in 
any of the indices calculated from calcium transients (Figure 9-3C and Figure 9-3D). 
 
 
Figure 9-3. Effects of Altered LV Volume 
Effects of altered LV volume on indices of pressure (A and B) and [Ca]i (C and D). With increments in LV volume, 
LV end-diastolic pressure (●) and developed pressure (○) significantly increased ( A), with no changes in either 
pressure rise time (●) or pressure relaxation time (○) (B). In contrast, neither the magnitude (C; ●: diastolic [Ca]i, ○: 
developed [Ca]i) nor the morphology (D; ●: [Ca]i rise time, ○: [Ca] i relaxation time) were altered with increments in 
LV volume. Data are mean ± S.E.M. *: P<0.05 for ANOVA with repeated measures. 
 
At 10 minutes after the increase in LV volume to Vmax, there was a small, but significant, 
decrease in Pdev and Pdia (6% and 8% respectively, both P<0.05) (Figure 9-4A). None of the 
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[Ca]i indices (e.g., [Ca]i-sys, [Ca]i-dia, Trelax-Ca) changed significantly over this time (Figure 9-4B 
and Figure 9-4C). 
 
 
Figure 9-4. Effects of Sustained Volume 
Effects of sustained volume over a 10-minute period. A: LV developed pressure (○) and LV end-diastolic pressure 
(●). B: systolic [Ca]i (○) and diastolic [Ca]i (●). C: [Ca]i relaxation time (○) and LV pressure relaxation time (●). 
There were small, but significant, decrements in LV developed and end-diastolic pressures over the 10-minute 
period, though there were no changes in any of the [Ca]i indices or LV pressure relaxation time. Data are mean ± 
S.E.M. *: P<0.05 ANOVA with repeated measures. 
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Mechanical restitution protocol. An example of the mechanical restitution protocol data 
from one heart is illustrated in Figure 9-1B, showing marked changes in pressure due to TPI 
alterations at a fixed LV volume. As summarized in Table 10, an increase in TPI increased Psys, 
Pdev , (dP/dt)max, (dP/dt)min, and Trelax-P. For example, with respect to the control beat values, Psys, 
Pdev, (dP/dt)max, (dP/dt)min, and Trelax-P increased at TPI = 600 ms by 23.8±1.2% (P<0.01), 
31.3±1.2% (P<0.01), 28.0±1.4% (P<0.01), 7.8±1.1% (P<0.01), and 21.2±1.9% (P<0.01), 
respectively. 
Unlike the results from the Frank-Starling protocol, there were significant changes in 
[Ca]i dynamics, along with small, but significant, changes in [Ca]i peak magnitude. As illustrated 
in Table 10, an increase in TPI increased [Ca]i-sys, [Ca]i-dev, Trelax-Ca, and [Ca]i-area. For example, 
with respect to the control beat values, [Ca]i-sys, [Ca]i-dev, Trelax-Ca, and [Ca]i-area increased at TPI = 
600 ms by 7.4±1.4% (P<0.01), 10.6±1.8% (P<0.01), 30.0±5.5% (P<0.01), and 29.2±2.2% 
(P<0.01), respectively. TPI did not affect Trise-Ca; it remained very fast under all conditions (Trise-
Ca = 8±1 ms). Given that [Ca]i-area increased much more than [Ca]i-sys, the major contributor to the 
area increase was the prolonged time of calcium transient decay (i.e., increased Trelax-Ca). These 
results indicate that the increase in developed pressure with increasing TPI is associated with a 
small, but significant, increase in peak systolic calcium and marked prolongation of both 
pressure and calcium relaxation.  
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Table 10. Mechanical Restitution Data 
 
Values are means ± S.E.M.. Psys: LV peak systolic pressure; Pdia: LV diastolic pressure; Pdev: LV developed pressure; 
dP/dtmax: maximal rate of rise of LV pressure; dP/dtmin: maximal rate of fall of LV pressure; Trise-P: LV pressure rise 
time; ; Trelax-P: LV pressure fall time; [Ca]i-sys: peak systolic intracellular free calcium; [Ca]i-dia: diastolic intracellular 
free calcium; [Ca]i-dev: developed intracellular free calcium; [Ca]i-area: area under the intracellular free calcium 
transient; Trise-Ca: calcium rise time; ; Trelax-Ca: calcium fall time. (Note: Limited data were available at TPI = 800 ms 
because there was often a spontaneous contraction before the desired stimulation interval. Therefore, data for this 
TPI are not included in this Table; though they are included Figures 9-5 through 9-7.) *P<0.05, †P<0.01, versus 
240 ms pacing interval, Tukey’s HSD post-hoc test if repeated measures ANOVA showed a significant difference. 
 
As mentioned earlier, the three TPI deployment modes (Figure 9-1) were used merely to 
create a wide variety of pressure and calcium pairs. Clearly, changes in pressure at a given TPI 
are not expected to be the same for the three TPI deployment modes. This is the reason for the 
relatively large standard errors in Table 10. Instead of pooling data by TPI, we plotted 
  Interval (ms) 
 200 240 (control) 400 600 
Pressure data     
Psys (mmHg) 102.9 ± 4.3 106.5 ± 4.0  123.9 ± 4.7†  133.3 ± 5.1† 
Pdia (mmHg) 28.5 ± 1.7 28.4 ± 1.7  29.2 ± 1.7†  29.6 ± 1.9† 
Pdev (mmHg) 74.4 ± 4.2 78.1 ± 4.0  94.7 ± 4.9†  103.8 ± 5.5† 
dP/dtmax (mmHg•s-1) 3028 ± 138 3108 ± 123  3657 ± 148†  3960 ± 155† 
dP/dtmin (mmHg•s-1) -1916 ± 107 -1982 ± 102  -2148 ± 105†  -2159 ± 105† 
Trise-P (ms)  26.2 ± 1.0† 26.7 ± 1.0 27.1 ± 1.1 27.2 ± 1.2 
Trelax-P (ms) 43.1 ± 2.9 43.8 ± 3.0  49.0 ± 3.6†  53.6 ± 4.4† 
Calcium data     
[Ca]i-sys (nM)  948 ± 59* 990 ± 63 1009 ± 63  1094 ± 72† 
[Ca]i-dia (nM)  365 ± 14* 381 ± 15 375 ± 15 394 ± 15 
[Ca]i-dev (nM) 582 ± 54 610 ± 57 633 ± 58  700 ± 66† 
[Ca]i-area (nM•s) 24.8 ± 2.3 25.3 ± 2.1  29.8 ± 2.7†  34.0 ± 2.9† 
Trise-Ca (ms) 8.3 ± 0.3 8.4 ± 0.4 8.2 ± 0.4 8.3 ± 0.4 
Trelax-Ca (ms) 79.9 ± 4.2 82.5 ± 3.6 91.6 ± 5.2  105.9 ± 5.1† 
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percentage changes in rise and relaxation times against the corresponding percentage change in 
Pdev and [Ca]i-dev for all experiments and all conditions within an experiment (i.e., 4 TPI settings 
and 3 TPI deployment modes). This was done to assess whether changes in waveform 
morphology were related to the changes in waveform magnitude. All percentage changes were 
computed with respect to the control beat values (i.e., steady-state contractions at pacing interval 
of 240 ms).  
 
 
Figure 9-5. Analysis of Mechanical Restitution Data 
Analysis of mechanical restitution data from all experiments to examine morphological changes in LV pressure and 
[Ca]i signals individually. A and B: Percentage changes in LV pressure rise (∆Trise-P) and relaxation (∆Trelax-P) times 
with respect to the control beat values are plotted as a function of the percentage change in LV developed pressure 
(∆Pdev). ∆Trise-P was independent of ∆Pdev (A; slope = 0.05, P<0.001). In contrast, ∆Trelax-P increased with increasing 
∆Pdev (B; slope = 0.63, P<0.001), indicating relative slowing of pressure relaxation. C and D: Percentage changes in 
[Ca]i rise (∆Trise-Ca) and relaxation (∆Trelax-Ca) times with respect to the control beat values are plotted as a function 
the percentage change in developed [Ca]i (∆[Ca]i-dev). ∆Trise-Ca was independent of ∆[Ca]i-dev (C; slope = 0.07, 
P=0.73). In contrast, ∆Trelax-Ca increased with increasing ∆[Ca]i-dev (D;   slope = 1.48, P<0.001), indicating relative 
slowing of calcium relaxation. 
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As Pdev increased, there was no change in Trise-P (Figure 9-5A) and Trelax-P increased 
(Figure 9-5B). Similar correlations existed for the calcium data as well (Figure 9-5C and 
Figure 9-5D), i.e., invariant Trise-Ca (Figure 9-5C) and increasing Trelax-Ca (Figure 9-5D) with 
increments in [Ca]i-dev. There was greater variability in the calcium data, which is attributable to 
lower signal-to-noise ratio associated with fluorescence-based calcium measurements.  
The percentage change in Trelax-P (ΔTrelax-P) was positively correlated to the percentage 
change in Trelax-Ca (ΔTrelax-Ca) (Figure 9-6, R2=0.53; P<0.001), indicating that the slower pressure 
relaxation can be explained in terms of the slower calcium relaxation. To examine how 
percentage changes in Pdev (ΔPdev) are related to changes in various indices of [Ca]i, ΔPdev is 
plotted against percentage changes in three selected indices of [Ca]i (Figure 9-7): Δ[Ca]i-sys, 
ΔTrelax-Ca, and Δ[Ca]i-area. While each of the three relationships had a significant positive 
correlation, the slope of ΔPdev-Δ[Ca]i-sys relationship (2.30, Figure 9-7A) was significantly 
greater than that of ΔPdev-ΔTrelax-Ca relationship (0.96, Figure 9-7B) or ΔPdev-Δ[Ca]i-area 
relationship (0.93, Figure 9-7C). Thus, TPI-induced changes in developed pressure are 
associated with small changes in peak systolic calcium and large changes in [Ca]i-area (almost 
1:1) that are mostly due to the marked prolongation of calcium relaxation. Furthermore, slower 
pressure relaxation is mostly attributable to this prolongation of calcium relaxation. 
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Figure 9-6. Pressure versus Calcium Relaxation 
Analysis of mechanical restitution data from all experiments to examine the relationship between morphological 
changes in LV pressure and [Ca]i signals. The percentage change in LV pressure relaxation (∆Trelax-P) was positively 
correlated with the percentage change in [∆Ca]i relaxation (Trelax-Ca): slope = 0.48, R2 = 0.53, P<0.001. 
 
DISCUSSION 
Our data demonstrate unique features of the calcium-pressure relationship in the intact 
mouse heart. During the length-dependent increase in contraction, left ventricular developed 
pressure increased immediately, but the secondary rise seen in larger mammals was absent. None 
of the indices of pressure waveform shape or the calcium transient (magnitude and/or waveform 
shape including relaxation) were altered significantly. Single-beat changes in stimulus interval at 
a fixed ventricular volume also produced marked changes in developed pressure. However, an 
increase in pressure in this case was associated with marked increases in pressure and calcium 
relaxation times and a small, but significant, rise in the peak of the calcium transient. Finally, 
pressure relaxation was load-independent and primarily governed by calcium relaxation 
(removal). 
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Figure 9-7. Determinants of Developed Pressure 
Analysis of mechanical restitution data from all experiments to examine how the percentage change in LV 
developed pressure (∆Pdev) is related to percentage changes in various indices of [Ca]i. A: ∆Pdev −∆[Ca]i-sys (changes 
in peak systolic [Ca]i). B: ∆Pdev −∆Trelax-Ca (changes in [Ca]i relaxation time). C: ∆Pdev−∆[Ca]i-area (change in area 
under the calcium transient). While ∆Pdev was positively correlated with all three ∆[Ca]i indices, the slope of 
∆Pdev−∆[Ca]i-sys relationship was significantly greater than the slopes of the other two relationships. 
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Pressure modulation via changes in muscle length. Studies in isolated muscles from rats 
and cats have shown that increases in muscle length produce an immediate increase in force, 
though no change in the peak of the calcium transient, followed by slow increases in calcium and 
force that are similar in both magnitude and time course (1). Todaka et al. [149] have observed a 
similar pattern of response in the canine, blood-perfused isolated heart; following the immediate 
increase in pressure resulting from myocardial stretch, pressure and intracellular free calcium 
rose slowly for three minutes. In contrast to these studies, Reyes et al. [145], who studied in vivo 
hemodynamics in the mouse, showed that there was no secondary (late) increase in contractility 
(pressure) following an increase in left ventricular end-diastolic volume brought about by aortic 
constriction. Our data are consistent with these observations and add to the study of Reyes et al. 
by showing that the constant pressure is accompanied by an absence of changes in the 
intracellular free calcium transient over a 10-minute period.  
The explanation for the difference between the mouse and other mammalian hearts could 
be based on the aforementioned limited dependence upon sarcolemmal calcium transport. 
Alvarez et al. [144] demonstrated that the secondary increase in force and calcium in rat 
ventricular trabeculae is related to activation of the Na+/H+ exchanger, which increases 
intracellular sodium and leads to an increase in intracellular calcium. However, since 
sarcolemmal calcium transport in the mouse plays such a small role in excitation-contraction 
coupling [2, 142], this sarcolemmal mechanism of the secondary increase in intracellular calcium 
may not be operative in the mouse, leading to a lack in augmentation of the calcium transient 
found in other species. Additionally, a tertiary decrease has been observed following the 
secondary rise that returned calcium and pressure levels to the pre-secondary-rise levels [149]. 
The mechanism for this tertiary drop is not understood, but if the time courses of the late-phase-
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rise and tertiary drop are comparable in the mouse, these two phenomena can offset each other, 
resulting in no late changes in calcium.  
Pressure modulation via transient changes in stimulation interval. Wier and Yue [150] 
have described the relationship between calcium and force during transient alterations of 
stimulation interval in isolated ferret papillary muscles. They demonstrated a linear relationship 
between force and peak intracellular free calcium, with an increase in peak intracellular free 
calcium of 1 μM producing a large increase in force of 0.03 N•mm-2. Moreover, they showed 
that the percentage increase in peak force was nearly equal to the percentage increase in peak 
calcium, indicating a one-to-one relative increase over a wide range (several times the baseline 
values). While we also saw large increases in peak pressure (up to 50%), the maximum increase 
in peak calcium was only 20%. In other words, an increase in systolic calcium was associated 
with an increase in developed pressure of much greater magnitude (Figure 9-7A). This 
observation of high calcium-pressure “gain” is consistent with significantly greater cooperativity 
(Hill coefficient = 9.9) reported by Gao et al. [94] in constantly activated mouse myocardium as 
compared to that of larger mammals. They also reported that that the positive force-frequency 
relationship (FFR) in mouse myocardium was accompanied by relatively small changes in 
intracellular free calcium for stimulation frequencies above 2 Hz, a phenomenon they referred to 
as “frequency-dependent sensitization of myofilaments.” 
Our results show that Pdev and [Ca]i-area in the mouse increase almost one-to-one (Figure 
9-7C). The increased [Ca]i-area is only slightly modulated by the increased peak; instead, a slowed 
decay of the calcium transient is the major contributor (Figure 9-7B). This observation supports 
the premise that the temporal pattern of the calcium transient, not just the peak, significantly 
influences developed pressure in the mouse heart. Slower decay of the calcium transient may be 
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due to one or more of the following: (1) the rate of calcium uptake is near maximal under 
baseline conditions so that the calcium transient amplitude would be higher and calcium decay 
would be slower when more calcium is released (as would be expected for a contraction with 
increased pacing interval); (2) sarcoplasmic reticulum calcium uptake is reduced; and/or (3) there 
is increased troponin C calcium binding [151] due to increased myofilament calcium sensitivity. 
All of these postulated mechanisms of delayed decay of the calcium transient are likely to 
increase pressure, as there is prolonged calcium binding to troponin C and consequent prolonged 
actomyosin crossbridge interactions. 
Developed pressure and calcium. Our data indicate that significant changes in LV peak 
developed pressure can occur in the mouse heart with little or no change in peak of the calcium 
transient. This behavior in the mouse heart is quite different from what has been reported for 
higher mammals [143, 149, 152]. This lack of peak calcium variation may be a result of calcium 
cycling functioning at near maximal capacity at baseline in the mouse heart. We recognize that 
β-adrenergic agonists can significantly increase peak intracellular free calcium in the isolated 
mouse heart [46]. However, given its high baseline heart rate and limited ability to increase heart 
rate via sympathetic activation, indicating high basal sympathetic tone [153], this physiological 
mechanism may not be available to the mouse in-vivo. Our observation of high calcium-pressure 
gain and increased cooperativity reported by others [94] can be considered as compensatory 
responses to offset the limited ability for modulating calcium transient amplitude in the mouse 
heart. 
Determinants of pressure relaxation. Increased load prolongs force relaxation in 
mammalian ventricular muscle preparations [154]. Specifically, an increase in developed stress, 
brought about by an increase in muscle stretch, is associated with prolonged relaxation in 
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isolated, isovolumically contracting ferret hearts [155] and in isosarcometrically contracting 
isolated rat trabeculae [156]. Two potential mechanisms have been postulated for this 
prolongation of pressure (force) relaxation: (1) changes in calcium transient, particularly its 
prolonged relaxation, and (2) existence of cooperative feedback mechanisms, including 
crossbridge-myofilamental activation cooperativity and crossbridge-crossbridge cooperativity 
[155-157]. In contrast to these observations from other mammalian species, we did not observe 
any load-dependent changes in calcium transients or pressure waveform morphology in the 
Frank-Starling protocol. In agreement with these findings, Reyes et al. [145] have shown that 
afterload increases in the in-vivo mouse model do not affect active relaxation.  
We did observe prolonged pressure relaxation with increasing developed pressure in the 
mechanical restitution protocol (Figure 9-5B). However, this prolongation can be attributed to 
slower decay of the calcium transient (Figure 9-6). This observation, together with results from 
the Frank-Starling protocol, indicates that pressure (force) relaxation in the mouse is primarily 
governed by calcium removal; crossbridge-mediated control of relaxation, typically seen other 
mammalian species, is either absent (minimal) or operating near saturation under the baseline 
conditions. Given the increased cooperativity of constantly activated mouse myocardium (Hill 
coefficient = 9.9) (12), the latter possibility is more likely. Teleologically, this load-
independence of pressure relaxation may help maintain cardiac function in the setting of high 
heart rates. 
Model-based analysis. A model-based analysis was performed to obtain additional 
insights into the dynamics of pressure-calcium relationships. Specifically, the four-state model 
(see Section 7.2.2) was used to predict the pressure waveform for a given calcium transient and 
model parameters.  
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Figure 9-8. Model-Based Interpretation: Mechanical Restitution Protocol 
Comparison of the model-based prediction and experimentally measured data obtained with the mechanical 
restitution protocol. A: Experimentally measured LV developed pressure waveform, Pdev(t) and developed [Ca]i 
waveform, [Ca]i-dev(t) (solid lines: control pacing interval of 240 ms; dashed lines: test pulse interval of 600 ms). 
Data are normalized by the peak value of each signal under the control condition. When the pacing interval was 
transiently increased to 600 ms, both pressure and [Ca]i changed as indicated. ∆[Ca]i-dev: change in developed [Ca]i; 
∆Trelax-Ca: change in [Ca]i relaxation time; ∆Pdev: change in LV developed pressure; ∆Trelax-P: change in pressure 
relaxation time. B: Model-based analysis (solid lines: control pacing interval of 240 ms; dashed lines: test pulse 
interval of 600 ms). Experimentally measured pressure and calcium data for the control condition were first used to 
estimate the calcium input function and the four-state model parameters (see Appendix). When the calcium input 
function was altered to match experimentally observed data, the model pressure output reproduced experimentally 
observed alterations in the developed pressure waveform, without any need to change the four-state model 
parameters. 
 
In the mechanical restitution protocol there were changes in the magnitude and shape of 
calcium and pressure waveforms (Figure 9-8A). Given the similarity in directional changes in 
the indices of calcium and pressure transients, we hypothesized that the changes in the pressure 
waveform were due entirely to changes in the calcium transient. Specifically, with respect to the 
control condition, [Ca]i-dev, Trelax-Ca, Pdev, and Trelax-P increased at TPI of 600 ms by 13%, 28%, 
39%, and 22%, respectively. When the magnitude and relaxation of the model-input calcium 
transient were altered to match experimentally observed changes during altered stimulation 
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interval, the model output reproduced experimentally observed alterations in the developed 
pressure waveform (Figure 9-8B) without any perturbations in the model parameters. These 
results support our hypothesis and indicate that there is no need to invoke any changes in the 
dynamic processes that link calcium to pressure (i.e., model parameters) to reconcile observed 
calcium-pressure data from the mechanical restitution protocol. However, one cannot rule out the 
possibility of multiple, mutually offsetting changes in model parameters on the basis of this 
analysis.  
In the Frank-Starling protocol there were no changes in the calcium transient, but the 
developed pressure increased significantly (101%), while Trise-P and Trelax-P increased by modest 
amounts (8% and 5%, respectively) (Figure 9-9A). From the modeling perspective, if the input 
to the system (calcium transient) is not changing and the output (pressure transient) is then the 
parameters describing the system must be changing. In other words, certain model parameters 
are volume- or stretch-dependent. Based on the results of Shimizu et al. [104], the following 
model parameters were considered to be stretch-dependent: (1) two parameters (K3 and K4) 
corresponding to calcium dissociation from troponin C, (2) two parameters corresponding to 
crossbridge formation (f) and dissolution (g’), and (3) the gain parameter (γ) that converts molar 
concentration of force generating states to pressure (force).  
Effects of changes in stretch-dependent model kinetic parameters (i.e., categories (1) and 
(2) listed above) are illustrated in Figure 9-9B. Data from Shimizu et al. [104] were used to alter 
these model parameter values. While this perturbation increased developed pressure by an 
appropriate amount (109%), it also increased Trise-P and Trelax-P by 14% and 94%, respectively, 
which is inconsistent with the experimental observations (especially for the change in Trelax-P).  
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Effects of an increase in the gain parameter (γ) are illustrated in Figure 9-9C. We see a 
simple amplification of the pressure waveform by 100%, with no change in either Trise-P or Trelax-
P. Clearly, this perturbation satisfactorily captures both the magnitude and temporal features of 
the pressure response to increased volume. Although the physiologic meaning of this gain 
parameter is not entirely understood, an increase in its value may indicate an increase in force 
generated per cross-bridge. Unfortunately, if we accept that changes in LV volume (muscle 
length) only affect this gain parameter, the model fails to reproduce length-dependent changes in 
the steady-state force-pCa relationship observed in the mouse myocardium [35, 158]. We are 
unable to identify specific mechanisms that can simultaneously reproduce both the length-
dependent changes in force-pCa and the disconnect between increased Pdev and Trelax-P. Further 
studies are necessary to explain this unique length-dependent behavior in the mouse heart.  
Conclusions. The mouse myocardium appears to be unique in that significant changes in 
peak developed pressure can occur with little or no change in the peak of the calcium transient. 
In addition, unlike other mammalian species, pressure relaxation is load-independent and 
primarily governed by calcium removal. Thus, although genetically engineered mouse models 
are commonly used to study cardiac structure-function relationships, caution must be exercised 
while extrapolating findings from these models to the human setting. 
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Figure 9-9. Model-Based Interpretation: Frank Starling Protocol 
Comparison of the model-based prediction and experimentally measured data obtained with the Frank-Starling 
protocol. A: Experimentally measured LV developed pressure waveform, Pdev(t), at two LV volumes: low (solid 
line) and high (dashed line). Data are normalized by the peak developed pressure (Pdev) at low volume. Pdev doubled 
with the increase in LV volume, with little changes in pressure rise (Trise-P) and relaxation (Trelax-P) times and [Ca]i 
(not shown). B, C: Model-based analysis. Experimentally measured pressure and calcium data for the low volume 
condition were first used to estimate the calcium input function and the four-state model parameters. Model-based 
prediction of changes in Pdev(t) when the stretch-dependent kinetic parameters were altered (B) and when the stretch-
dependent gain parameter was altered (C) (see text).  
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APPENDIX B 
IDENTIFIABILITY IN OTHER MODELS 
In addition to the four-state model, DAISY (see Section 7.2.3.1) was used to determine 
the identifiability in other models of cardiovascular function.  
Model #1. Windkessel Models 
Using analogous electrical circuits to model the arterial system is an old concept, 
described by Hales in 1733. By assuming pressure analogous to voltage and blood flow 
analogous to current, the Windkessel model is a robust and ubiquitous technique used to study 
arterial systems [159]. One of the simplest forms is the three-element Windkessel, which consists 
of a total arterial resistance (R), a total arterial compliance (C) and a characteristic impedance (r), 
as shown in Figure 9-10A. The model is described by one differential equation, Equation B.1, 
and one output equation, Equation B.2.  
 𝑑𝑑𝑃𝑃𝑐𝑐(𝑡𝑡)
𝑑𝑑𝑡𝑡
= − 1
𝐶𝐶𝑅𝑅𝑃𝑃
𝑃𝑃𝐶𝐶(𝑡𝑡) + 1𝐶𝐶 𝑄𝑄𝐶𝐶𝑎𝑎 (𝑡𝑡) (B.1) 
 𝑃𝑃𝐶𝐶𝑎𝑎 (𝑡𝑡) = 𝑃𝑃𝐶𝐶(𝑡𝑡) + 𝑟𝑟𝑄𝑄𝐶𝐶𝑎𝑎 (𝑡𝑡) (B.2) 
where PC is a state variable for pressure across the capacitor, Qao is the aortic flow (model input) 
and Pao is the aortic pressure (model output). Total arterial resistance can be estimated from the 
input and output, so there are only two free parameters to be estimated: r and C. 
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There is a variation of this 3-element Windkessel where the characteristic impedance (r) 
is in series with the compliance. This is shown in Figure 9-10B. 
By combining the two 3-element Windkessel models, we obtain a 4-element Windkessel 
shown in Figure 9-10C. It is important to note that this form of Windkessel is not regularly used, 
and is only shown here as an extension of the 3-element Windkessel models. 
While the three-element Windkessel models capture many of the major characteristics of 
the aortic pressure and flow relationship, greater fidelity comes from adding additional elements. 
For example, the 5-element Windkessel adds the effects of blood inertance [160] and a more 
complicated structure (Figure 9-10D). The model is described by three differential equations and 
one output equation. 
 𝑑𝑑𝑃𝑃𝐶𝐶1 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 1
𝐶𝐶1 𝑄𝑄𝐶𝐶𝑎𝑎 (𝑡𝑡) − 1𝐶𝐶1 𝑄𝑄𝐿𝐿(𝑡𝑡) (B.3) 
 𝑑𝑑𝑄𝑄𝐿𝐿(𝑡𝑡)
𝑑𝑑𝑡𝑡
= − 1
𝐿𝐿
𝑃𝑃𝐶𝐶2 (𝑡𝑡) − 1𝐿𝐿 𝑃𝑃𝐶𝐶1 (𝑡𝑡) (B.4) 
 𝑑𝑑𝑃𝑃𝐶𝐶2 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 1
𝐶𝐶2 𝑄𝑄𝐿𝐿(𝑡𝑡) − 1𝑅𝑅𝐶𝐶2 𝑃𝑃𝐶𝐶2 (𝑡𝑡) (B.5) 
 𝑃𝑃𝐶𝐶𝑎𝑎 (𝑡𝑡) = 𝑃𝑃𝐶𝐶1 (𝑡𝑡) + 𝑟𝑟𝑄𝑄𝐶𝐶𝑎𝑎 (𝑡𝑡) (B.6) 
where PC1, PC2, and QL are the state variables, Pao is the output, and Qao in the input. There are 
five free parameters to be estimated: r, R, C1, C2, and L. 
 Similar to the two 3-element Windkessel models shown, there are multiple arrangements 
of the 5-element Windkessel; one such variation is shown in Figure 9-10E. 
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Figure 9-10. Windkessel Models 
Schematics of Windkessel model variations. There are two 3-element (A and B), one 4-element (C) and two 5-
element (D and E) Windkessel models. 
 
Model #2: Stiffness Model.  
Cardiac muscle responds to changes in length with alterations in force development, by 
the so called force-length relationship (FLR). A common experiment involves altering muscle 
length sinusoidally, and observing the resultant sinusoidal force response. The ratio of the 
magnitudes of the force response and length perturbation at each sinusoid frequency represents 
the complex stiffness at that particular frequency. The complex stiffness over a wide range of 
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frequencies (experimentally this is done by a length “chirp”, a sinusoid of continuously 
increasing frequency) is a useful indicator of a muscle’s dynamic FLR.  
The stiffness model was developed to analyze chirp data from skinned fibers in the time 
domain, and is based on system of two force producing dynamics: recruitment and distortion of 
crossbridges. The model has been rigorously validated [161], and used for parameter estimation 
[162, 163], but has never been tested for identifiability. The model itself is a black box model 
described by two differential equations, Equations B.11 represents the recruitment dynamics, 
Equation B.12 represents the distortion dynamics, and the output equation is Equation B.13: 
 𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏[𝑑𝑑(𝑡𝑡) − ∆𝐿𝐿(𝑡𝑡)] (B.11) 
 𝑑𝑑𝑚𝑚 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑐𝑐𝑚𝑚(𝑡𝑡) + 𝑑𝑑∆𝐿𝐿(𝑡𝑡)
𝑑𝑑𝑡𝑡
 (B.12) 
 ∆𝐹𝐹 = 𝐸𝐸0𝑑𝑑(𝑡𝑡) + 𝐸𝐸∞𝑚𝑚(𝑡𝑡) (B.13) 
where η(t) is the recruitment variable, x(t) is the distortion variable, ΔL is the length change 
(model input), and ΔF is the force change (model output). There are four free parameters to be 
estimated: E0, E∞, b, and c. 
 
Model #3: Three State Model.  
It is possible to group cardiac contraction/relaxation processes into three main categories: 
1) activator calcium, 2) myofilament activation, and 3) myofilament contraction. There are no 
experimental techniques to reliably measure myofilament properties, and so their measurement is 
handled indirectly, through identifying model parameter values. There exist several models of 
myofilament function that can be used for this approach, often taking the form of compartment 
or state models. The three-state examined here was developed to analyze the effects of acidosis 
[164], and is shown in Figure 9-11. It is described by the following three differential equations, 
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𝑑𝑑𝑋𝑋𝐶𝐶𝐶𝐶
𝑑𝑑𝑡𝑡
= −�𝑓𝑓 + 𝑘𝑘𝑎𝑎𝑓𝑓𝑓𝑓 + 𝑘𝑘𝑎𝑎𝑚𝑚 [𝐶𝐶𝐶𝐶]𝑖𝑖�𝑋𝑋𝐶𝐶𝐶𝐶 + (𝑑𝑑 − 𝑘𝑘𝑎𝑎𝑚𝑚 [𝐶𝐶𝐶𝐶]𝑖𝑖)𝑋𝑋𝐶𝐶𝐶𝐶 − 𝑘𝑘𝑎𝑎𝑚𝑚 [𝐶𝐶𝐶𝐶]𝑖𝑖𝑋𝑋𝐶𝐶𝐹𝐹 − 𝑘𝑘𝑎𝑎𝑚𝑚 [𝐶𝐶𝐶𝐶]𝑖𝑖𝑋𝑋𝑇𝑇 
 (B.14) 
 𝑑𝑑𝑋𝑋𝐶𝐶𝐶𝐶
𝑑𝑑𝑡𝑡
= 𝑓𝑓𝑋𝑋𝐶𝐶𝐶𝐶 − (𝑑𝑑 + ℎ)𝑋𝑋𝐶𝐶𝐶𝐶 (B.15) 
 𝑑𝑑𝑋𝑋𝐶𝐶𝐹𝐹
𝑑𝑑𝑡𝑡
= ℎ𝑋𝑋𝐶𝐶𝐶𝐶 − 𝑔𝑔𝑋𝑋𝐶𝐶𝐹𝐹 (B.16) 
The input is the intracellular calcium concentration, [Ca]i (either a time time-dependent 
transient, or a steady state value) and the output is XCF, which is proportional to force. There are 
seven free parameters to estimate: koff, kon, f, d, g, h, and XT.  
The model can also include a feedback algebraic equation, which will decrease koff when 
the value of Xcf, force producing crossbridges, gets larger. This feedback attempts to describe the 
concept of cooperativity in the model. The feedback equation is: 
 𝑘𝑘𝑎𝑎𝑓𝑓𝑓𝑓 = 𝑘𝑘𝑎𝑎𝑓𝑓𝑓𝑓 ,01+𝛽𝛽𝑋𝑋𝑐𝑐𝑓𝑓2  (B.17) 
Where koff,0 is the baseline value of koff, and β is a cooperatively parameter. This removes 
one free parameter (koff), but introduces two, increasing the number of free parameters to eight. 
 
Figure 9-11. Schematic of Three-State Model 
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RESULTS AND DISCUSSION 
 
A total of eight models (not including the four-state model) were run through DAISY to 
determine identifiability. The results obtained from DAISY can be seen in Table 11. 
Table 11. Results of Identifiability Analysis 
 
The models that are tested for a priori identifiability using DAISY, along with the number of state variables, 
measured outputs, free parameters to estimate, whether it is algebraically observable and identifiable. 
 
 All of the models were found to be globally identifiable, except the 4-element 
Windkessel. This particular model is a variation created for this study, and there is no evidence 
of its prior use. These results suggest that models of cardiovascular function which are 
functionally identifiable (have been successfully used in parameter identification) are a priori 
identifiable using DAISY. It is important to note that a positive result from the a priori model 
identifiability analysis constitutes a necessary, but not sufficient, condition for successful 
parameter identification from real input-output data. In summary, DAISY is a very useful tool 
for conducting a priori model identifiability analysis. Such an analysis, performed prior to 
conducting extensive experiments, is likely to help optimize model structure and/or experimental 
design.  
Model # State Var. # Outputs # Paramters Observable Identifiable
3-element Windkessel
     Variant 1 1 1 2  Globally
     Variant 2 1 1 3  Globally
4-element Windkessel 1 1 4  Non
5-element Windkessel
     Variant 1 3 1 5  Globally
     Variant 2 3 1 5  Globally
Stiffness Model 2 1 4  Globally
3 state Model
     Without Feedback 3 1 7  Globally
     With Feedback 3 1 8  Globally
-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
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APPENDIX C 
MATLAB PROGRAMS 
MODEL ANALYSIS – MAIN PROGRAM 
clear 
close all 
  
% Program that uses the four-state model, with variations in the 
% model parameters to help forward-fit the solution to data 
% Developed 10/08 by Jonathan Kirk, revised 5/09 
% Developed for S43E/S45E/T144E manuscript data analysis 
  
%% Parameter Sets  
K2 = 25;   
K3 = 84;   
K4 = 84;   
g = 205.3;  
alpha_K1 = 2.0;   
beta_K1 = 3;    
alpha_f = 0.15;  
beta_f = 0.7;  
d = 44.6;  
  
% Baseline Set 
Params(1) = K2; 
Params(2) = K3; 
Params(3) = K4; 
Params(4) = g; 
Params(5) = alpha_K1; 
Params(6) = beta_K1; 
Params(7) = alpha_f; 
Params(8) = beta_f; 
Params(9) = d; 
  
% Perturbation One 
Params2(1) = K2; 
Params2(2) = K3; 
Params2(3) = K4; 
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Params2(4) = g; 
Params2(5) = alpha_K1; 
Params2(6) = beta_K1; 
Params2(7) = alpha_f; 
Params2(8) = beta_f * 0.77;  
Params2(9) = d; 
  
% Perturbation Two 
Params3(1) = K2; 
Params3(2) = K3; 
Params3(3) = K4; 
Params3(4) = g; 
Params3(5) = alpha_K1; 
Params3(6) = beta_K1; 
Params3(7) = alpha_f; 
Params3(8) = beta_f*0.77;%0.77; 
Params3(9) = d*0.65;%*0.65; 
  
%% Steady state solutions 
Ca_array1 = 0.01:0.01:.1; 
Ca_array2 = 0.2:0.1:10; 
Ca_array3 = 11:1:100; 
Ca_array = [Ca_array1 Ca_array2 Ca_array3]; 
Yo = [70,20,0,0,0]; 
  
Timef = 0:0.001:0.5; 
Inputs = 0; 
F = zeros(1,length(Ca_array)); 
F2 = zeros(1,length(Ca_array)); 
F3 = zeros(1,length(Ca_array)); 
%% Baseline 
  
for i = 1:length(Ca_array) 
Params(10) = Ca_array(i); 
[T,Y] = ode45(@B_Model3,Timef,Yo,[],Inputs,Params); 
F(i) = Y(length(Timef),4)+Y(length(Timef),5); 
state41(i) = Y(length(Timef),4); 
state51(i) = Y(length(Timef),5); 
MgATP11(i) = Params(4)*state41(i); 
MgATP12(i) = Params(9)*state51(i); 
end 
  
%% Perturbation One 
  
for i = 1:length(Ca_array) 
Params2(10) = Ca_array(i); 
[T,Y] = ode45(@B_Model3,Timef,Yo,[],Inputs,Params2); 
F2(i) = Y(length(Timef),4)+Y(length(Timef),5); 
state42(i) = Y(length(Timef),4); 
state52(i) = Y(length(Timef),5); 
MgATP21(i) = Params2(4)*state42(i); 
MgATP22(i) = Params2(9)*state52(i); 
end 
  
%% Perturbation Two 
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for i = 1:length(Ca_array) 
Params3(10) = Ca_array(i); 
[T,Y] = ode45(@B_Model3,Timef,Yo,[],Inputs,Params3); 
F3(i) = Y(length(Timef),4)+Y(length(Timef),5); 
state43(i) = Y(length(Timef),4); 
state53(i) = Y(length(Timef),5); 
MgATP31(i) = Params3(4)*state43(i); 
MgATP32(i) = Params3(9)*state53(i); 
end 
  
%% Calculate SS Indices 
  
% Calculates Fmax, pCa50 and Hill Coefficient from force values 
Fmax1 = max(F); 
halfmax1 = findnearest((Fmax1)/2,F); 
pCa1 = -log10(Ca_array(halfmax1)*10^-6); 
nH1 = max(gradient(F/Fmax1,log10(Ca_array))); 
  
Fmax2 = max(F2); 
halfmax2 = findnearest((Fmax2)/2,F2); 
pCa2 = -log10(Ca_array(halfmax2)*10^-6); 
nH2 = max(gradient(F2/Fmax2,log10(Ca_array))); 
  
Fmax3 = max(F3); 
halfmax3 = findnearest((Fmax3)/2,F3); 
pCa3 = -log10(Ca_array(halfmax3)*10^-6); 
nH3 = max(gradient(F3/Fmax3,log10(Ca_array))); 
  
% Calculates Max ATPase, pCa50 and Hill coefficient from ATPase values 
MgATP1 = (MgATP11 + MgATP12); 
MgATP2 = (MgATP21 + MgATP22); 
MgATP3 = (MgATP31 + MgATP32); 
  
ATPmax1 = max(MgATP1); 
halfmaxATP1 = findnearest((ATPmax1)/2,MgATP1); 
ATPpCa1 = -log10(Ca_array(halfmaxATP1)*10^-6); 
ATPnH1 = max(gradient(MgATP1/ATPmax1,log10(Ca_array))); 
  
ATPmax2 = max(MgATP2); 
halfmaxATP2 = findnearest((ATPmax2)/2,MgATP2); 
ATPpCa2 = -log10(Ca_array(halfmaxATP2)*10^-6); 
ATPnH2 = max(gradient(MgATP2/ATPmax2,log10(Ca_array))); 
  
ATPmax3 = max(MgATP3); 
halfmaxATP3 = findnearest((ATPmax3)/2,MgATP3); 
ATPpCa3 = -log10(Ca_array(halfmaxATP3)*10^-6); 
ATPnH3 = max(gradient(MgATP3/ATPmax3,log10(Ca_array))); 
  
% Collect values into result arrays 
data_static = [Fmax1 Fmax2 Fmax3;pCa1 pCa2 pCa3;nH1 nH2 nH3]; 
data_ATP = [ATPmax1 ATPmax2 ATPmax3;ATPpCa1 ATPpCa2 ATPpCa3;ATPnH1 ATPnH2 
ATPnH3]; 
  
%% Dynamic Calcium Solution 
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% Simulation of calcium transient 
A = 1.739; 
B = 205.89; 
C = 30.52; 
t = 0:0.0001:0.25; 
Ca = A.*(1-exp(-B.*t)).*(exp(-C.*t)); 
  
% Specifices Time Dependent 
Params(10) = 1; 
Params2(10) = 1; 
Params3(10) = 1; 
Timef2 = 0:0.001:0.25; 
Inputs = [t' Ca']; 
  
% Runs Differential Equations for three parameter sets 
[T1,Y1] = ode45(@B_Model3,Timef2,Yo,[],Inputs,Params); 
[T2,Y2] = ode45(@B_Model3,Timef2,Yo,[],Inputs,Params2); 
[T3,Y3] = ode45(@B_Model3,Timef2,Yo,[],Inputs,Params3); 
  
% Force is addition of two states 
F1d = Y1(:,4)+Y1(:,5); 
F2d = Y2(:,4)+Y2(:,5); 
F3d = Y3(:,4)+Y3(:,5); 
  
% Developed force  
DevP1 = max(F1d); 
DevP2 = max(F2d); 
DevP3 = max(F3d); 
  
% Diastolic values (should be close to zero) 
Dia1 = F1d(length(F1d)); 
Dia2 = F2d(length(F2d)); 
Dia3 = F3d(length(F3d)); 
  
% Time to max 
time_max1 = find(F1d == DevP1); 
time_max2 = find(F2d == DevP2); 
time_max3 = find(F3d == DevP3); 
  
%% Rise/relax time for baseline 
  
rise_phase1 = F1d(1:time_max1); 
t25_1 = findnearest(DevP1*0.25,rise_phase1); 
t75_1 = findnearest(DevP1*0.75,rise_phase1); 
rise_time1 = T1(t75_1) - T1(t25_1); 
  
relax_phase1 = F1d(time_max1:length(F1d)); 
t25_1 = findnearest(DevP1*0.25,relax_phase1); 
t75_1 = findnearest(DevP1*0.75,relax_phase1); 
relax_time1 = T1(t25_1) - T1(t75_1); 
  
%% Rise/relax for Perturbation One 
rise_phase2 = F2d(1:time_max2); 
t25_2 = findnearest(DevP2*0.25,rise_phase2); 
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t75_2 = findnearest(DevP2*0.75,rise_phase2); 
rise_time2 = T2(t75_2) - T2(t25_2); 
  
relax_phase2 = F2d(time_max2:length(F2d)); 
t25_2 = findnearest(DevP2*0.25,relax_phase2); 
t75_2 = findnearest(DevP2*0.75,relax_phase2); 
relax_time2 = T2(t25_2) - T2(t75_2); 
  
%% Rise/relax for Perturbation Two 
rise_phase3 = F3d(1:time_max3); 
t25_3 = findnearest(DevP3*0.25,rise_phase3); 
t75_3 = findnearest(DevP3*0.75,rise_phase3); 
rise_time3 = T3(t75_3) - T3(t25_3); 
  
relax_phase3 = F3d(time_max3:length(F3d)); 
t25_3 = findnearest(DevP3*0.25,relax_phase3); 
t75_3 = findnearest(DevP3*0.75,relax_phase3); 
relax_time3 = T3(t25_3) - T3(t75_3); 
  
%% Collect Data 
  
P_title = ['   Set 1     ' 'Set 2     ' 'Set 3    ']; 
Parameter_set = [Params' Params2' Params3']; 
  
disp(P_title) 
disp(Parameter_set) 
disp(data_static) 
  
s_change = [(Fmax3 - Fmax1)/Fmax1 (pCa3-pCa1)/pCa1 (nH3-nH1)/nH1]; 
S_title = ['   Fmax      ' 'pCa50     ' 'nH    ']; 
disp(S_title) 
disp(s_change) 
  
data_dynamic = [DevP1 DevP2 DevP3;rise_time1 rise_time2 
rise_time3;relax_time1 relax_time2 relax_time3]; 
disp(data_dynamic) 
  
p_change = [(DevP3 - DevP1)/DevP1 (rise_time3-rise_time1)/rise_time1 
(relax_time3-relax_time1)/relax_time1]; 
D_title = ['   DevP      ' 'RiseT     ' 'RelaxT    ']; 
disp(D_title) 
disp(p_change) 
  
ATP_title = ['   ATPmax     ' 'pCa50     ' 'nH    ']; 
data_ATP = [ATPmax1 ATPmax2 ATPmax3;ATPpCa1 ATPpCa2 ATPpCa3;ATPnH1 ATPnH2 
ATPnH3]; 
ATP_change = [(ATPmax3 - ATPmax1)/ATPmax1 (ATPpCa3 - ATPpCa1)/ATPpCa1 (ATPnH3 
- ATPnH1)/ATPnH1]; 
disp(ATP_title) 
disp(ATP_change) 
  
TensionCost1 = (MgATP1(length(MgATP1))-MgATP1(1))/(F(length(F))-F(1)); 
TensionCost3 = (MgATP3(length(MgATP3))-MgATP3(1))/(F3(length(F3))-F3(1)); 
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%% Plot Twitch and Steady State Data 
figure 
colormap gray 
  
subplot(221),plot(log10(Ca_array*10^-6),F,'k',log10(Ca_array*10^-6),F2,'--
k',log10(Ca_array*10^-6),F3,':k','LineWidth',2) 
legend('BL','Pert. 1','Pert. 2','Location','NorthWest') 
title('Absolute Force-pCa plot') 
xlabel('pCa') 
ylabel('Force') 
  
subplot(222),plot(log10(Ca_array*10^-6),F/Fmax1,'k',log10(Ca_array*10^-
6),F2/Fmax2,'k--', ... 
    log10(Ca_array*10^-6),F3/Fmax3,':k','LineWidth',2) 
legend('BL','Pert. 1','Pert. 2','Location','NorthWest') 
title('Normalized Force-pCa plot') 
xlabel('pCa') 
ylabel('Normalized Force') 
  
subplot(223), 
plot(T1,F1d,'k',T2,F2d,'--k',T3,F3d,':k','LineWidth',2) 
legend('BL','Pert. 1','Pert. 2') 
title('Absolute Force Twitch Plot') 
xlabel('Time (s)') 
ylabel('Force') 
v = axis; 
axis([0 0.25 v(3) v(4)]) 
  
subplot(224), 
plot(T1,F1d/DevP1,'k',T2,F2d/DevP2,'--k',T3,F3d/DevP3,':k','LineWidth',2) 
legend('BL','Pert. 1','Pert. 2') 
title('Normalized Force Twitch Plot') 
xlabel('Time (s)') 
ylabel('Normalized Force') 
v = axis; 
axis([0 0.25 v(3) v(4)]) 
  
%% Plot Feedback values 
figure 
  
subplot(131) 
plot(F1d, 
Params(5).*F1d.^0.5+Params(6),'k',F3d,Params3(5).*F3d.^0.5+Params3(6),':k','L
ineWidth',2) 
legend('Baseline','Pert. 2','Location','SouthEast') 
title('K1 feedback, twitch') 
xlabel('Force Generating States') 
ylabel('K1') 
  
subplot(132) 
plot(F1d, 
Params(7).*F1d.^1.5+Params(8),'k',F3d,Params3(7).*F3d.^1.5+Params3(8),'k:','L
ineWidth',2) 
legend('Baseline','Pert. 2','Location','SouthEast') 
title('f feedback, twitch') 
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xlabel('Force Generating States') 
ylabel('f') 
  
subplot(133) 
plot(F1d, 
Params(9).*F1d.^1.0+Params(10),'k',F3d,Params3(9).*F3d.^1.0+Params3(10),'k:',
'LineWidth',2) 
legend('Baseline','Pert. 2','Location','East') 
title('d feedback, twitch') 
xlabel('Force Generating States') 
ylabel('d') 
  
%% Plot Steady State Data by force generating state 
figure 
set(gcf,'DefaultAxesColorOrder',[0 0 0;0 0 0;0 0 0;.6 .6 .6;.6 .6 .6;.6 .6 
.6;]) 
  
subplot(121) 
plot(T1,F1d,T1,Y1(:,4),'--',T1,Y1(:,5),':',T3,F3d,T3,Y3(:,4),'--
',T3,Y3(:,5),':','LineWidth',2) 
legend('Total BL','State4 BL','State5 BL', ... 
    'Total Pert. 2','State4 Pert. 2','State5 Pert 2') 
title('State 4 and State 5 during twitch') 
xlabel('Time (s)') 
ylabel('Force') 
colormap gray 
  
subplot(122) 
plot(log10(Ca_array*10^-6),F,log10(Ca_array*10^-6),state41,'--
',log10(Ca_array*10^-6),state51,':', ... 
    log10(Ca_array*10^-6),F3,log10(Ca_array*10^-6),state43,'--
',log10(Ca_array*10^-6),state53,':','LineWidth',2) 
legend('Total WT','WT State4','WT State5','Total TG','TG State4','TG 
State5','Location','Northwest') 
title('State 4 and State 5 during SS') 
xlabel('pCa') 
ylabel('Force') 
  
%% Feedback by time 
figure 
  
subplot(131) 
plot(T1, 
Params(5).*F1d.^0.5+Params(6),'k',T3,Params3(5).*F3d.^0.5+Params3(6),':k','Li
neWidth',2) 
legend('Baseline','Pert. 2','Location','NorthEast') 
title('K1 feedback, twitch') 
xlabel('Time (s)') 
ylabel('K1') 
v = axis; 
axis([0 0.25 v(3) v(4)]) 
  
subplot(132) 
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plot(T1, 
Params(7).*F1d.^1.5+Params(8),'k',T3,Params3(7).*F3d.^1.5+Params3(8),'k:','Li
neWidth',2) 
legend('Baseline','Pert. 2','Location','NorthEast') 
title('f feedback, twitch') 
xlabel('Time (s)') 
ylabel('f') 
v = axis; 
axis([0 0.25 v(3) v(4)]) 
  
subplot(133) 
plot(T1, 
Params(9).*F1d.^1.0+Params(10),'k',T3,Params3(9).*F3d.^1.0+Params3(10),'k:','
LineWidth',2) 
legend('Baseline','Pert. 2','Location','East') 
title('d feedback, twitch') 
xlabel('Time (s)') 
ylabel('d') 
v = axis; 
axis([0 0.25 v(3) v(4)]) 
  
%% ATPase Results 
  
figure 
set(gcf,'DefaultAxesColorOrder',[0 0 0;0 0 0;0 0 0;.6 .6 .6;.6 .6 .6;.6 .6 
.6;]) 
colormap gray 
  
subplot(221),plot(log10(Ca_array*10^-6),MgATP11+MgATP12,log10(Ca_array*10^-
6),MgATP11,'--',log10(Ca_array*10^-6),MgATP12,':', ... 
    log10(Ca_array*10^-6),MgATP31+MgATP32,log10(Ca_array*10^-6),MgATP31,'--
',log10(Ca_array*10^-6),MgATP32,':','LineWidth',2) 
legend('Total BL','BL State4','BL State5','Total Pert.','Pert. State4','Pert. 
State5','Location','Northwest') 
title('ATPase Activity') 
xlabel('pCa') 
ylabel('ATPase Activity') 
  
subplot(222),plot(log10(Ca_array*10^-
6),MgATP1/ATPmax1,'k',log10(Ca_array*10^-6),MgATP2/ATPmax2,'k--', ... 
    log10(Ca_array*10^-6),MgATP3/ATPmax3,':k','LineWidth',2) 
legend('BL','Pert. 1','Pert. 2','Location','NorthWest') 
title('Normalized MgATP-pCa plot') 
xlabel('pCa') 
ylabel('Normalized ATPase') 
  
subplot(223), plot(F,MgATP1,'k',F3,MgATP3,'k--
',F,(F'\MgATP1')*F,'k',F3,(F3'\MgATP3')*F3,'k--') 
    legend('BL','Pert. 2') 
    xlabel('Force') 
    ylabel('MgATP') 
 
MODEL ANALYSIS – B_MODEL3.M 
 
function Sysdot = B_Model3(t,Sys,Inputs,Params) 
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% Equation function, called by ode45 from main program 
  
% Re establish the parameter set 
K2 = Params(1);  
K3 = Params(2);  
K4 = Params(3);  
g = Params(4); 
alpha_K1 = Params(5); 
beta_K1 = Params(6); 
alpha_f = Params(7); 
beta_f = Params(8); 
d = Params(9); 
  
% Calculate the feedback parameters 
K1 = alpha_K1*(Sys(4) + Sys(5))^1.25 + beta_K1;  
f = alpha_f*(Sys(4) + Sys(5)) + beta_f; 
  
% Is it dynamic or steady state? 
Ca = Params(10); 
if length(Inputs) > 2 
Calcium = Inputs(:,2); 
Timeca = Inputs(:,1); 
Ca = interp1(Timeca,Calcium,t); 
end 
  
% Differential equations describing the model 
Sysdot(1,:) = -K1*Ca*Sys(1) + K3*Sys(3) + d*Sys(5); %dTnCAdt 
Sysdot(2,:) = d*Sys(5) - f*Sys(3)*Sys(2) + g*Sys(4); %dMdt 
Sysdot(3,:) = K1*Ca*Sys(1) - K3*Sys(3) - f*Sys(3)*Sys(2) + g*Sys(4); 
%dCa_TnCAdt 
Sysdot(4,:) = (f*Sys(3)*Sys(2) + K2*Ca*Sys(5) - (g+K4)*Sys(4)); %dCa_TnCA_Mdt 
Sysdot(5,:) = (K4*Sys(4) - d*Sys(5) - K2*Ca*Sys(5)); %dTnCA_Mdt 
 
MODEL ANALYSIS – FINDNEAREST.M 
 
function [r,c,V] = findnearest(srchvalue,srcharray,bias) 
  
% Usage: 
% Find the nearest numerical value in an array to a search value 
% All occurances are returned as array subscripts 
% 
% Output: 
% 
% For 2D matrix subscripts (r,c) use: 
% 
%       [r,c] = findnearest(srchvalue,srcharray,gt_or_lt) 
% 
% 
% To also output the found value (V) use: 
% 
%       [r,c,V] = findnearest(srchvalue,srcharray,gt_or_lt) 
% 
% 
% For single subscript (i) use: 
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% 
%         i   = findnearest(srchvalue,srcharray,gt_or_lt) 
%  
% 
% Inputs: 
% 
%    srchvalue = a numerical search value 
%    srcharray = the array to be searched 
%    bias      = 0 (default) for no bias 
%                -1 to bias the output to lower values 
%                 1 to bias the search to higher values 
%                (in the latter cases if no values are found 
%                 an empty array is ouput) 
% 
% 
% By Tom Benson (2002) 
% University College London 
% t.benson@ucl.ac.uk 
  
if nargin<2 
    error('Need two inputs: Search value and search array') 
elseif nargin<3 
    bias = 0; 
end 
  
% find the differences 
srcharray = srcharray-srchvalue; 
  
if bias == -1   % only choose values <= to the search value 
     
    srcharray(srcharray>0) =inf; 
         
elseif bias == 1  % only choose values >= to the search value 
     
    srcharray(srcharray<0) =inf; 
         
end 
  
% give the correct output 
if nargout==1 | nargout==0 
     
    if all(isinf(srcharray(:))) 
        r = []; 
    else 
        r = find(abs(srcharray)==min(abs(srcharray(:)))); 
    end  
         
elseif nargout>1 
    if all(isinf(srcharray(:))) 
        r = [];c=[]; 
    else 
        [r,c] = find(abs(srcharray)==min(abs(srcharray(:)))); 
    end 
     
    if nargout==3 
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        V = srcharray(r,c)+srchvalue; 
    end 
end 
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APPENDIX D 
FOUR-STATE SENSITIVITY ANALYSIS 
The following tables (Table 12 through Table 20) show the effects of changes in the 
parameters of the four-state model on the each of the calculated parameters (steady-state and 
time-varying). Each table shows the effects of changes for an individual parameter. Sensitivity 
for a continuous relationship is described by:  
 𝑆𝑆𝑋𝑋
𝑌𝑌 = 𝛿𝛿𝑌𝑌 𝛿𝛿𝑋𝑋�𝑌𝑌
𝑋𝑋�
 (D.1) 
where 𝑆𝑆𝑋𝑋𝑌𝑌 is the sensitivity of Y to X. Equation D.1 can be converted for use with discreet data, 
which we have used for the tables below: 
 𝑆𝑆𝑋𝑋
𝑌𝑌 = ∆𝑌𝑌 ∆𝑋𝑋�𝑌𝑌
𝑋𝑋�
 (D.2) 
 The average and S.E.M. sensitivity values in Table 2 1 were calculated from the 
sensitivity values over 50% to 150% of the baseline value of the parameter. 
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Table 12. Effect of Changes in k2 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 1.25 2.5 12.5 18.75 25 31.25 37.5 50 250
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 10.07 9.39 7.27 6.99 6.93 6.90 6.88 6.85 6.78
   pCa50 5.54 5.54 5.46 5.41 5.37 5.34 5.31 5.27 5.15
   nH 3.69 3.69 2.89 2.45 2.15 1.97 1.87 1.75 1.58
   TC 152 170 196 199 200 201 202 203 205
   Pdev 0.215 0.214 0.210 0.207 0.204 0.202 0.200 0.196 0.166
   Trise 0.012 0.012 0.013 0.013 0.013 0.012 0.012 0.012 0.011
   Trelax 0.048 0.048 0.048 0.048 0.049 0.049 0.049 0.05 0.052
Δ (% from BL)
   Fmax 45.2 35.5 4.9 0.8 0.0 -0.5 -0.8 -1.2 -2.2
   pCa50 3.2 3.2 1.7 0.8 0.0 -0.5 -1.1 -1.8 -3.9
   nH 71.4 71.3 34.3 13.8 0.0 -8.3 -13.3 -18.8 -26.5
   TC -24.0 -15.3 -2.3 -0.8 0.0 0.5 0.8 1.3 2.3
   Pdev 5.1 4.8 2.5 1.2 0.0 -1.1 -2.2 -4.2 -19.0
   Trise -7.7 -7.7 0.0 0.0 0.0 -7.7 -7.7 -7.7 -15.4
   Trelax -2.0 -2.0 -2.0 -2.0 0.0 0.0 0.0 2.0 6.1
Sensitivity
   Fmax -0.48 -0.39 -0.10 -0.03 0.00 -0.02 -0.02 -0.01 0.00
   pCa50 -0.03 -0.04 -0.03 -0.03 0.00 -0.02 -0.02 -0.02 0.00
   nH -0.75 -0.79 -0.69 -0.55 0.00 -0.33 -0.27 -0.19 -0.03
   TC 0.25 0.17 0.05 0.03 0.00 0.02 0.02 0.01 0.00
   Pdev -0.05 -0.05 -0.05 -0.05 0.00 -0.05 -0.04 -0.04 -0.02
   Trise 0.08 0.09 0.00 0.00 0.00 -0.31 -0.15 -0.08 -0.02
   Trelax 0.02 0.02 0.04 0.08 0.00 0.00 0.00 0.02 0.01
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Table 13. Effects of Changes in k3 
 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 4.2 8.4 42 63 84 105 126 168 840
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 9.46 9.01 7.26 6.99 6.93 6.88 6.82 6.71 4.66
   pCa50 6.40 6.30 5.74 5.52 5.37 5.24 5.14 4.96 4.26
   nH 2.32 2.48 2.80 2.43 2.15 1.99 1.88 1.78 2.30
   TC 201 200 200 200 200 200 200 200 200
   Pdev 1.019 0.833 0.350 0.258 0.204 0.169 0.144 0.111 0.023
   Trise 0.031 0.027 0.016 0.014 0.013 0.011 0.011 0.01 0.007
   Trelax 0.087 0.099 0.054 0.051 0.049 0.049 0.049 0.048 0.049
Δ (% from BL)
   Fmax 36.4 30.0 4.7 0.8 0.0 -0.8 -1.6 -3.2 -32.8
   pCa50 19.2 17.4 7.0 2.9 0.0 -2.3 -4.3 -7.6 -20.6
   nH 7.6 15.4 30.1 13.0 0.0 -7.7 -12.5 -17.3 6.7
   TC 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
   Pdev 398.5 307.3 71.2 26.3 0.0 -17.3 -29.6 -45.9 -88.8
   Trise 138.5 107.7 23.1 7.7 0.0 -15.4 -15.4 -23.1 -46.2
   Trelax 77.6 102.0 10.2 4.1 0.0 0.0 0.0 -2.0 0.0
Sensitivity
   Fmax -0.38 -0.33 -0.09 -0.03 0.00 -0.03 -0.03 -0.03 -0.04
   pCa50 -0.20 -0.19 -0.14 -0.12 0.00 -0.09 -0.09 -0.08 -0.02
   nH -0.08 -0.17 -0.60 -0.52 0.00 -0.31 -0.25 -0.17 0.01
   TC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   Pdev -4.19 -3.41 -1.42 -1.05 0.00 -0.69 -0.59 -0.46 -0.10
   Trise -1.46 -1.20 -0.46 -0.31 0.00 -0.62 -0.31 -0.23 -0.05
   Trelax -0.82 -1.13 -0.20 -0.16 0.00 0.00 0.00 -0.02 0.00
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Table 14. Effects of Changes in k4 
 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 4.2 8.4 42 63 84 105 126 168 840
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 6.77 6.78 6.85 6.89 6.93 6.98 7.05 7.42 11.80
   pCa50 5.14 5.15 5.25 5.31 5.37 5.42 5.47 5.54 5.80
   nH 1.58 1.59 1.77 1.93 2.15 2.43 2.74 3.34 5.75
   TC 205 205 203 201 200 199 198 195 165
   Pdev 0.140 0.144 0.172 0.189 0.204 0.219 0.232 0.254 0.384
   Trise 0.009 0.009 0.011 0.012 0.013 0.012 0.013 0.014 0.014
   Trelax 0.042 0.043 0.048 0.049 0.049 0.049 0.049 0.049 0.047
Δ (% from BL)
   Fmax -2.4 -2.2 -1.2 -0.6 0.0 0.6 1.7 7.0 70.2
   pCa50 -4.3 -4.1 -2.1 -1.1 0.0 1.0 1.9 3.2 8.0
   nH -26.4 -25.9 -18.0 -10.2 0.0 12.8 27.3 55.2 167.0
   TC 2.4 2.3 1.3 0.6 0.0 -0.6 -1.2 -2.4 -17.3
   Pdev -31.5 -29.8 -15.8 -7.6 0.0 7.0 13.3 24.3 87.9
   Trise -30.8 -30.8 -15.4 -7.7 0.0 -7.7 0.0 7.7 7.7
   Trelax -14.3 -12.2 -2.0 0.0 0.0 0.0 0.0 0.0 -4.1
Sensitivity
   Fmax 0.02 0.02 0.02 0.02 0.00 0.02 0.03 0.07 0.08
   pCa50 0.05 0.05 0.04 0.04 0.00 0.04 0.04 0.03 0.01
   nH 0.28 0.29 0.36 0.41 0.00 0.51 0.55 0.55 0.19
   TC -0.03 -0.03 -0.03 -0.02 0.00 -0.02 -0.02 -0.02 -0.02
   Pdev 0.33 0.33 0.32 0.30 0.00 0.28 0.27 0.24 0.10
   Trise 0.32 0.34 0.31 0.31 0.00 -0.31 0.00 0.08 0.01
   Trelax 0.15 0.14 0.04 0.00 0.00 0.00 0.00 0.00 0.00
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Table 15. Effects of Changes in g 
 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 10.265 20.53 102.65 153.975 205.3 256.625 307.95 410.6 2053
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 18.80 17.82 11.63 8.94 6.93 5.47 4.41 3.06 0.43
   pCa50 6.10 6.05 5.72 5.54 5.37 5.24 5.13 5.00 4.85
   nH 4.51 4.80 4.93 3.30 2.15 1.57 1.27 0.99 0.68
   TC 11 21 101 151 200 250 300 399 1990
   Pdev 0.685 0.613 0.328 0.252 0.204 0.172 0.148 0.116 0.026
   Trise 0.017 0.016 0.013 0.013 0.013 0.012 0.012 0.011 0.011
   Trelax 0.046 0.046 0.048 0.048 0.049 0.049 0.049 0.05 0.051
Δ (% from BL)
   Fmax 171.1 157.0 67.7 28.9 0.0 -21.1 -36.4 -55.8 -93.9
   pCa50 13.6 12.7 6.6 3.2 0.0 -2.4 -4.4 -6.7 -9.6
   nH 109.6 122.8 128.9 53.4 0.0 -26.8 -41.1 -53.8 -68.5
   TC -94.3 -89.4 -49.6 -24.8 0.0 24.8 49.7 99.3 894.0
   Pdev 234.8 199.9 60.4 23.4 0.0 -16.0 -27.6 -43.4 -87.4
   Trise 30.8 23.1 0.0 0.0 0.0 -7.7 -7.7 -15.4 -15.4
   Trelax -6.1 -6.1 -2.0 -2.0 0.0 0.0 0.0 2.0 4.1
Sensitivity
   Fmax -1.80 -1.74 -1.35 -1.16 0.00 -0.84 -0.73 -0.56 -0.10
   pCa50 -0.14 -0.14 -0.13 -0.13 0.00 -0.10 -0.09 -0.07 -0.01
   nH -1.15 -1.36 -2.58 -2.14 0.00 -1.07 -0.82 -0.54 -0.08
   TC 0.99 0.99 0.99 0.99 0.00 0.99 0.99 0.99 0.99
   Pdev -2.47 -2.22 -1.21 -0.93 0.00 -0.64 -0.55 -0.43 -0.10
   Trise -0.32 -0.26 0.00 0.00 0.00 -0.31 -0.15 -0.15 -0.02
   Trelax 0.06 0.07 0.04 0.08 0.00 0.00 0.00 0.02 0.00
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Table 16. Effects of Changes in α1 
 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α 1 0.1 0.2 1 1.5 2 2.5 3 4 20
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 5.89 6.12 6.76 6.87 6.93 6.97 7.02 7.21 9.30
   pCa50 4.77 4.80 5.10 5.24 5.37 5.47 5.55 5.68 4.00
   nH 0.79 0.84 1.29 1.67 2.15 2.76 3.46 5.08 4.84
   TC 200 200 200 200 200 200 200 200 200
   Pdev 0.195 0.195 0.199 0.202 0.204 0.207 0.210 0.216 0.375
   Trise 0.012 0.012 0.012 0.012 0.013 0.013 0.013 0.012 0.018
   Trelax 0.05 0.05 0.049 0.049 0.049 0.048 0.048 0.048 0.042
Δ (% from BL)
   Fmax -15.1 -11.7 -2.5 -0.9 0.0 0.6 1.2 4.0 34.2
   pCa50 -11.1 -10.6 -5.0 -2.3 0.0 1.9 3.5 5.8 -25.5
   nH -63.1 -61.1 -40.1 -22.5 0.0 28.0 60.5 135.8 124.8
   TC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
   Pdev -4.8 -4.5 -2.6 -1.3 0.0 1.3 2.7 5.5 83.3
   Trise -7.7 -7.7 -7.7 -7.7 0.0 0.0 0.0 -7.7 38.5
   Trelax 2.0 2.0 0.0 0.0 0.0 -2.0 -2.0 -2.0 -14.3
Sensitivity
   Fmax 0.16 0.13 0.05 0.04 0.00 0.02 0.02 0.04 0.04
   pCa50 0.12 0.12 0.10 0.09 0.00 0.08 0.07 0.06 -0.03
   nH 0.66 0.68 0.80 0.90 0.00 1.12 1.21 1.36 0.14
   TC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   Pdev 0.05 0.05 0.05 0.05 0.00 0.05 0.05 0.06 0.09
   Trise 0.08 0.09 0.15 0.31 0.00 0.00 0.00 -0.08 0.04
   Trelax -0.02 -0.02 0.00 0.00 0.00 -0.08 -0.04 -0.02 -0.02
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Table 17. Effects of Changes in β1 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β 1 0.15 0.3 1.5 2.25 3 3.75 4.5 6 30
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 6.91 6.91 6.92 6.93 6.93 6.94 6.95 6.96 7.28
   pCa50 5.10 5.17 5.29 5.33 5.37 5.40 5.43 5.49 6.00
   nH 33.24 19.10 3.63 2.60 2.15 1.90 1.73 1.53 1.06
   TC 200 200 200 200 200 200 200 200 201
   Pdev 0.010 0.020 0.101 0.153 0.204 0.256 0.309 0.413 2.056
   Trise 0.012 0.012 0.012 0.012 0.013 0.013 0.013 0.013 0.013
   Trelax 0.049 0.049 0.049 0.049 0.049 0.049 0.049 0.048 0.049
Δ (% from BL)
   Fmax -0.4 -0.4 -0.2 -0.1 0.0 0.1 0.2 0.3 4.9
   pCa50 -4.9 -3.7 -1.4 -0.7 0.0 0.6 1.2 2.4 11.8
   nH 1444.1 787.2 68.8 20.8 0.0 -11.8 -19.5 -28.8 -50.5
   TC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2
   Pdev -95.1 -90.2 -50.4 -25.3 0.0 25.4 50.9 102.1 905.5
   Trise -7.7 -7.7 -7.7 -7.7 0.0 0.0 0.0 0.0 0.0
   Trelax 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -2.0 0.0
Sensitivity
   Fmax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
   pCa50 0.05 0.04 0.03 0.03 0.00 0.02 0.02 0.02 0.01
   nH -15.20 -8.75 -1.38 -0.83 0.00 -0.47 -0.39 -0.29 -0.06
   TC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   Pdev 1.00 1.00 1.01 1.01 0.00 1.02 1.02 1.02 1.01
   Trise 0.08 0.09 0.15 0.31 0.00 0.00 0.00 0.00 0.00
   Trelax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00
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Table 18. Effects of Changes in αf 
 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   α f 0.0075 0.015 0.075 0.1125 0.15 0.1875 0.225 0.3 1.5
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 3.70 3.82 5.00 5.93 6.93 7.96 8.93 10.66 17.67
   pCa50 5.25 5.25 5.28 5.31 5.37 5.43 5.51 5.62 6.10
   nH 0.97 1.00 1.26 1.57 2.15 3.29 5.67 12.36 8.73
   TC 200 200 200 200 200 200 200 200 200
   Pdev 0.197 0.198 0.201 0.203 0.204 0.206 0.208 0.212 0.303
   Trise 0.012 0.012 0.012 0.012 0.013 0.013 0.013 0.013 0.014
   Trelax 0.05 0.05 0.049 0.049 0.049 0.049 0.049 0.049 0.044
Δ (% from BL)
   Fmax -46.7 -45.0 -27.9 -14.6 0.0 14.7 28.8 53.7 154.8
   pCa50 -2.1 -2.1 -1.7 -1.1 0.0 1.2 2.6 4.7 13.6
   nH -55.0 -53.8 -41.7 -26.9 0.0 52.9 163.2 474.2 305.6
   TC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
   Pdev -3.5 -3.3 -1.9 -0.9 0.0 1.0 1.9 3.9 48.1
   Trise -7.7 -7.7 -7.7 -7.7 0.0 0.0 0.0 0.0 7.7
   Trelax 2.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 -10.2
Sensitivity
   Fmax 0.49 0.50 0.56 0.58 0.00 0.59 0.58 0.54 0.17
   pCa50 0.02 0.02 0.03 0.04 0.00 0.05 0.05 0.05 0.02
   nH 0.58 0.60 0.83 1.08 0.00 2.11 3.26 4.74 0.34
   TC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   Pdev 0.04 0.04 0.04 0.04 0.00 0.04 0.04 0.04 0.05
   Trise 0.08 0.09 0.15 0.31 0.00 0.00 0.00 0.00 0.01
   Trelax -0.02 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
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Table 19. Effects of Changes in βf 
 
 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   β f 0.035 0.07 0.35 0.525 0.7 0.875 1.05 1.4 7
   d 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6 44.6
Indices
   Fmax 1.23 2.17 5.17 6.17 6.93 7.57 8.11 9.00 14.48
   pCa50 4.32 4.46 5.06 5.24 5.37 5.47 5.55 5.66 6.22
   nH 1.69 1.46 1.82 2.02 2.15 2.24 2.29 2.34 2.07
   TC 200 200 200 200 200 200 200 200 200
   Pdev 0.010 0.020 0.102 0.153 0.204 0.256 0.309 0.415 2.690
   Trise 0.012 0.012 0.012 0.012 0.013 0.013 0.013 0.012 0.017
   Trelax 0.05 0.05 0.049 0.049 0.049 0.048 0.048 0.048 0.043
Δ (% from BL)
   Fmax -82.2 -68.8 -25.4 -11.1 0.0 9.1 16.9 29.8 108.8
   pCa50 -19.5 -17.0 -5.8 -2.4 0.0 1.9 3.5 5.4 15.9
   nH -21.4 -32.1 -15.3 -6.1 0.0 3.9 6.4 8.8 -3.6
   TC 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1
   Pdev -95.0 -90.0 -50.1 -25.1 0.0 25.3 50.9 102.9 1215.8
   Trise -7.7 -7.7 -7.7 -7.7 0.0 0.0 0.0 -7.7 30.8
   Trelax 2.0 2.0 0.0 0.0 0.0 -2.0 -2.0 -2.0 -12.2
Sensitivity
   Fmax 0.87 0.76 0.51 0.44 0.00 0.37 0.34 0.30 0.12
   pCa50 0.21 0.19 0.12 0.10 0.00 0.08 0.07 0.05 0.02
   nH 0.23 0.36 0.31 0.24 0.00 0.16 0.13 0.09 0.00
   TC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   Pdev 1.00 1.00 1.00 1.01 0.00 1.01 1.02 1.03 1.35
   Trise 0.08 0.09 0.15 0.31 0.00 0.00 0.00 -0.08 0.03
   Trelax -0.02 -0.02 0.00 0.00 0.00 -0.08 -0.04 -0.02 -0.01
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Table 20. Effects of Changes in d 
 
Parameter 5% 10% 50% 75% BL 125% 150% 200% 1000%
   k 2 25 25 25 25 25 25 25 25 25
   k 3 84 84 84 84 84 84 84 84 84
   k 4 84 84 84 84 84 84 84 84 84
   g 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3 205.3
   α1 2 2 2 2 2 2 2 2 2
   β1 3 3 3 3 3 3 3 3 3
   αf 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
   βf 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
   d 2.23 4.46 22.3 33.45 44.6 55.75 66.9 89.2 446
Indices
   Fmax 6.99 6.98 6.96 6.95 6.93 6.92 6.91 6.88 6.54
   pCa50 5.80 5.72 5.49 5.42 5.37 5.33 5.29 5.24 5.00
   nH 3.15 3.12 2.50 2.29 2.15 2.06 1.98 1.87 1.35
   TC 199 199 200 200 200 201 201 202 212
   Pdev 0.361 0.333 0.246 0.221 0.204 0.192 0.182 0.167 0.114
   Trise 0.023 0.021 0.015 0.013 0.013 0.012 0.011 0.011 0.009
   Trelax 0 0.077 0.068 0.055 0.049 0.046 0.043 0.041 0.039
Δ (% from BL)
   Fmax 0.9 0.7 0.4 0.2 0.0 -0.2 -0.4 -0.7 -5.7
   pCa50 8.0 6.6 2.4 1.0 0.0 -0.7 -1.4 -2.3 -6.7
   nH 46.4 45.1 16.1 6.5 0.0 -4.5 -8.1 -13.3 -37.2
   TC -0.4 -0.5 -0.4 -0.2 0.0 0.2 0.4 0.7 5.9
   Pdev 76.7 63.1 20.1 8.2 0.0 -6.1 -10.9 -18.1 -44.2
   Trise 76.9 61.5 15.4 0.0 0.0 -7.7 -15.4 -15.4 -30.8
   Trelax -100.0 57.1 38.8 12.2 0.0 -6.1 -12.2 -16.3 -20.4
Sensitivity
   Fmax -0.01 -0.01 -0.01 -0.01 0.00 -0.01 -0.01 -0.01 -0.01
   pCa50 -0.08 -0.07 -0.05 -0.04 0.00 -0.03 -0.03 -0.02 -0.01
   nH -0.49 -0.50 -0.32 -0.26 0.00 -0.18 -0.16 -0.13 -0.04
   TC 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01
   Pdev -0.81 -0.70 -0.40 -0.33 0.00 -0.25 -0.22 -0.18 -0.05
   Trise -0.81 -0.68 -0.31 0.00 0.00 -0.31 -0.31 -0.15 -0.03
   Trelax 1.05 -0.63 -0.78 -0.49 0.00 -0.24 -0.24 -0.16 -0.02
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Table 21. Index Sensitivity to All Parameters 
 
Average sensitivity was calculated as the average sensitivity over 50% to 150% of the baseline value of the parameter.  
 
Parameter Fmax pCa50 nH TC Pdev Trise Trelax
k 2 -0.04 ± 0.04 -0.03 ± 0.01 -0.46 ± 0.19 0.03 ± 0.01 -0.05 ± 0 -0.12 ± 0.15 0.03 ± 0.04
k 3 -0.05 ± 0.03 -0.11 ± 0.03 -0.42 ± 0.17 0 ± 0 -0.94 ± 0.38 -0.42 ± 0.15 -0.09 ± 0.11
k 4 0.03 ± 0 0.04 ± 0 0.46 ± 0.09 -0.02 ± 0 0.29 ± 0.02 0.08 ± 0.29 0.01 ± 0.02
g -1.02 ± 0.29 -0.11 ± 0.02 -1.65 ± 0.84 0.99 ± 0 -0.83 ± 0.3 -0.12 ± 0.15 0.03 ± 0.04
α1 0.03 ± 0.01 0.08 ± 0.01 1.01 ± 0.19 0 ± 0 0.05 ± 0 0.12 ± 0.15 -0.03 ± 0.04
β1 0 ± 0 0.03 ± 0 -0.77 ± 0.45 0 ± 0 1.01 ± 0 0.12 ± 0.15 0 ± 0
αf 0.58 ± 0.01 0.04 ± 0.01 1.82 ± 1.11 0 ± 0 0.04 ± 0 0.12 ± 0.15 0 ± 0
βf 0.41 ± 0.08 0.09 ± 0.02 0.21 ± 0.08 0 ± 0 1.01 ± 0.01 0.12 ± 0.15 -0.03 ± 0.04
d -0.01 ± 0 -0.04 ± 0.01 -0.23 ± 0.07 0.01 ± 0 -0.3 ± 0.08 -0.23 ± 0.15 -0.44 ± 0.25
Indices (Steady State Data) Indices (Time Varying Data)
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APPENDIX E 
CALCIUM CALIBRATION EQUATION DERIVATION 
The calibration equation for the fluorescence recorded during measurement of 
intracellular calcium transients with fura-2 (or its derivatives) is shown in Equation E.1: 
 [𝐶𝐶𝐶𝐶2+]𝑖𝑖 =  𝐾𝐾𝑑𝑑 �𝑆𝑆𝑓𝑓−380𝑆𝑆𝑏𝑏−380� �𝑅𝑅−𝑅𝑅𝑚𝑚𝑖𝑖𝑚𝑚𝑅𝑅𝑚𝑚𝐶𝐶𝑚𝑚 −𝑅𝑅� (E.1) 
 This equation is presented in the literature many times, and is well known [100]. While it 
has been partially derived in the literature [91], we will derive it here in full as a reference.  
 We will begin by setting up the chemical equilibria of fura binding to calcium.  
 
Figure 9-12. Fura Binding to Calcium 
 In Figure 9-12, Cf is concentration of free dye, Ca2+ is concentration of calcium, Cb is 
concentration of bound dye, kl is the binding constant and k-l is the unbinding constant. The 
following relationships can be made: 
 𝐶𝐶𝑏𝑏 =  𝑘𝑘𝑙𝑙𝐶𝐶𝑓𝑓𝐶𝐶𝐶𝐶2+𝑘𝑘−𝑙𝑙  (E.2) 
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 𝑘𝑘𝑑𝑑 =  𝑘𝑘−𝑙𝑙𝑘𝑘𝑙𝑙  (E.3) 
 𝐶𝐶𝑏𝑏 = 𝐶𝐶𝑓𝑓𝐶𝐶𝐶𝐶2+𝑘𝑘𝑑𝑑  (E.4) 
where kd is the dye dissociation constant. 
 There are two excitation wavelengths for fura dyes: λ1 = 340 nm, and λ2 = 380 nm. 
Fluorescence at each wavelength is composed of bound dye and free dye (bound dye increases 
fluorescence primarily at 340 nm and free dye increases fluorescence primarily at 380 nm), 
leading to four fluorescence intensities: Sf1 (free dye at λ1), Sf2 (free dye at λ2), Sb1 (bound dye at 
λ1), and Sb2 (bound dye at λ2). Therefore, there are two total fluorescences, one at each 
wavelength: 
 𝐹𝐹1 = 𝑆𝑆𝑓𝑓1𝐶𝐶𝑓𝑓 + 𝑆𝑆𝑏𝑏1𝐶𝐶𝑏𝑏  (E.5) 
 𝐹𝐹2 = 𝑆𝑆𝑓𝑓2𝐶𝐶𝑓𝑓 + 𝑆𝑆𝑏𝑏2𝐶𝐶𝑏𝑏  (E.6) 
 The ratio of the total fluorescence at 340 nm excitation over 380 nm excitation represents 
the fluorescence ratio R: 
 𝑅𝑅 = 𝐹𝐹1
𝐹𝐹2 = 𝑆𝑆𝑓𝑓1𝐶𝐶𝑓𝑓+𝑆𝑆𝑏𝑏1𝐶𝐶𝑏𝑏𝑆𝑆𝑓𝑓2𝐶𝐶𝑓𝑓+𝑆𝑆𝑏𝑏2𝐶𝐶𝑏𝑏  (E.7) 
 The vales of Cb in Equation E.7 can be replaced with Equation E.4 to yield: 
 𝑅𝑅 = 𝑆𝑆𝑓𝑓1+𝑆𝑆𝑏𝑏1𝐶𝐶𝐶𝐶 2+𝑘𝑘𝑑𝑑
𝑆𝑆𝑓𝑓2+𝑆𝑆𝑏𝑏2𝐶𝐶𝐶𝐶 2+𝑘𝑘𝑑𝑑  (E.8) 
which can be rearranged: 
 𝑅𝑅 �𝑆𝑆𝑓𝑓2 + 𝑆𝑆𝑏𝑏2 𝐶𝐶𝐶𝐶2+𝑘𝑘𝑑𝑑 � = 𝑆𝑆𝑓𝑓1 + 𝑆𝑆𝑏𝑏1 𝐶𝐶𝐶𝐶2+𝑘𝑘𝑑𝑑  (E.9) 
 𝑅𝑅𝑆𝑆𝑓𝑓2 − 𝑆𝑆𝑓𝑓1 = 𝐶𝐶𝐶𝐶2+𝑘𝑘𝑑𝑑 (𝑆𝑆𝑏𝑏1 − 𝑅𝑅𝑆𝑆𝑏𝑏2) (E.10) 
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𝐶𝐶𝐶𝐶2+
𝑘𝑘𝑑𝑑
= 𝑅𝑅𝑆𝑆𝑓𝑓2−𝑆𝑆𝑓𝑓1
𝑆𝑆𝑏𝑏1−𝑅𝑅𝑆𝑆𝑏𝑏2 (E.11) 
Two new parameters can be defined: 
 𝑅𝑅𝑚𝑚𝑖𝑖𝑚𝑚 = 𝑆𝑆𝑓𝑓1𝑆𝑆𝑓𝑓2 (E.12) 
 𝑅𝑅𝑚𝑚𝐶𝐶𝑚𝑚 = 𝑆𝑆𝑏𝑏1𝑆𝑆𝑏𝑏2 (E.13) 
In order to introduce these two parameters into Equation E.11, the following multiplication is 
introduced:  
 
𝐶𝐶𝐶𝐶2+
𝑘𝑘𝑑𝑑
= 𝑅𝑅𝑆𝑆𝑓𝑓2−𝑆𝑆𝑓𝑓1
𝑆𝑆𝑏𝑏1−𝑅𝑅𝑆𝑆𝑏𝑏2 �
1
𝑆𝑆𝑓𝑓2𝑆𝑆𝑏𝑏2�1
𝑆𝑆𝑓𝑓2𝑆𝑆𝑏𝑏2� � (E.14) 
which can be rearranged: 
 
𝐶𝐶𝐶𝐶2+
𝑘𝑘𝑑𝑑
= 1 𝑆𝑆𝑏𝑏2� −�𝑅𝑅−𝑆𝑆𝑓𝑓1𝑆𝑆𝑓𝑓2�1
𝑆𝑆𝑓𝑓2� −�𝑆𝑆𝑏𝑏1𝑆𝑆𝑏𝑏2−𝑅𝑅� (E.15) 
Inserting Equation E.12 and Equation E.13 and rearranging yields the calibration equation: 
 𝐶𝐶𝐶𝐶2+ =  𝐾𝐾𝑑𝑑 �𝑆𝑆𝑓𝑓2𝑆𝑆𝑏𝑏2� �𝑅𝑅−𝑅𝑅𝑚𝑚𝑖𝑖𝑚𝑚𝑅𝑅𝑚𝑚𝐶𝐶𝑚𝑚 −𝑅𝑅� (E.16) 
 
 
 182 
BIBLIOGRAPHY 
1. Bers, D.M., Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res, 
2000. 87(4): p. 275-81. 
 
2. Bers, D .M., Excitation-Contraction Coupling and Cardiac Contractile Force. 
Developments in Cardiovascular Medicine. 2001, New York, NY: Springer. 
 
3. Perry, S.V., Vertebrate tropomyosin: distribution, properties and function. J Muscle Res 
Cell Motil, 2001. 22(1): p. 5-49. 
 
4. Cooke, R., Actomyosin interaction in striated muscle. Physiol Rev, 1997. 77(3): p. 671-
97. 
 
5. Maughan, D.W., Kinetics and energetics of the crossbridge cycle. Heart Fail Rev, 2005. 
10(3): p. 175-85. 
 
6. Puceat, M. and G. Vassort, Signalling by protein kinase C isoforms in the heart. Mol 
Cell Biochem, 1996. 157(1-2): p. 65-72. 
 
7. Sabri, A . a nd S.F. St einberg, Protein kinase C isoform-selective signals that lead to 
cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem, 2003. 251(1-
2): p. 97-101. 
 
8. Takai, Y ., A . K ishimoto, Y . I wasa, Y . K awahara, T . M ori, an d Y. N ishizuka, 
Calcium-dependent activation of a multifunctional protein kinase by membrane 
phospholipids. J Biol Chem, 1979. 254(10): p. 3692-5. 
 
9. Kuo, J.F ., R .G. A ndersson, B .C. Wi se, L . M ackerlova, I . S alomonsson, N .L. 
Brackett, N . Katoh, M . S hoji, an d R .W. Wr enn, Calcium-dependent protein kinase: 
widespread occurrence in various tissues and phyla of the animal kingdom and 
comparison of effects of phospholipid, calmodulin, and trifluoperazine. Proc Natl Acad 
Sci U S A, 1980. 77(12): p. 7039-43. 
 
10. Steinberg, S.F., Structural basis of protein kinase C isoform function. Physiol Rev, 2008. 
88(4): p. 1341-78. 
 
 183 
11. Wu, S .C. an d R .J. S olaro, Protein kinase c zeta : A novel regulator of both 
phosphorylation and de-phosphorylation of cardiac sarcomeric proteins. J Biol Chem, 
2007. 
 
12. Mohamed, A.S., J.D. Dignam, and K.K. Schlender, Cardiac myosin-binding protein C 
(MyBP-C): identification of protein kinase A and protein kinase C phosphorylation sites. 
Arch Biochem Biophys, 1998. 358(2): p. 313-9. 
 
13. Xiao, L ., Q . Zhao, Y . Du, C . Y uan, R .J. S olaro, an d P.M. B uttrick, PKCepsilon 
increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in 
vitro and in vivo. Biochemistry, 2007. 46(23): p. 7054-61. 
 
14. Tong, C.W., J.E. Stelzer, M.L. Greaser, P.A. Powers, and R.L. Moss, Acceleration of 
crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding 
protein C modulates cardiac function. Circ Res, 2008. 103(9): p. 974-82. 
 
15. Noland, T .A., Jr . an d J.F. K uo, Phosphorylation of cardiac myosin light chain 2 by 
protein kinase C and myosin light chain kinase increases Ca(2+)-stimulated actomyosin 
MgATPase activity. Biochem Biophys Res Commun, 1993. 193(1): p. 254-60. 
 
16. Venema, R.C., R.L. Raynor, T.A. Noland, Jr., and J.F. Kuo, Role of protein kinase C 
in the phosphorylation of cardiac myosin light chain 2. Biochem J, 1993. 294 ( Pt 2): p. 
401-6. 
 
17. Noland, T.A., Jr., R.L. Raynor, and J.F. Kuo, Identification of sites phosphorylated in 
bovine cardiac troponin I and troponin T by protein kinase C and comparative substrate 
activity of synthetic peptides containing the phosphorylation sites. J Biol Chem, 1989. 
264(34): p. 20778-85. 
 
18. Layland, J., R.J. Solaro, and A.M. Shah, Regulation of cardiac contractile function by 
troponin I phosphorylation. Cardiovasc Res, 2005. 66(1): p. 12-21. 
 
19. Jobsis, F .F. an d M .J. O'Connor, Calcium release and reabsorption in the sartorius 
muscle of the toad. Biochem Biophys Res Commun, 1966. 25(2): p. 246-52. 
 
20. Wickenden, A .D., R . Kaprielian, Z . Kassiri, J.N . T soporis, R . T sushima, G .I. 
Fishman, an d P .H. B ackx, The role of action potential prolongation and altered 
intracellular calcium handling in the pathogenesis of heart failure. Cardiovasc Res, 1998. 
37(2): p. 312-23. 
 
21. Beuckelmann, D.J., M. Nabauer, and E. Erdmann, Intracellular calcium handling in 
isolated ventricular myocytes from patients with terminal heart failure. Circulation, 1992. 
85(3): p. 1046-55. 
 
 184 
22. Beuckelmann, D .J., M . N abauer, C . Kruger, an d E . E rdmann, Altered diastolic 
[Ca2+]i handling in human ventricular myocytes from patients with terminal heart 
failure. Am Heart J, 1995. 129(4): p. 684-9. 
 
23. Del M onte, F., C .M. Johnson, A .C. S tepanek, A .A. D oye, an d J. K. Gwathmey, 
Defects in calcium control. J Card Fail, 2002. 8(6 Suppl): p. S421-31. 
 
24. Chang, K .C., J.H . S chreur, M .W. We iner, an d S .A. C amacho, Impaired Ca2+ 
handling is an early manifestation of pressure-overload hypertrophy in rat hearts. Am J 
Physiol, 1996. 271(1 Pt 2): p. H228-34. 
 
25. Solaro, R.J., Is calcium the 'cure' for dilated cardiomyopathy? Nat Med, 1999. 5(12): p. 
1353-4. 
 
26. Camacho, S .A., R. B randes, V .M. F igueredo, an d M .W. We iner, Ca2+ transient 
decline and myocardial relaxation are slowed during low flow ischemia in rat hearts. J 
Clin Invest, 1994. 93(3): p. 951-7. 
 
27. Saini, H .K. and N.S. D halla, Defective calcium handling in cardiomyocytes isolated 
from hearts subjected to ischemia-reperfusion. Am J Physiol Heart Circ Physiol, 2005. 
288(5): p. H2260-70. 
 
28. Stefenelli, T ., J.  Wikman-Coffelt, S .T. Wu, and W.W. P armley, Calcium-dependent 
fluorescence transients during ventricular fibrillation. Am Heart J, 1990. 120(3): p. 590-7. 
 
29. Varian, K .D., S . R aman, an d P .M. Jan ssen, Measurement of myofilament calcium 
sensitivity at physiological temperature in intact cardiac trabeculae. Am J Physiol Heart 
Circ Physiol, 2006. 290(5): p. H2092-7. 
 
30. Varian, K .D. an d P .M. Jan ssen, Frequency-dependent acceleration of relaxation 
involves decreased myofilament calcium sensitivity. Am J Physiol Heart Circ Physiol, 
2007. 292(5): p. H2212-9. 
 
31. Takimoto, E., D.G. Soergel, P.M. Janssen, L.B. Stull, D.A. Kass, and A.M. Murphy, 
Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with 
constitutively active protein kinase A phosphorylation sites. Circ Res, 2004. 94(4): p. 
496-504. 
 
32. Yasuda, S ., P . C outu, S . Sadayappan, J. R obbins, and J .M. Met zger, Cardiac 
transgenic and gene transfer strategies converge to support an important role for troponin 
I in regulating relaxation in cardiac myocytes. Circ Res, 2007. 101(4): p. 377-86. 
 
33. Kentish, J.C ., D .T. McCloskey, J. L ayland, S . P almer, J. M. L eiden, A .F. M artin, 
and R.J. Solaro, Phosphorylation of troponin I by protein kinase A accelerates relaxation 
and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res, 2001. 88(10): p. 
1059-65. 
 185 
 
34. Pi, Y., D. Zhang, K.R. Kemnitz, H. Wang, and J.W. Walker, Protein kinase C and A 
sites on troponin I regulate myofilament Ca2+ sensitivity and ATPase activity in the 
mouse myocardium. J Physiol, 2003. 552(Pt 3): p. 845-57. 
 
35. Konhilas, J.P., T.C. Irving, B.M. Wolska, E.E. Jweied, A.F. Martin, R.J. Solaro, and 
P.P. d e T ombe, Troponin I in the murine myocardium: influence on length-dependent 
activation and interfilament spacing. J Physiol, 2003. 547(Pt 3): p. 951-61. 
 
36. Kajiwara, H ., S . M orimoto, N . Fukuda, I . O htsuki, a nd S . K urihara, Effect of 
troponin I phosphorylation by protein kinase A on length-dependence of tension 
activation in skinned cardiac muscle fibers. Biochem Biophys Res Commun, 2000. 
272(1): p. 104-10. 
 
37. Buscemi, N., D .B. Foster, I . N everova, an d J.E . V an E yk, p21-activated kinase 
increases the calcium sensitivity of rat triton-skinned cardiac muscle fiber bundles via a 
mechanism potentially involving novel phosphorylation of troponin I. Circ Res, 2002. 
91(6): p. 509-16. 
 
38. Zabrouskov, V ., Y . Ge, J. S chwartz, an d J.W. W alker, Unraveling molecular 
complexity of phosphorylated human cardiac troponin I by top down electron capture 
dissociation/electron transfer dissociation mass spectrometry. Mol Cell Proteomics, 2008. 
7(10): p. 1838-49. 
 
39. You, B., G. Yan, Z. Zhang, L. Yan, J. Li, Q. Ge, J.P. Jin, and J. Sun, Phosphorylation 
of cardiac troponin I by mammalian sterile 20-like kinase 1. Biochem J, 2008. 
 
40. Haworth, R.S., F. Cuello, T.J. Herron, G. Franzen, J.C. Kentish, M. Gautel, and M. 
Avkiran, Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and 
regulates myofilament function. Circ Res, 2004. 95(11): p. 1091-9. 
 
41. Sakthivel, S ., N .L. F inley, P .R. R osevear, J.N. L orenz, J. Gulick, S . K im, P. 
VanBuren, L .A. M artin, an d J. R obbins, In vivo and in vitro analysis of cardiac 
troponin I phosphorylation. J Biol Chem, 2005. 280(1): p. 703-14. 
 
42. Noland, T .A., Jr ., R .L. R aynor, N .M. Ji deama, X . Guo, M .G. K azanietz, P.M. 
Blumberg, R.J. Solaro, and J.F. Kuo, Differential regulation of cardiac actomyosin S-1 
MgATPase by protein kinase C isozyme-specific phosphorylation of specific sites in 
cardiac troponin I and its phosphorylation site mutants. Biochemistry, 1996. 35(47): p. 
14923-31. 
 
43. Kobayashi, T., X. Yang, L.A. Walker, R.B. Van Breemen, and R.J. Solaro, A non-
equilibrium isoelectric focusing method to determine states of phosphorylation of cardiac 
troponin I: identification of Ser-23 and Ser-24 as significant sites of phosphorylation by 
protein kinase C. J Mol Cell Cardiol, 2005. 38(1): p. 213-8. 
 
 186 
44. McClellan, G., A. Weisberg, and S. Winegrad, Effect of endothelin-1 on actomyosin 
ATPase activity. Implications for the efficiency of contraction. Circ Res, 1996. 78(6): p. 
1044-50. 
 
45. Pi, Y ., R . S reekumar, X. H uang, an d J.W. Walker, Positive inotropy mediated by 
diacylglycerol in rat ventricular myocytes. Circ Res, 1997. 81(1): p. 92-100. 
 
46. MacGowan, G.A., C. Du, and A.P. Koretsky, High calcium and dobutamine positive 
inotropy in the perfused mouse heart: myofilament calcium responsiveness, energetic 
economy, and effects of protein kinase C inhibition. BMC Physiol, 2001. 1: p. 12. 
 
47. Jideama, N .M., T .A. N oland, Jr ., R .L. R aynor, G .C. B lobe, D . F abbro, M .G. 
Kazanietz, P.M. Blumberg, Y.A. Hannun, and J.F. Kuo, Phosphorylation specificities 
of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites 
within these proteins and regulation of myofilament properties. J Biol Chem, 1996. 
271(38): p. 23277-83. 
 
48. Shistik, E., T. Ivanina, Y. Blumenstein, and N. Dascal, Crucial role of N terminus in 
function of cardiac L-type Ca2+ channel and its modulation by protein kinase C. J Biol 
Chem, 1998. 273(28): p. 17901-9. 
 
49. Dorn, G .W., 2n d an d T. F orce, Protein kinase cascades in the regulation of cardiac 
hypertrophy. J Clin Invest, 2005. 115(3): p. 527-37. 
 
50. Sumandea, M .P., W. G. Pyle, T . Kobayashi, P .P. d e T ombe, an d R .J. S olaro, 
Identification of a functionally critical protein kinase C phosphorylation residue of 
cardiac troponin T. J Biol Chem, 2003. 278(37): p. 35135-44. 
 
51. Burkart, E .M., M.P. Sumandea, T . Kobayashi, M. Nili, A .F. Martin, E . Homsher, 
and R.J. Solaro, Phosphorylation or glutamic acid substitution at protein kinase C sites 
on cardiac troponin I differentially depress myofilament tension and shortening velocity. 
J Biol Chem, 2003. 278(13): p. 11265-72. 
 
52. Noland, T.A., Jr., X. Guo, R.L. Raynor, N.M. Jideama, V. Averyhart-Fullard, R.J. 
Solaro, and J.F. Kuo, Cardiac troponin I mutants. Phosphorylation by protein kinases C 
and A and regulation of Ca2+-stimulated MgATPase of reconstituted actomyosin S-1. J 
Biol Chem, 1995. 270(43): p. 25445-54. 
 
53. Westfall, M.V., A.M. Lee, and D.A. Robinson, Differential contribution of troponin I 
phosphorylation sites to the endothelin-modulated contractile response. J Biol Chem, 
2005. 280(50): p. 41324-31. 
 
54. Tachampa, K ., H . Wan g, G .P. Farman, an d P .P. d e T ombe, Cardiac troponin I 
threonine 144: role in myofilament length dependent activation. Circ Res, 2007. 101(11): 
p. 1081-3. 
 
 187 
55. Pi, Y., K.R. Kemnitz, D. Zhang, E.G. Kranias, and J.W. Walker, Phosphorylation of 
troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants 
expressed on a troponin I-null background in mice. Circ Res, 2002. 90(6): p. 649-56. 
 
56. Bilchick, K.C., J.G. Duncan, R. Ravi, E. Takimoto, H.C. Champion, W.D. Gao, L.B. 
Stull, D.A. Kass, and A.M. Murphy, Heart failure-associated alterations in troponin I 
phosphorylation impair ventricular relaxation-afterload and force-frequency responses 
and systolic function. Am J Physiol Heart Circ Physiol, 2007. 292(1): p. H318-25. 
 
57. MacGowan, G.A., C. Du, D.B. Cowan, C. Stamm, F.X. McGowan, R.J. Solaro, A.P. 
Koretsky, an d P .J. D el N ido, Ischemic dysfunction in transgenic mice expressing 
troponin I lacking protein kinase C phosphorylation sites. Am J Physiol Heart Circ 
Physiol, 2001. 280(2): p. H835-43. 
 
58. Takeishi, Y ., G . C hu, D.M. K irkpatrick, Z . Li, H . Wak asaki, E .G. K ranias, G .L. 
King, and R.A. Walsh, In vivo phosphorylation of cardiac troponin I by protein kinase 
CβΙΙ decreases cardiomyocyte calcium responsiveness and contractility in transgenic 
mouse hearts. J Clin Invest, 1998. 102(1): p. 72-8. 
 
59. Roman, B.B., P.H. Goldspink, E. Spaite, D. Urboniene, R. McKinney, D.L. Geenen, 
R.J. Solaro, and P.M. Buttrick, Inhibition of PKC phosphorylation of cTnI improves 
cardiac performance in vivo. Am J Physiol Heart Circ Physiol, 2004. 286(6): p. H2089-
95. 
 
60. MacGowan, G .A., C . Evans, T .C. H u, D . D ebrah, S . M ullet, H .H. C hen, C .F. 
McTiernan, A.F. Stewart, A.P. Koretsky, and S.G. Shroff, Troponin I protein kinase 
C phosphorylation sites and ventricular function. Cardiovasc Res, 2004. 63(2): p. 245-55. 
 
61. Pyle, W. G., M .P. S umandea, R .J. S olaro, an d P .P. D e T ombe, Troponin I serines 
43/45 and regulation of cardiac myofilament function. Am J Physiol Heart Circ Physiol, 
2002. 283(3): p. H1215-24. 
 
62. Rosenblueth, A. and N. Wiener, The Role of Models in Science. Philosophy of Science, 
1945. 12(4): p. 316-321. 
 
63. Roberts, M .S. an d F .A. S onnenberg, Decision Modeling Techniques, in Decision 
Making in Health Care, G.B. Chapman and F.A. Sonnenberg, Editors. 2003, Cambridge 
University Press: Cambridge, UK. p. 20-64. 
 
64. Bassingthwaighte, J.B ., Using computer models to understand complex systems. 
Physiologist, 1985. 28(5): p. 439-42. 
 
65. Rosamond, W., K . Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M. 
Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd-Jones, M. McDermott, J. Meigs, C. 
Moy, G. Nichol, C.J. O'Donnell, V. Roger, J. Rumsfeld, P. Sorlie, J. Steinberger, T. 
Thom, S. Wasserthiel-Smoller, and Y. Hong, Heart disease and stroke statistics--2007 
 188 
update: a report from the American Heart Association Statistics Committee and Stroke 
Statistics Subcommittee. Circulation, 2007. 115(5): p. e69-171. 
 
66. Bodor, G .S., A .E. O akeley, P.D. A llen, D .L. Crimmins, J.H . L adenson, an d P .A. 
Anderson, Troponin I phosphorylation in the normal and failing adult human heart. 
Circulation, 1997. 96(5): p. 1495-500. 
 
67. van der Velden, J., Z. Papp, R. Zaremba, N.M. Boontje, J.W. de Jong, V.J. Owen, 
P.B. Burton, P. Goldmann, K. Jaquet, and G.J. Stienen, Increased Ca2+-sensitivity of 
the contractile apparatus in end-stage human heart failure results from altered 
phosphorylation of contractile proteins. Cardiovasc Res, 2003. 57(1): p. 37-47. 
 
68. Zakhary, D.R., C.S. Moravec, R.W. Stewart, and M. Bond, Protein kinase A (PKA)-
dependent troponin-I phosphorylation and PKA regulatory subunits are decreased in 
human dilated cardiomyopathy. Circulation, 1999. 99(4): p. 505-10. 
 
69. Messer, A .E., A .M. Jac ques, an d S.B. M arston, Troponin phosphorylation and 
regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I 
could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol, 
2007. 42(1): p. 247-59. 
 
70. Bowling, N ., R .A. Wal sh, G . S ong, T . E stridge, G .E. S andusky, R .L. F outs, K. 
Mintze, T. Pickard, R. Roden, M.R. Bristow, H.N. Sabbah, J.L. Mizrahi, G. Gromo, 
G.L. K ing, an d C .J. Vlahos, Increased protein kinase C activity and expression of 
Ca2+-sensitive isoforms in the failing human heart. Circulation, 1999. 99(3): p. 384-91. 
 
71. Vlahos, C .J., S .A. M cDowell, an d A . C lerk, Kinases as therapeutic targets for heart 
failure. Nat Rev Drug Discov, 2003. 2(2): p. 99-113. 
 
72. Day, S .M., M.V. W estfall, E .V. F omicheva, K. H oyer, S . Y asuda, N .C. L a C ross, 
L.G. D'Alecy, J.S. Ingwall, and J.M. Metzger, Histidine button engineered into cardiac 
troponin I protects the ischemic and failing heart. Nat Med, 2006. 12(2): p. 181-9. 
 
73. Subramaniam, A ., W. K. Jon es, J. G ulick, S . We rt, J. N eumann, and J . R obbins, 
Tissue-specific regulation of the α-myosin heavy chain gene promoter in transgenic 
mice. J Biol Chem, 1991. 266(36): p. 24613-20. 
 
74. Steinberg, T.H., B.J. Agnew, K.R. Gee, W.Y. Leung, T. Goodman, B. Schulenberg, 
J. Hendrickson, J.M. Beechem, R.P. Haugland, and W.F. Patton, Global quantitative 
phosphoprotein analysis using Multiplexed Proteomics technology. Proteomics, 2003. 
3(7): p. 1128-44. 
 
75. Solaro, R.J., D.C. Pang, and F.N. Briggs, The purification of cardiac myofibrils with 
Triton X-100. Biochim Biophys Acta, 1971. 245(1): p. 259-62. 
 
 189 
76. Lim, C .C., H . Y ang, M. Y ang, C .K. Wan g, J. S hi, E .A. B erg, D .R. P imentel, J. K. 
Gwathmey, R .J. H ajjar, M . H elmes, C .E. C ostello, S . H uo, an d R . Liao, A novel 
mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity 
and cardiomyocyte contractility. Biophys J, 2008. 94(9): p. 3577-89. 
 
77. Warren, C .M., G.M. Arteaga, S . R ajan, R .P. Ahmed, D .F. Wi eczorek, an d R .J. 
Solaro, Use of 2-D DIGE analysis reveals altered phosphorylation in a tropomyosin 
mutant (Glu54Lys) linked to dilated cardiomyopathy. Proteomics, 2008. 8(1): p. 100-5. 
 
78. Scruggs, S.B., A.C. Hinken, A. Thawornkaiwong, J. R obbins, L.A. Walker, P.P. de 
Tombe, D.L. Geenen, P.M. Buttrick, and R.J. Solaro, Ablation of ventricular Myosin 
regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and 
affects neighboring myofilament protein phosphorylation. J Biol Chem, 2009. 284(8): p. 
5097-106. 
 
79. Fritz, J.D ., D .R. S wartz, an d M .L. G reaser, Factors affecting polyacrylamide gel 
electrophoresis and electroblotting of high-molecular-weight myofibrillar proteins. Anal 
Biochem, 1989. 180(2): p. 205-10. 
 
80. Layland, J., A .C. C ave, C . Wa rren, D .J. Grieve, E . S parks, J.C . K entish, R .J. 
Solaro, and A.M. Shah, Protection against endotoxemia-induced contractile dysfunction 
in mice with cardiac-specific expression of slow skeletal troponin I. Faseb J, 2005. 19(9): 
p. 1137-9. 
 
81. Skrzypiec-Spring, M., B. Grotthus, A. Szelag, and R. Schulz, Isolated heart perfusion 
according to Langendorff---still viable in the new millennium. J Pharmacol Toxicol 
Methods, 2007. 55(2): p. 113-26. 
 
82. Sahn, D .J., A . D eMaria, J. K isslo, an d A . We yman, Recommendations regarding 
quantitation in M-mode echocardiography: results of a survey of echocardiographic 
measurements. Circulation, 1978. 58(6): p. 1072-83. 
 
83. Macgowan, G.A., J.A. Kirk, C. Evans, and S.G. Shroff, Pressure-calcium relationships 
in perfused mouse hearts. Am J Physiol Heart Circ Physiol, 2006. 290(6): p. H2614-24. 
 
84. Berger, D.S., K. Vlasica, C.M. Quick, K.A. Robinson, and S.G. Shroff, Ejection has 
both positive and negative effects on left ventricular isovolumic relaxation. Am J Physiol, 
1997. 273(6 Pt 2): p. H2696-707. 
 
85. Wu, Y., A.H. Tobias, K. Bell, W. Barry, M. Helmes, K. Trombitas, R. Tucker, K.B. 
Campbell, an d H .L. Granzier, Cellular and molecular mechanisms of systolic and 
diastolic dysfunction in an avian model of dilated cardiomyopathy. J Mol Cell Cardiol, 
2004. 37(1): p. 111-9. 
 
86. Eberli, F .R., F. S am, S. N goy, C .S. A pstein, an d W.S . C olucci, Left-ventricular 
structural and functional remodeling in the mouse after myocardial infarction: assessment 
 190 
with the isovolumetrically-contracting Langendorff heart. J Mol Cell Cardiol, 1998. 
30(7): p. 1443-7. 
 
87. Liou, Y .M. a nd F . F uchs, Pyrene-labeled cardiac troponin C. Effect of Ca2+ on 
monomer and excimer fluorescence in solution and in myofibrils. Biophys J, 1992. 61(4): 
p. 892-901. 
 
88. Grabarek, Z ., R .Y. T an, J. Wan g, T . T ao, and J. G ergely, Inhibition of mutant 
troponin C activity by an intra-domain disulphide bond. Nature, 1990. 345(6271): p. 132-
5. 
 
89. Fiske, C.H. and Y. Subbarow, The Colorimetric Determination of Phosphorus. J Biol 
Chem, 1925. 66(2): p. 375-400. 
 
90. Gao, W.D., D. Atar, P.H. Backx, and E. Marban, Relationship between intracellular 
calcium and contractile force in stunned myocardium. Direct evidence for decreased 
myofilament Ca2+ responsiveness and altered diastolic function in intact ventricular 
muscle. Circ Res, 1995. 76(6): p. 1036-48. 
 
91. Grynkiewicz, G., M. Poenie, and R.Y. Tsien, A new generation of Ca2+ indicators with 
greatly improved fluorescence properties. J Biol Chem, 1985. 260(6): p. 3440-50. 
 
92. Molecular_Probes, Product Information: Fura and Indo Ratiometric Calcium 
Indicators, in http://probes.invitrogen.com/media/pis/mp01200.pdf. 2005. 
 
93. Gao, W.D ., P .H. B ackx, M . A zan-Backx, an d E . Marban, Myofilament Ca2+ 
sensitivity in intact versus skinned rat ventricular muscle. Circ Res, 1994. 74(3): p. 408-
15. 
 
94. Gao, W.D., N.G. Perez, and E. Marban, Calcium cycling and contractile activation in 
intact mouse cardiac muscle. J Physiol, 1998. 507 ( Pt 1): p. 175-84. 
 
95. Montgomery, D .E., B .M. Wol ska, W.G . Pyle, B .B. R oman, J. C. Dowell, P .M. 
Buttrick, A.P. Koretsky, P. Del Nido, and R.J. Solaro, alpha-Adrenergic response and 
myofilament activity in mouse hearts lacking PKC phosphorylation sites on cardiac TnI. 
Am J Physiol Heart Circ Physiol, 2002. 282(6): p. H2397-405. 
 
96. Chandra, M., M.L. Tschirgi, S.J. Ford, B.K. Slinker, and K.B. Campbell, Interaction 
between myosin heavy chain and troponin isoforms modulate cardiac myofiber 
contractile dynamics. Am J Physiol Regul Integr Comp Physiol, 2007. 293(4): p. R1595-
607. 
 
97. Chandra, M., V.L. Rundell, J.C. Tardiff, L.A. Leinwand, P.P. De Tombe, and R.J. 
Solaro, Ca(2+) activation of myofilaments from transgenic mouse hearts expressing 
R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol, 2001. 280(2): p. 
H705-13. 
 191 
 
98. de T ombe, P.P. a nd G .J. St ienen, Protein kinase A does not alter economy of force 
maintenance in skinned rat cardiac trabeculae. Circ Res, 1995. 76(5): p. 734-41. 
 
99. Fabiato, A. and F. Fabiato, Calculator programs for computing the composition of the 
solutions containing multiple metals and ligands used for experiments in skinned muscle 
cells. J Physiol (Paris), 1979. 75(5): p. 463-505. 
 
100. Takahashi, A ., P. C amacho, J.D . L echleiter, an d B . H erman, Measurement of 
intracellular calcium. Physiol Rev, 1999. 79(4): p. 1089-125. 
 
101. Tong, C .W., R .D. G affin, D .C. Z awieja, an d M . M uthuchamy, Roles of 
phosphorylation of myosin binding protein-C and troponin I in mouse cardiac muscle 
twitch dynamics. J Physiol, 2004. 558(Pt 3): p. 927-41. 
 
102. Baran, D., K. Ogino, R. Stennett, M. Schnellbacher, D. Zwas, J.P. Morgan, and D. 
Burkhoff, Interrelating of ventricular pressure and intracellular calcium in intact hearts. 
Am J Physiol, 1997. 273(3 Pt 2): p. H1509-22. 
 
103. Burkhoff, D ., Explaining load dependence of ventricular contractile properties with a 
model of excitation-contraction coupling. J Mol Cell Cardiol, 1994. 26(8): p. 959-78. 
 
104. Shimizu, J., K. Todaka, and D. Burkhoff, Load dependence of ventricular performance 
explained by model of calcium-myofilament interactions. Am J Physiol Heart Circ 
Physiol, 2002. 282(3): p. H1081-91. 
 
105. Rhodes, S .S., K.M. Ropella, S .H. Audi, A .K. Camara, L .G. Kevin, P .S. Pagel, and 
D.F. Stowe, Cross-bridge kinetics modeled from myoplasmic [Ca2+] and LV pressure at 
17°C and after 37°C and 17°C ischemia. Am J Physiol Heart Circ Physiol, 2003. 284(4): 
p. H1217-29. 
 
106. Peterson, J.N., W.C. Hunter, and M.R. Berman, Estimated time course of Ca2+ bound 
to troponin C during relaxation in isolated cardiac muscle. Am J Physiol, 1991. 260(3 Pt 
2): p. H1013-24. 
 
107. Forsman, K ., Constructive Commutative Algebra in Nonlinear Control Theory, 
Linköping Studies in Science and Technology, Dissertation, No. 261, in Department of 
Electrical Engineering. 1992, Linköping University: Linköping, Sweden. 
 
108. Forsman, K . an d T . G lad. Constructive algebraic geometry in nonlinear control. in 
Decision and Control, 1990., Proceedings of the 29th IEEE Conference on. 1990. 
 
109. Audoly, S ., G . B ellu, L . D 'Angio, M .P. S accomani, an d C . C obelli, Global 
identifiability of nonlinear models of biological systems. IEEE Trans Biomed Eng, 2001. 
48(1): p. 55-65. 
 
 192 
110. Bellu, G., M.P. Saccomani, S. Audoly, and L. D'Angio, DAISY: a new software tool to 
test global identifiability of biological and physiological systems. Comput Methods 
Programs Biomed, 2007. 88(1): p. 52-61. 
 
111. Cobelli, C . an d J.J. D iStefano, 3r d, Parameter and structural identifiability concepts 
and ambiguities: a critical review and analysis. Am J Physiol, 1980. 239(1): p. R7-24. 
 
112. Brenner, B ., Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit 
psoas fibers: implications for regulation of muscle contraction. Proc Natl Acad Sci U S A, 
1988. 85(9): p. 3265-9. 
 
113. de Tombe, P.P., A. Belus, N. Piroddi, B. Scellini, J.S. Walker, A.F. Martin, C. Tesi, 
and C. Poggesi, Myofilament calcium sensitivity does not affect cross-bridge activation-
relaxation kinetics. Am J Physiol Regul Integr Comp Physiol, 2007. 292(3): p. R1129-36. 
 
114. Sancho Solis, R., Y. Ge, and J.W. Walker, Single amino acid sequence polymorphisms 
in rat cardiac troponin revealed by top-down tandem mass spectrometry. J Muscle Res 
Cell Motil, 2008. 29(6-8): p. 203-12. 
 
115. Shusterman, V., I. Usiene, C. Harrigal, J.S. Lee, T. Kubota, A.M. Feldman, and B. 
London, Strain-specific patterns of autonomic nervous system activity and heart failure 
susceptibility in mice. Am J Physiol Heart Circ Physiol, 2002. 282(6): p. H2076-83. 
 
116. Saurin, A .T., D .J. Pennington, N .J. R aat, D .S. L atchman, M.J. O wen, an d M.S. 
Marber, Targeted disruption of the protein kinase C epsilon gene abolishes the infarct 
size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse 
hearts. Cardiovasc Res, 2002. 55(3): p. 672-80. 
 
117. Turnbull, L ., J.F . H oh, R .I. L udowyke, and G .H. R ossmanith, Troponin I 
phosphorylation enhances crossbridge kinetics during beta-adrenergic stimulation in rat 
cardiac tissue. J Physiol, 2002. 542(Pt 3): p. 911-20. 
 
118. Neher, E ., The use of fura-2 for estimating Ca buffers and Ca fluxes. 
Neuropharmacology, 1995. 34(11): p. 1423-42. 
 
119. Baylor, S .M. an d S . H ollingworth, Measurement and Interpretation of Cytoplasmic 
[Ca2+] Signals From Calcium-Indicator Dyes. News Physiol Sci, 2000. 15: p. 19-26. 
 
120. Blatter, L.A. and W.G. Wier, Intracellular diffusion, binding, and compartmentalization 
of the fluorescent calcium indicators indo-1 and fura-2. Biophys J, 1990. 58(6): p. 1491-
9. 
 
121. Steinberg, S.F., J.P. Bilezikian, and Q. Al-Awqati, Fura-2 fluorescence is localized to 
mitochondria in endothelial cells. Am J Physiol, 1987. 253(5 Pt 1): p. C744-7. 
 
 193 
122. Tanaka, H ., S . M anita, T . M atsuda, M . A dachi, an d K . S higenobu, Sustained 
negative inotropism mediated by alpha-adrenoceptors in adult mouse myocardia: 
developmental conversion from positive response in the neonate. Br J Pharmacol, 1995. 
114(3): p. 673-7. 
 
123. MacGowan, G.A., J. Rager, S.G. Shroff, and M.A. Mathier, In vivo alpha-adrenergic 
responses and troponin I phosphorylation: anesthesia interactions. J Appl Physiol, 2005. 
98(4): p. 1163-70. 
 
124. Dunaway, S., Q. Yu, and D.F. Larson, Effect of acute alpha adrenergic stimulation on 
cardiac function. Perfusion, 2007. 22(4): p. 289-92. 
 
125. Wang, H., J.E . Grant, C.M. Doede, S . Sadayappan, J. R obbins, and J.W. Walker, 
PKC-βΙΙ sensitizes cardiac myofilaments to Ca2+ by phosphorylating troponin I on 
threonine-144. J Mol Cell Cardiol, 2006. 41(5): p. 823-33. 
 
126. Sumandea, M.P., V.O. Rybin, A.C. Hinken, C. Wang, T. Kobayashi, E. Harleton, G. 
Sievert, C .W. B alke, S.J. F einmark, R .J. Solaro, an d S.F. S teinberg, Tyrosine 
phosphorylation modifies protein kinase C δ-dependent phosphorylation of cardiac 
troponin I. J Biol Chem, 2008. 283(33): p. 22680-9. 
 
127. Mathur, M.C., T. Kobayashi, and J.M. Chalovich, Negative Charges at Protein Kinase 
C Sites of Troponin I Stabilize the Inactive State of Actin. Biophys J, 2007. 
 
128. Solaro, R.J., P. Rosevear, and T. Kobayashi, The unique functions of cardiac troponin 
I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res 
Commun, 2007. 
 
129. Finley, N .L. an d P .R. R osevear, Introduction of negative charge mimicking protein 
kinase C phosphorylation of cardiac troponin I. Effects on cardiac troponin C. J Biol 
Chem, 2004. 279(52): p. 54833-40. 
 
130. Stelzer, J.E ., H .S. N orman, P.P. C hen, J.R . P atel, an d R .L. M oss, Transmural 
variation in myosin heavy chain isoform expression modulates the timing of myocardial 
force generation in porcine left ventricle. J Physiol, 2008. 586(Pt 21): p. 5203-14. 
 
131. Brandt, P .W., M .S. Diamond, J .S. R utchik, a nd F .H. Sc hachat, Co-operative 
interactions between troponin-tropomyosin units extend the length of the thin filament in 
skeletal muscle. J Mol Biol, 1987. 195(4): p. 885-96. 
 
132. Colson, B .A., T . B ekyarova, M .R. L ocher, D .P. Fitzsimons, T .C. I rving, an d R .L. 
Moss, Protein kinase A-mediated phosphorylation of cMyBP-C increases proximity of 
myosin heads to actin in resting myocardium. Circ Res, 2008. 103(3): p. 244-51. 
 
 194 
133. Day, S.M., M.V. Westfall, and J.M. Metzger, Tuning cardiac performance in ischemic 
heart disease and failure by modulating myofilament function. J Mol Med, 2007. 85(9): p. 
911-21. 
 
134. Scruggs, S .B., L .A. Wa lker, T . Lyu, D .L. Geenen, R .J. Solaro, P.M. Buttrick, and 
P.H. Goldspink, Partial replacement of cardiac troponin I with a non-phosphorylatable 
mutant at serines 43/45 attenuates the contractile dysfunction associated with PKCε 
phosphorylation. J Mol Cell Cardiol, 2006. 40(4): p. 465-73. 
 
135. Pyle, W.G., Y. Chen, and P.A. Hofmann, Cardioprotection through a PKC-dependent 
decrease in myofilament ATPase. Am J Physiol Heart Circ Physiol, 2003. 285(3): p. 
H1220-8. 
 
136. Brown, E.B., J. B. S hear, S .R. A dams, R .Y. T sien, an d W.W. We bb, Photolysis of 
caged calcium in femtoliter volumes using two-photon excitation. Biophys J, 1999. 76(1 
Pt 1): p. 489-99. 
 
137. Lenart, T .D., J. M. M urray, C . Franzini-Armstrong, an d Y .E. G oldman, Structure 
and periodicities of cross-bridges in relaxation, in rigor, and during contractions initiated 
by photolysis of caged Ca2+. Biophys J, 1996. 71(5): p. 2289-306. 
 
138. Campbell, K.B. and M. Chandra, Functions of stretch activation in heart muscle. J Gen 
Physiol, 2006. 127(2): p. 89-94. 
 
139. Xing, J., M. Chinnaraj, Z. Zhang, H.C. Cheung, and W.J. Dong, Structural studies of 
interactions between cardiac troponin I and actin in regulated thin filament using Forster 
resonance energy transfer. Biochemistry, 2008. 47(50): p. 13383-93. 
 
140. Molkentin, J.D . an d J.  R obbins, With great power comes great responsibility: using 
mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol, 2009. 46(2): 
p. 130-6. 
 
141. Kass, D.A., J.M. Hare, and D. Georgakopoulos, Murine cardiac function: a cautionary 
tail. Circ Res, 1998. 82(4): p. 519-22. 
 
142. Li, L ., G. Chu, E .G. Kranias, and D.M. Bers, Cardiac myocyte calcium transport in 
phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J 
Physiol, 1998. 274(4 Pt 2): p. H1335-47. 
 
143. Allen, D .G. an d S . K urihara, The effects of muscle length on intracellular calcium 
transients in mammalian cardiac muscle. J Physiol, 1982. 327: p. 79-94. 
 
144. Alvarez, B .V., N .G. Perez, I .L. E nnis, M .C. C amilion d e H urtado, an d H .E. 
Cingolani, Mechanisms underlying the increase in force and Ca(2+) transient that follow 
stretch of cardiac muscle: a possible explanation of the Anrep effect. Circ Res, 1999. 
85(8): p. 716-22. 
 195 
 
145. Reyes, M., G.L. Freeman, D. E scobedo, S . L ee, M.E. S teinhelper, an d M .D. 
Feldman, Enhancement of contractility with sustained afterload in the intact murine 
heart: blunting of length-dependent activation. Circulation, 2003. 107(23): p. 2962-8. 
 
146. Du, C., G.A. MacGowan, D.L. Farkas, and A.P. Koretsky, Calcium measurements in 
perfused mouse heart: quantitating fluorescence and absorbance of Rhod-2 by application 
of photon migration theory. Biophys J, 2001. 80(1): p. 549-61. 
 
147. MacGowan, G .A., C . D u, V . Glonty, J.P . S uhan, A .P. Koretsky, an d D .L. Farkas, 
Rhod-2 based measurements of intracellular calcium in the perfused mouse heart: cellular 
and subcellular localization and response to positive inotropy. J Biomed Opt, 2001. 6(1): 
p. 23-30. 
 
148. Del N ido, P .J., P. Glynn, P . B uenaventura, G . S alama, an d A .P. Koretsky, 
Fluorescence measurement of calcium transients in perfused rabbit heart using rhod 2. 
Am J Physiol, 1998. 274(2 Pt 2): p. H728-41. 
 
149. Todaka, K ., K . O gino, A . G u, an d D . Burkhoff, Effect of ventricular stretch on 
contractile strength, calcium transient, and cAMP in intact canine hearts. Am J Physiol, 
1998. 274(3 Pt 2): p. H990-1000. 
 
150. Wier, W. G. an d D .T. Yue, Intracellular calcium transients underlying the short-term 
force-interval relationship in ferret ventricular myocardium. J Physiol, 1986. 376: p. 507-
30. 
 
151. Hajjar, R .J., U . S chmidt, P . H elm, an d J.K . G wathmey, Ca++ sensitizers impair 
cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther, 1997. 280(1): p. 
247-54. 
 
152. Maier, L .S., P . B arckhausen, J. We isser, I . Aleksic, M . B aryalei, an d B . P ieske, 
Ca(2+) handling in isolated human atrial myocardium. Am J Physiol Heart Circ Physiol, 
2000. 279(3): p. H952-8. 
 
153. Georgakopoulos, D. and D. Kass, Minimal force-frequency modulation of inotropy and 
relaxation of in situ murine heart. J Physiol, 2001. 534(Pt. 2): p. 535-45. 
 
154. Brutsaert, D.L., N.M. de Clerck, M.A. Goethals, and P.R. Housmans, Relaxation of 
ventricular cardiac muscle. J Physiol, 1978. 283: p. 469-80. 
 
155. Tobias, A .H., B .K. S linker, R .D. K irkpatrick, an d K .B. C ampbell, Mechanical 
determinants of left ventricular relaxation in isovolumically beating hearts. Am J Physiol, 
1995. 268(1 Pt 2): p. H170-7. 
 
156. Campbell, K.B., M.V. Razumova, R.D. Kirkpatrick, and B.K. Slinker, Myofilament 
kinetics in isometric twitch dynamics. Ann Biomed Eng, 2001. 29(5): p. 384-405. 
 196 
 
157. Janssen, P .M. an d W.C . H unter, Force, not sarcomere length, correlates with 
prolongation of isosarcometric contraction. Am J Physiol, 1995. 269(2 Pt 2): p. H676-85. 
 
158. Cazorla, O., Y. Wu, T.C. Irving, and H. Granzier, Titin-based modulation of calcium 
sensitivity of active tension in mouse skinned cardiac myocytes. Circ Res, 2001. 88(10): 
p. 1028-35. 
 
159. Toy, S.M., J. Melbin, and A. Noordergraaf, Reduced models of arterial systems. IEEE 
Trans Biomed Eng, 1985. 32(2): p. 174-6. 
 
160. Stergiopulos, N ., B .E. Westerhof, an d N . We sterhof, Total arterial inertance as the 
fourth element of the windkessel model. Am J Physiol, 1999. 276(1 Pt 2): p. H81-8. 
 
161. Campbell, K .B., M. C handra, R .D. K irkpatrick, B .K. S linker, an d W.C. H unter, 
Interpreting cardiac muscle force-length dynamics using a novel functional model. Am J 
Physiol Heart Circ Physiol, 2004. 286(4): p. H1535-45. 
 
162. Campbell, K .B., Y . Wu, A .M. S impson, R.D. K irkpatrick, S .G. S hroff, H .L. 
Granzier, a nd B .K. Sl inker, Dynamic myocardial contractile parameters from left 
ventricular pressure-volume measurements. Am J Physiol Heart Circ Physiol, 2005. 
289(1): p. H114-30. 
 
163. Chandra, M ., M .L. Tschirgi, I . R ajapakse, an d K .B. C ampbell, Troponin T 
modulates sarcomere length-dependent recruitment of cross-bridges in cardiac muscle. 
Biophys J, 2006. 90(8): p. 2867-76. 
 
164. Berger, D.S., S.K. Fellner, K.A. Robinson, K. Vlasica, I.E. Godoy, and S.G. Shroff, 
Disparate effects of three types of extracellular acidosis on left ventricular function. Am J 
Physiol, 1999. 276(2 Pt 2): p. H582-94. 
 
 
 
